


Copper-Catalyzed Oxyvinylation of Diazo Compounds

Guillaume Pisella, Alec Gagnebin and Jerome Waser*

Laboratory of Catalysis and Organic Synthesis, Institut des Sciences et Ingénierie Chimique, Ecole Polytechnique Fédérale de Lausanne, CH-1015, Lausanne, Switzerland

Supporting Information Placeholder




ABSTRACT: A copper(I)-catalyzed vinylation of diazo compounds with VinylBenziodoxolone reagents (VBX) as partners is reported. The transformation tolerates diverse functionalities on both reagents delivering polyfunctionalized vinyated products. The strategy was successfully extended to a three-component/intermolecular version with alcohols. The obtained products contain synthetically versatile functional groups, such as an aryl iodide, an ester and an allylic leaving group, enabling further modification.

Metal carbenes obtained from diazo compounds have been extensively used in synthetic chemistry¹ and their *gem*-difunctionalization is a powerful method to access complex products (Scheme 1A).² The formation of at least one new C-C bond in this process has been realized for alkylation, arylation and alkynylation reactions using palladium,³ copper⁴ and rhodium⁵ catalysis. The most successful approaches involve cross-coupling through carbene migratory insertion (path **a**),^{2b} or trapping of transient ylides with carbon electrophiles (path **b**).^{2a}

The introduction of an olefin in such processes has been limited to the formation of a C-alkenyl and a C-H bond,⁶ with the exception of a palladium-catalyzed cross-coupling combining vinylhalides and nucleophiles (Scheme 1B).⁷ The reaction proceeds via a π -allyl palladium species, resulting in a 1,3 relationship between the nucleophile and the vinyl group. We considered a reverse approach to develop an unprecedented 1,1-oxyvinylation: Addition of an oxygen nucleophile first, followed by reaction with an electrophilic hypervalent iodine vinylation reagent (Scheme 1C). Our group established an efficient copper-catalyzed 1,1-oxyalkynylation of diazo compounds based on the use of electrophilic ethynylbenziodoxolone (EBX) hypervalent iodine reagents.^{8,9} To develop the first direct vinylation of diazo compounds, we envisaged the use of the corresponding vinylbenziodoxolone (VBX) reagents recently reported by Olsson and co-workers.¹⁰

In this work, we report a copper-catalyzed insertion of diazo compounds into VBX reagents proceeding with broad scope at room temperature. The transformation was successfully extended to the synthesis of allylic ethers using alcohols as external nucleophiles.


Scheme 1. General difunctionalization of metal carbenes (A) and vinylation of diazo compounds (B and C).



We started our optimization by reacting Ph-VBX (**1a**) with ethyl diazoacetate (**2a**) (Table 1; See Supporting Information for other tested conditions, Table S1). No desired product was isolated without copper catalyst or ligand (entries 1 and 2). Allylic ester **4a** was formed in 90% yield when $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (4 mol%) was used in combination with diimine **3a** (5 mol%) (entry 3).^{8a} A lower yield was obtained with more electron-rich VBX **1c** (entry 4). No reaction occurred using the alkyl-substituted substrate **1j** even at a higher temperature (entry 5). We therefore investigated bisoxazoline (BOX) ligands, which had


also been successful in our previous work.^{8b} Using *t*Bu-BOX ligand **3b** the reaction could be performed in one hour at room temperature to give **4a** in 95% yield as a racemate (entry 6). The non-chiral ligand **3c** gave a similar result (entry 7). These conditions performed well with the more electron-rich and aliphatic substrates (entries 8 and 9), but were not successful for substituted diazo compound **2b** (entry 10). Product **5a** could be obtained in 80% yield using ligand **3a** (entry 11). In all reactions, only the *E*-olefin was obtained.

Table 1. Optimization of the insertion of diazo compounds 2a and 2b into VBX (1).^a



entry	ligand	diazo R ¹ =	VBX R ² =	product	temp	time	yield ^b
1 ^c	3a	H (2a)	Ph (1a)	4a	40 °C	4 h	0%
2	none	H (2a)	Ph (1a)	4a	40 °C	4 h	< 5%
3	3a	H (2a)	Ph (1a)	4a	40 °C	4 h	90%
4	3a	H (2a)	PMP (1c)	4b	60 °C	24 h	50%
5	3a	H (2a)	Cy (1j)	4j	60 °C	24 h	< 5%
6	3b	H (2a)	Ph (1a)	4a	25 °C	1 h	95%
7 ^d	3c	H (2a)	Ph (1a)	4a	25 °C	1 h	95%
8 ^d	3c	H (2a)	PMP (1c)	4b	25 °C	4 h	81%
9 ^d	3c	H (2a)	Cy (1j)	4j	25 °C	4 h	99%
10	3c	Ph (2b)	Ph (1a)	5a	40 °C	4 h	< 5%
11	3a	Ph (2b)	Ph (1a)	5a	40 °C	4 h	80%


^aReactions on 0.10 mmol scale with 2.0 equiv. of **2**, 4 mol% of Cu(CH₃CN)₄BF₄, 5 mol% of ligand in DCE (0.04 M). ^bIsolated yields. ^cWithout Cu(CH₃CN)₄BF₄. ^dOn 0.20 mmol scale. Ph = phenyl, Cy = cyclohexyl, PMP = *para*-methoxyphenyl.



Diverse aryl-substituted VBXs were then explored with ethyl diazoacetate (**2a**) (Scheme 2A).¹¹ Electron donating ether and alkyl groups on the arene afforded products **4b-c** in 81% and 92% yields. Fluorinated compounds **4d** and **4e** were obtained in 72% and 66% yield. A naphthyl-substituted VBX led to the formation of **4f** in 81% yield. A slightly diminished yield was obtained for thiophene-substituted **4g** (76% yield). Both electron-rich and -poor substituents on the benziodoxolone backbone were tolerated affording **4h** and **4i**. Next, we turned our attention to alkyl-substituted VBX reagents (Scheme 2B). VBXs bearing aliphatic chains (Cy, Bn and *n*Pr) provided allylic esters **4j-l** in 90-99% yield. The incorporation of an ester (**4m**) or a chloride (**4n**) group could also be achieved. Trisubstituted alkene **4o** was accessed in 97% yield. VBXs with amines, silyl ethers, and chlorides in allylic position delivered the corresponding products **4p-r**. A lower yield was obtained for **4p** and **4r**, maybe due to the low solubility of the corresponding VBX reagents in DCE. π -Conjugated systems were readily incorporated (Scheme 2C). An isoprene skeleton was introduced to give

4s in 82% yield. Conjugated diene **4t** and enyne **4u** were also successfully synthesized.


Scheme 2. Scope of VBX reagents.



Reactions using VBX **1** (0.2 mmol) and **2a** (0.4 mmol) in DCE (0.04 M).

We next investigated the scope of the acceptor substituent on the diazo compounds (Scheme 3A). Various esters such as *t*Bu or BHT were tolerated giving **5b** and **5c** in quantitative yield.¹² Product **5d** bearing a benzyl group was obtained in 92% yield and **5e** with an allyl group in 91%. 2-Diazo-*N,N*-diethylacetamide provided **5f** in 94% yield. Weinreb amide derivative **5g** was isolated in 99% yield. Sulfonate- and phosphonate-diazo compounds were efficient coupling partners, generating products **5h** and **5i** in quantitative yields.¹³ Unfortunately, diazoketones underwent degradation through Wolff rearrangement (**5j**) and no conversion was obtained using trimethylsilyldiazomethane (**5k**, 0% yield). However, compound **5l** incorporating a trifluoromethyl group was isolated in quantitative yield. Organofluorine compounds are important for the pharmaceutical, agrochemical and materials industry.¹⁴ Other less stable diazo compounds lacking an electron-withdrawing group were not yet investigated. Finally, the reaction of disubstituted diazo compounds was investigated using diimine ligand **3a** (Scheme 3B). Products **5a** and **5m** with tertiary allylic centers were formed in 71 and 89% yield. A second electron-withdrawing group suppressed the reactivity (**5n**, 0% yield). A cyclic diazo compound afforded the desired product **5o** in 90% yield. Diene product **5p** could be obtained in good yield when starting from a vinyl diazo precursor. Attack of the nucleophile at the vinylogous center was favored.¹⁵


Scheme 3. Scope of diazo compounds 2.



Reactions using Ph-VBX (1a) (0.2 mmol) and 2 (0.4 mmol) in DCE (0.04 M). ^a3c as ligand at 25 °C. ^b3a as ligand at 40 °C.

We then investigated an enantioselective version of the reaction. Testing various substrates, chiral ligands and reaction conditions, we achieved a maximum of 75:25 er with ligand **3d** for the formation of **5c** (See Table S3 for details).¹⁶ Interestingly, with *tert*-amyl alcohol as co-solvent, we observed ¹H NMR signals tentatively assigned to allylic ether product **6a** in the crude reaction mixture, in addition to expected **4a** for the reaction of VBX **1a** and **2a** (Scheme 4A).

Scheme 4. Extension to three-component reaction.




Reactions using VBX (**1v-z**) (0.3 mmol) and R³OH (0.9 mmol) in DCM (0.075 M). Diazo **2** (0.6 mmol, 0.6 M in DCM) added via syringe pump over 1 h.

To favor the three-component reaction, we used less nucleophilic bis-trifluoromethyl benziodoxole VBX **1'** and removed the ligand (See Table S2 for details).¹⁷ With 3 equivalents of alcohol, the three-component products were obtained in 23–72% yield (Scheme 4B). Primary, secondary and tertiary alcohols were combined with different VBXs and diazo compounds leading to functionalized allylic ethers bearing esters (**6b**, **6c** and **6e**), phosphonate (**6d**), chloride (**6f**), furan (**6c**), indanyl (**6e**), adamantyl (**6c**) or trifluoromethyl (**6e** and **6f**) groups. The vinylation of cholesterol was achieved in 61% yield affording **6g** with a trifluoromethyl and a phthalimide group.

Product **4a** was synthesized on 2.0 mmol scale using a lower catalyst loading at higher concentration (Scheme 5A). The esters groups in **4a** were readily reduced with LiAlH₄ to produce diol **8** (Scheme 5B). Butenolide **9** resulting from the formation of an α -keto ester followed by dimerization was formed under basic conditions. Treatment of **4a** with TiCl₄ and allyl-TMS led to the formation of conjugated ester **10**. Propargyl-TMS could also be used as nucleophile giving allene-containing product **11**. The introduction of an azide was accomplished using TMSN₃ to form **12**, which isomerizes spontaneously.¹⁸ A Heck reaction between **5m** and methyl acrylate afforded **13** in 66% yield. Hydrogenolysis of the iodoarene was achieved with hydrogen and poisoned Pd/C to give product **14** in 77% yield. Visible light photoredox catalysis gave access to the deiodinated product **15** in 82% yield with *E* to *Z* isomerization of the olefin.

Scheme 5. Scale-up synthesis and product modifications.



^aReaction conditions: a) LiAlH₄ (3.00 equiv.), THF, 0 °C to rt, 1 h, 91%; b) DBU (10 equiv.), MeOH, 50 °C, 6 h, 93%; c) Allyl-TMS (1.5 equiv.), TiCl₄ (1.05 equiv.), DCM, 0 °C, 15 min, 83%; d) Propargyl-TMS (2.0 equiv.), TiCl₄ (1.05 equiv.), DCM, -78 °C to 0 °C, 59%; e) TMSN₃ (1.5 equiv.), TiCl₄ (1.05 equiv.), DCM, -20 °C to 0 °C, **12/12'** 70:30, 86%; f) methyl acrylate (5.0 equiv.), PdCl₂(PPh₃)₃ (5 mol%), PPh₃ (5 mol%), Et₃N, 80 °C, 24 h, 66%; g) H₂, Pd/C (10 mol%, 10% w/w), DABCO (10 equiv.), MeOH, rt,

10 min, 77%; h) *fac*-Ir(ppy)₃ (2.5 mol%), NBu₃ (10 equiv.), HCO₂H (10 equiv.), blue LED, MeCN, 40 °C, 18 h, 82%.

Based on literature precedence and our work on the copper-catalyzed oxy-alkynylation reaction,^{8a-c} a tentative reaction mechanism would involve an electrophilic copper-carbene generated from the diazo compound (See Scheme S1 in the Supporting Information). Nucleophilic attack of the carboxylate part of the VBX reagent or the alcohol nucleophile would generate an ylide intermediate, which is then vinylylated.

In summary, we have developed a copper-catalyzed insertion of diazo compounds into vinylbenziodoxolone (VBX) reagents. The transformation provides access to a broad scope of functionalized allylic esters.¹⁹ Extension of the strategy to a three-component reaction with alcohol nucleophiles allowed the synthesis of structurally diverse allylic ethers. The obtained products can be further modified to give important building blocks. Ongoing research is focused on the elucidation of the reaction mechanism and the development of the asymmetric version of the transformation based on our preliminary results.

ASSOCIATED CONTENT

Supporting Information

Supplementary tables and schemes, experimental procedures and characterization data (NMR, IR, MS, X-ray). The Supporting Information is available free of charge on the ACS Publications website. Raw NMR, IR and MS data is available at zenodo.org, DOI: 10.5281/zenodo.3764827.

AUTHOR INFORMATION

Corresponding Author

* jerome.waser@epfl.ch

ACKNOWLEDGMENT

We thank ERC (European Research Council, Starting Grant iTools4MC, number 334840) and the Swiss National Science Foundation (SNSF, grant 200020_182798). We thank Dr R. Scopelliti and Dr F. F. Tirani from ISIC at EPFL for X-ray analysis. We thank Dr Durga Prasad Hari (University of Bristol) for insightful discussions during the project.

REFERENCES

- (1) (a) Doyle, M. P.; Duffy, R.; Ratnikov, M.; Zhou, L. Catalytic Carbene Insertion into C–H Bonds. *Chem. Rev.* **2010**, *110*, 704. (b) Ford, A.; Miel, H.; Ring, A.; Slattery, C. N.; Maguire, A. R.; McKervy, M. A. Modern Organic Synthesis with α -Diazocarbonyl Compounds. *Chem. Rev.* **2015**, *115*, 9981.
- (2) (a) Guo, X.; Hu, W. Novel Multicomponent Reactions via Trapping of Protic Onium Ylides with Electrophiles. *Acc. Chem. Res.* **2013**, *46*, 2427. (b) Xia, Y.; Qiu, D.; Wang, J. Transition-Metal-Catalyzed Cross-Couplings through Carbene Migratory Insertion. *Chem. Rev.* **2017**, *117*, 13810.
- (3) Selected examples: (a) Chen, Z.-S.; Duan, X.-H.; Zhou, P.-X.; Ali, S.; Luo, J.-Y.; Liang, Y.-M. Palladium-Catalyzed Divergent Reactions of α -Diazocarbonyl Compounds with Allylic Esters: Construction of Quaternary Carbon Centers. *Angew. Chem. Int. Ed.* **2012**, *51*, 1370. (b) Zhou, P.-X.; Zhou, Z.-Z.; Chen, Z.-S.; Ye, Y.-Y.; Zhao, L.-B.; Yang, Y.-F.; Xia, X.-F.; Luo, J.-Y.; Liang, Y.-M. Palladium-Catalyzed Insertion of α -Diazocarbonyl Compounds for the Synthesis of Cyclic Amino Esters. *Chem. Commun.* **2013**, *49*, 561. (c) Qin, G.; Li, L.; Li, J.; Huang, H. Palladium-Catalyzed Formal Insertion of Carbenoids into Aminals via C–N Bond Activation. *J. Am. Chem. Soc.* **2015**, *137*, 12490. (d) Liu, Z.; Tan, H.; Fu, T.; Xia, Y.; Qiu, D.; Zhang, Y.; Wang, J. Pd(0)-Catalyzed Carbene Insertion into Si–Si and Sn–Sn Bonds. *J. Am. Chem. Soc.* **2015**, *137*, 12800. (e) Dai, Q.; Jiang, Y.; Guo, S.; Yu, J.-T.; Cheng, J. 3-Aza π -Allyl Palladium Derived from Imino Migration in Palladium–Carbene: MCRs toward Multiple Substituted Indole Skeleton. *Chem. Commun.* **2015**, *51*, 14781. (f) Gutiérrez-Bonet, Á.; Juliá-Hernández, F.; de Luis, B.; Martín, R. Pd-Catalyzed C(sp³)-H Functionalization/Carbenoid Insertion: All-Carbon Quaternary Centers via Multiple C–C Bond Formation. *J. Am. Chem. Soc.* **2016**, *138*, 6384. (g) Pérez-Gómez, M.; Hernández-Ponte, S.; Bautista, D.; García-López, J.-A. Synthesis of Spiro-Oxindoles through Pd-Catalyzed Remote C–H Alkylation Using α -Diazocarbonyl Compounds. *Chem. Commun.* **2017**, *53*, 2842.
- (4) Selected examples: (a) Zhu, Y.; Zhai, C.; Yang, L.; Hu, W. Copper(II)-Catalyzed Highly Diastereoselective Three-Component Reactions of Aryl Diazoacetates with Alcohols and Chalcones: An Easy Access to Furan Derivatives. *Chem. Commun.* **2010**, *46*, 2865. (b) Wang, C.; Ye, F.; Wu, C.; Zhang, Y.; Wang, J. Construction of All-Carbon Quaternary Centers through Cu-Catalyzed Sequential Carbene Migratory Insertion and Nucleophilic Substitution/Michael Addition. *J. Org. Chem.* **2015**, *80*, 8748. (c) Lefebvre, Q.; Fava, E.; Nikolaienko, P.; Rueping, M. Hydrotrifluoromethylthiolation of α -Diazo Esters – Synthesis of α -SCF₃ Substituted Esters. *Chem. Commun.* **2014**, *50*, 6617. (d) Lv, X.; Kang, Z.; Xing, D.; Hu, W. Cu(I)-Catalyzed Three-Component Reaction of Diazo Compound with Terminal Alkyne and Nitrosobenzene for the Synthesis of Trifluoromethyl Dihydroisoxazoles. *Org. Lett.* **2018**, *20*, 4843. (e) Alavala, G. K. R.; Sajjad, F.; Shi, T.; Kang, Z.; Ma, M.; Xing, D.; Hu, W. Diastereoselective Synthesis of Isochromans via the Cu(II)-Catalyzed Intramolecular Michael-Type Trapping of Oxonium Ylides. *Chem. Commun.* **2018**, *54*, 12650.
- (5) Selected examples: (a) Huang, H.; Guo, X.; Hu, W. Efficient Trapping of Oxonium Ylides with Imines: A Highly Diastereoselective Three-Component Reaction for the Synthesis of β -Amino- α -Hydroxyesters with Quaternary Stereocenters. *Angew. Chem. Int. Ed.* **2007**, *46*, 1337. (b) Hu, W.; Xu, X.; Zhou, J.; Liu, W.-J.; Huang, H.; Hu, J.; Yang, L.; Gong, L.-Z. Cooperative Catalysis with Chiral Brønsted Acid-Rh₂(OAc)₄: Highly Enantioselective Three-Component Reactions of Diazo Compounds with Alcohols and Imines. *J. Am. Chem. Soc.* **2008**, *130*, 7782. (c) Guan, X.-Y.; Yang, L.-P.; Hu, W. Cooperative Catalysis in Multicomponent Reactions: Highly Enantioselective Synthesis of γ -Hydroxyketones with a Quaternary Carbon Stereocenter. *Angew. Chem. Int. Ed.* **2010**, *49*, 2190. (d) Jia, S.; Xing, D.; Zhang, D.; Hu, W. Catalytic Asymmetric Functionalization of Aromatic C-H Bonds by Electrophilic Trapping of Metal-Carbene-Induced Zwitterionic Intermediates. *Angew. Chem. Int. Ed.* **2014**, *53*, 13098. (e) Tsoi, Y.-T.; Zhou, Z.; Yu, W.-Y. Rhodium-Catalyzed Cross-Coupling Reaction of Arylboronates and Diazoesters and Tandem Alkylation Reaction for the Synthesis of Quaternary α,α -Heterodiaryl Carboxylic Esters. *Org. Lett.* **2011**, *13*, 5370. (f) Hyster, T. K.; Ruhl, K. E.; Rovis, T. A Coupling of Benzamides and Donor/Acceptor Diazo Compounds To Form γ -Lactams via Rh(III)-Catalyzed C–H Activation. *J. Am. Chem. Soc.* **2013**, *135*, 5364. (g) Ye, B.; Cramer, N. Asymmetric Synthesis of Isoindolones by Chiral Cyclopentadienyl-Rhodium(III)-Catalyzed C–H Functionalizations. *Angew. Chem. Int. Ed.* **2014**, *53*, 7896. (h) Xia, Y.; Liu, Z.; Liu, Z.; Ge, R.; Ye, F.; Hossain, M.; Zhang, Y.; Wang, J. Formal Carbene Insertion into C–C Bond: Rh(I)-Catalyzed Reaction of Benzocyclobutenols with Diazoesters. *J. Am. Chem. Soc.* **2014**, *136*, 3013. (i) Xia, Y.; Feng, S.; Liu, Z.; Zhang, Y.; Wang, J. Rhodium(I)-Catalyzed Sequential C(sp)–C(sp³) and C(sp³)–C(sp³) Bond Formation through Migratory Carbene Insertion. *Angew. Chem. Int. Ed.* **2015**, *54*, 7891. (j) Yada, A.; Fujita, S.; Murakami, M. Enantioselective Insertion of a Carbenoid Carbon into a C–C Bond To Expand Cyclobutanols to Cyclopentanols. *J. Am. Chem. Soc.* **2014**, *136*, 7217. (k) Alamsetti, S. K.; Spanka, M.; Schneider, C. Synergistic Rhodium/Phosphoric Acid Catalysis for the Enantioselective Addition of Oxonium Ylides to *Ortho*-Quinone Methides. *Angew. Chem. Int. Ed.* **2016**, *55*, 2392.
- (6) (a) Brown, H. C.; Salunkhe, A. M. Stereoselective Synthesis of *cis*- and *trans*- β , γ -Unsaturated Carboxylic Esters via Reaction of 1-Alkenyldichloroboranes with Ethyl Diazoacetate. *Synlett* **1991**, *1991*, 684. (b) Peng, C.; Zhang, W.; Yan, G.; Wang, J. Arylation and Vinylation of α -Diazocarbonyl Compounds with Boroxines. *Org. Lett.* **2009**, *11*, 1667. (c) Pérez-Aguilar, M. C.; Valdés, C. Olefination of Carbonyl Compounds through Reductive Coupling of Alkenylboronic Acids and

Tosylhydrazones. *Angew. Chem. Int. Ed.* **2012**, *51*, 5953. For a review, see: (d) Li, H.; Zhang, Y.; Wang, J. Reaction of Diazo Compounds with Organoboron Compounds. *Synthesis* **2013**, *45*, 3090.

(7) Selected examples: (a) Devine, S. K. J.; Van Vranken, D. L. Palladium-Catalyzed Carbene Insertion into Vinyl Halides and Trapping with Amines. *Org. Lett.* **2007**, *9*, 2047. (b) Devine, S. K. J.; Van Vranken, D. L. Palladium-Catalyzed Carbene Insertion and Trapping with Carbon Nucleophiles. *Org. Lett.* **2008**, *10*, 1909. (c) Kudirka, R.; Devine, S. K. J.; Adams, C. S.; Van Vranken, D. L. Palladium-Catalyzed Insertion of α -Diazoesters into Vinyl Halides To Generate α,β -Unsaturated γ -Amino Esters. *Angew. Chem. Int. Ed.* **2009**, *48*, 3677. (d) Khanna, A.; Maung, C.; Johnson, K. R.; Luong, T. T.; Van Vranken, D. L. Carbenylative Amination with *N*-Tosylhydrazones. *Org. Lett.* **2012**, *14*, 3233. (e) Zhou, P.-X.; Ye, Y.-Y.; Liang, Y.-M. Palladium-Catalyzed Insertion of *N*-Tosylhydrazones and Trapping with Carbon Nucleophiles. *Org. Lett.* **2013**, *15*, 5080. (f) Xia, Y.; Xia, Y.; Zhang, Y.; Wang, J. Palladium-Catalyzed Coupling of *N*-Tosylhydrazones and β -Bromostyrene Derivatives: New Approach to 2*H*-Chromenes. *Org. Biomol. Chem.* **2014**, *12*, 9333.

(8) (a) Hari, D. P.; Waser, J. Copper-Catalyzed Oxy-Alkynylation of Diazo Compounds with Hypervalent Iodine Reagents. *J. Am. Chem. Soc.* **2016**, *138*, 2190. (b) Hari, D. P.; Waser, J. Enantioselective Copper-Catalyzed Oxy-Alkynylation of Diazo Compounds. *J. Am. Chem. Soc.* **2017**, *139*, 8420. (c) Pisella, G.; Gagnebin, A.; Waser, J., Three-Component Reaction for the Synthesis of Highly Functionalized Propargyl Ethers. *Chem. Eur. J.* **2020**, DOI: 10.1002/chem.202001317. For other examples of multi-functionalization of diazo compounds with hypervalent iodine reagents, see: (d) Tao, J.; Tran, R.; Murphy, G. K. Dihaloiodoarenes: α,α -Dihalogenation of Phenylacetate Derivatives. *J. Am. Chem. Soc.* **2013**, *135*, 16312. (e) Yuan, W.; Eriksson, L.; Szabó, K. J. Rhodium-Catalyzed Geminal Oxyfluorination and Oxytrifluoromethylation of Diazocarbonyl Compounds. *Angew. Chem. Int. Ed.* **2016**, *55*, 8410.

(9) (a) Ochiai, M.; Masaki, Y.; Shiro, M. Synthesis and Structure of 1-Alkynyl-1,2-Benziodoxol-3(1*H*)-ones. *J. Org. Chem.* **1991**, *56*, 5511. (b) Zhdankin, V. V.; Kuehl, C. J.; Krasutsky, A. P.; Bolz, J. T.; Simonsen, A. J. 1-(Organosulfonyloxy)-3(1*H*)-1,2-benziodoxoles: Preparation and reactions with alkynyltrimethylsilanes. *J. Org. Chem.* **1996**, *61*, 6547. (c) Zhdankin, V. Benziodoxole-Based Hypervalent Iodine Reagents in Organic Synthesis. *Curr. Org. Synth.* **2005**, *2*, 121. (d) Yoshimura, A.; Zhdankin, V. V. Advances in Synthetic Applications of Hypervalent Iodine Compounds. *Chem. Rev.* **2016**, *116*, 3328. (e) Li, Y.; Hari, D. P.; Vita, M. V.; Waser, J. Cyclic Hypervalent Iodine Reagents for Atom-Transfer Reactions: Beyond Trifluoromethylation. *Angew. Chem. Int. Ed.* **2016**, *55*, 4436. (f) Hari, D. P.; Caramenti, P.; Waser, J. Cyclic Hypervalent Iodine Reagents: Enabling Tools for Bond Disconnection via Reactivity Umpolung. *Acc. Chem. Res.* **2018**, *51*, 3212.

(10) (a) Stridfeldt, E.; Seemann, A.; Bouma, M. J.; Dey, C.; Ertan, A.; Olofsson, B. Synthesis, Characterization and Unusual Reactivity of Vinylbenziodoxolones—Novel Hypervalent Iodine Reagents. *Chem.*

Eur. J. **2016**, *22*, 16066. For further applications of the reagents, see: (b) Boelke, A.; Caspers, L. D.; Nachtseim, B. J. NH_2 -Directed C–H Alkenylation of 2-Vinylanilines with Vinylbenziodoxolones. *Org. Lett.* **2017**, *19*, 5344. (c) Davies, J.; Sheikh, N. S.; Leonori, D. Photoredox Imino Functionalizations of Olefins. *Angew. Chem. Int. Ed.* **2017**, *56*, 13361; (d) Le Vaillant, F.; Garreau, M.; Nicolai, S.; Gryn'ova, G.; Corminboeuf, C.; Waser, J. Fine-Tuned Organic Photoredox Catalysts for Fragmentation-Alkynylation Cascades of Cyclic Oxime Ethers. *Chem. Sci.* **2018**, *9*, 5883.

(11) Aryl-VBX reagents were obtained in good yields using Olofsson's protocol (Ref. 10a). This method gave alkyl-VBX reagents in low yield only and a new method was developed to access this class of compounds. See Supporting Information for details.

(12) The structure of **5c** was confirmed by X-ray analysis. The data is available at the Cambridge Crystallographic Data Center (ccdc number 1897009).

(13) (a) Enders, D.; Vignola, N.; Berner, O. M.; Harnying, W. Efficient Asymmetric Synthesis of α -Alkylated Benzylic Methyl Sulfonates. *Tetrahedron* **2005**, *61*, 3231. (b) Le Flohic, A.; Meyer, C.; Cossy, J. Reactivity of Unsaturated Sulfones Synthesized from Unsaturated Alcohols by Ring-Closing Metathesis. Application to the Racemic Synthesis of the Originally Proposed Structure of Mycothiazole. *Tetrahedron* **2006**, *62*, 9017. (c) Rowe, B. J.; Spilling, C. D. Stereospecific Pd(0)-Catalyzed Arylation of an Allylic Hydroxy Phosphonate Derivative: Formal Synthesis of (*S*)-(+)-ar-Turmerone. *J. Org. Chem.* **2003**, *68*, 9502. (d) Yan, B.; Spilling, C. D. Synthesis of Cyclopentenones via Intramolecular HWE and the Palladium-Catalyzed Reactions of Allylic Hydroxy Phosphonate Derivatives. *J. Org. Chem.* **2008**, *73*, 5385.

(14) *Organofluorine Chemistry*; Banks, R. E., Smart, B. E., Tatlow, J. C., Eds.; Springer US: Boston, MA, 1994.

(15) Hansen, J. H.; Davies, H. M. L. Vinylogous Reactivity of Silver(I) Vinylcarbenoids. *Chem. Sci.* **2011**, *2*, 457.

(16) This result contrasts with the excellent e.r. obtained in the corresponding alkynylation using a very similar catalyst system. Nevertheless, this is not so surprising, considering that the geometry of the alkenyl and the alkynyl reagents, as well as in a lesser measure their reactivity, are very different, leading to different interactions with the ligands in the transition state. Obviously, another type of ligands will be needed to achieve high enantioinduction in this case.

(17) This approach was also successful for the development of the first three-component oxyalkynylation of diazo compounds (Ref. 8c).

(18) Sawama, Y.; Nagata, S.; Yabe, Y.; Morita, K.; Monguchi, Y.; Sajiki, H. Iron-Catalyzed Chemoselective Azidation of Benzylic Silyl Ethers. *Chem. Eur. J.* **2012**, *18*, 16608.

(19) This part of the work has previously appeared in a preprint: Pisella, G.; Gagnebin, A.; Waser, J. Copper-Catalyzed Insertion of Diazo Compounds into Vinyl Hypervalent Iodine Reagents to Generate Allylic Esters. *ChemRxiv.* **2019**, Preprint. <https://doi.org/10.26434/chemrxiv.7892513.v1>.

Copper-Catalyzed Oxyvinylation of Diazo Compounds

Guillaume Pisella, Alec Gagnebin and Jerome Waser

Laboratory of Catalysis and Organic Synthesis, Ecole Polytechnique Fédérale de Lausanne,
EPFL SB ISIC LCSO, BCH 4306, 1015 Lausanne, Switzerland.

Supporting Information

(159 pages)

Author contributions: G. P. performed and planned the experiments and prepared the manuscript and the experimental part, A. G. performed the experiments as a laboratory technician in formation under the supervision of G. P., J. W. supervised the project, prepared the manuscript and corrected the experimental part.

Table of Contents

1. General Methods.....	2
2. Synthesis of diazo compounds	3
3. Synthesis of ligands	11
4. Preparation of VBX reagents	14
5. Optimization of the reaction	36
6. Reaction mechanism	39
7. Oxy-vinylation reaction with VBX reagents.....	40
8. Product modifications	59
9. Enantioselective transformation	64
10. Crystals data	67
11. Spectra of new compounds.....	69

1. General Methods

All reactions were carried out in oven dried glassware under an atmosphere of nitrogen, unless stated otherwise. Heating was realized using heating blocks/mantles with external temperature control, unless indicated otherwise. For quantitative flash chromatography technical grade solvents were used. For flash chromatography for analysis, HPLC grade solvents from Sigma-Aldrich were used. THF, Et₂O, CH₃CN, toluene, hexane and CH₂Cl₂ were dried by passage over activated alumina under nitrogen atmosphere (H₂O content < 10 ppm, *Karl-Fischer* titration). The solvents were degassed by Freeze-Pump-Thaw method when mentioned. All chemicals were purchased from Acros, Aldrich, Fluka, VWR, Aplichem or Merck and used as such unless stated otherwise. Chromatographic purification was performed as flash chromatography using Macherey-Nagel silica 40-63, 60 Å, using the solvents indicated as eluent with 0.1-0.5 bar pressure. TLC was performed on Merck silica gel 60 F254 TLC aluminium plates and visualized with UV light, permanganate stain, CAN stain or Anisaldehyde stain. Melting points were measured on a Büchi B-540 melting point apparatus using open glass capillaries, the data is uncorrected. ¹H NMR spectra were recorded on a Bruker DPX-400 400 MHz spectrometer in CDCl₃, DMSO-*d*₆ or CD₃OD, all signals are reported in ppm with the internal chloroform signal at 7.26 ppm, the internal DMSO signal at 2.50 ppm or the internal methanol signal at 3.30 ppm as standard. The data is being reported as (s = singlet, d = doublet, t = triplet, q = quadruplet, qi = quintet, m = multiplet or unresolved, br = broad signal, app = apparent, coupling constant(s) in Hz, integration, interpretation). ¹³C NMR spectra were recorded with ¹H-decoupling on a Bruker DPX-400 100 MHz spectrometer in CDCl₃, DMSO-*d*₆ or CD₃OD, all signals are reported in ppm with the internal chloroform signal at 77.0 ppm, the internal DMSO signal at 39.5 ppm or the internal methanol signal at 49.0 ppm as standard. Infrared spectra were recorded on a JASCO FT-IR B4100 spectrophotometer with an ATR PRO410-S and a ZnSe prisma and are reported as cm⁻¹ (w = weak, m = medium, s = strong, br = broad). High resolution mass spectrometric measurements were performed by the mass spectrometry service of ISIC at the EPFL on a MICROMASS (ESI) Q-TOF Ultima API (Waters) or (APPI) LTQ Orbitrap ELITE ETD (Thermo Fisher). The raw data obtained from the Q-TOF Waters instrument does not take into account the mass of the electron for the ion, the obtained raw data has been therefore corrected by removing the mass of the electron (5 mDa). HPLC measurements were done on a Agilent 1260 Infinity autosampler using a CHIRALPAK IA, IB, IC or ID column from DAICEL Chemical. The diffraction data for crystal structures were collected at low temperature using Cu (323) or Mo (520) *K*_α radiation on a Rigaku SuperNova dual system in combination with Atlas type CCD detector. The data reduction and correction were carried out by *CrysAlis^{Pro}*.¹ The solutions and refinements were performed by *SHELXT*² and *SHELXL*³, respectively. The crystal structures were refined using full-matrix least-squares based on *F*² with all non-H atoms defined in anisotropic manner. Hydrogen atoms were placed in calculated positions by means of the “riding” model. The blue LEDs were bought on www.conrad.ch/fr (Ruban LED avec câble à extrémités ouvertes Barthelme Y51516414 182405 24 V 502 cm bleu 1 pc(s)).

¹ *CrysAlis^{Pro}*, Rigaku Oxford Diffraction, release 1.171.40.68a, 2019.


² *SHELXT* - Integrated space-group and crystal-structure determination, G. M. Sheldrick, *Acta Crystallogr., Sect. A* 2015, 71, 3.

³ *SHELXL* - Crystal structure refinement, G. M. Sheldrick, *Acta Crystallogr., Sect. C* 2015, 71, 3.


2. Synthesis of diazo compounds

CAUTION: Diazo compounds are toxic and potentially explosive and should be handled with care in a well-ventilated hood.⁴

Ethyl 2-diazoacetate (**2a**), *tert*-butyl 2-diazoacetate (**2c**) and benzyl 2-diazoacetate (**2e**) were directly purchased from Sigma Aldrich.




Ethyl 2-diazo-2-phenylacetate (**4b**)



Following a reported procedure,⁵ DBU (1.50 mL, 10.0 mmol, 2.00 equiv) was added slowly to a stirred solution of ethyl 2-phenylacetate (**16**) (0.80 mL, 5.0 mmol, 1.00 equiv) and *p*-ABSA (1.80 g, 7.50 mmol, 1.50 equiv) in dry MeCN (20 mL) at 0 °C. The reaction mixture was then allowed to warm to room temperature. After stirring for 14 h, the reaction mixture was quenched with water (15 mL), and extracted with diethyl ether (3 x 15 mL). The organic layers were combined and washed with 10% NH₄Cl (20 mL), brine (20 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography using EtOAc:pentane 3:97 as mobile phase affording the corresponding ethyl 2-diazo-2-phenylacetate (**2b**) as a red oil (0.80 g, 4.2 mmol, 84%). ¹H NMR (400 MHz, CDCl₃): δ 7.53 - 7.45 (m, 2H, ArH), 7.43 - 7.35 (m, 2H, ArH), 7.22 - 7.14 (m, 1H, ArH), 4.34 (q, *J* = 7.1 Hz, 2H, OCH₂CH₃), 1.35 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃). ¹³C NMR (101 MHz, CDCl₃): δ 165.2, 128.8, 125.6, 125.6, 124.0, 61.1, 14.6. The values of the NMR spectra are in accordance with reported literature data.⁶ One carbon was not resolved at 101 MHz.

2,6-Di-*tert*-butyl-4-methylphenyl 2-diazoacetate (**2d**)



Following a reported procedure,⁷ a mixture of 2,6-di-*tert*-butyl-4-methylphenol (**16**) (5.51 g, 25.0 mmol, 1.00 equiv), 2,2,6-trimethyl-4*H*-1,3-dioxin-4-one (**17**) (3.32 mL, 25.0 mmol, 1.00 equiv), and xylene (5 mL) was stirred at 140 °C for 1.5 h. After cooling to room temperature, the reaction mixture was directly loaded on silica and was purified by column chromatography using EtOAc:pentane 2:98 as mobile phase to afford 2,6-di-*tert*-butyl-4-methylphenyl 3-oxobutanoate (**18**) as a white solid (5.77 g,

⁴ S. P. Green, K. M. Wheelhouse, A. D. Payne, J. P. Hallett, P. W. Miller and J. A. Bull, *Org. Process Res. Dev.* **2020**, *24*, 67.

⁵ O. A. Davis, R. A. Croft and J. A. Bull, *Chem. Commun.*, **2015**, *51*, 15446.


⁶ H. Keipour and T. Ollevier, *Org. Lett.*, **2017**, *19*, 5736.

⁷ P. Müller and P. Polleux, *Helv. Chim. Acta* **1994**, *77*, 645.

19.0 mmol, 76%). colorless thick oil (5.00 g, 19.1 mmol, 76%). ¹H NMR (400 MHz, CDCl₃): δ 12.08 (s, 0.22H, OH of enol form), 7.31 - 7.24 (m, 1H, ArH of enol and keto form), 7.24 - 7.18 (m, 2H, ArH of enol and keto form), 5.38 (s, 0.2H, vinyl H of enol form), 3.81 (s, 1.56H, CH₃COCH₂ of keto form), 3.03 (m, 2H, 2 x CH(CH₃)₂ of enol and keto form), 2.41 (s, 2.32H, CH₃COCH₂ of keto form), 2.08 (s, 0.6H, CH₃ of enol form), 1.28 - 1.21 (m, 12H, 2 x CH(CH₃)₂); ¹³C NMR (101 MHz, CDCl₃), Enol form: δ 177.7, 171.5, 144.5, 140.5, 126.5, 123.9, 88.7, 23.7, 22.7, 21.4; ¹³C NMR (101 MHz, CDCl₃), Keto form: δ 199.9, 165.7, 145.1, 140.2, 126.8, 124.0, 49.6, 30.4, 27.4, 27.3. The values of the NMR spectra are in accordance with reported literature data.⁸

Following a reported procedure,⁷ to a solution of 2,6-di-*tert*-butyl-4-methylphenyl 3-oxobutanoate (**18**) (5.48 g, 18.00 mmol, 1.00 equiv) in MeCN (22 mL) was added triethylamine (3.26 mL, 23.40 mmol, 1.30 equiv). The reaction mixture was cooled in an ice bath and a solution of tosyl azide (3.9 g, 19.8 mmol, 1.1 equiv) in MeCN (22 mL) was added slowly. The reaction mixture was allowed to warm to room temperature and stirred for 20 h. 8% aqueous KOH solution (90 mL) was added and stirred vigorously for 4 h. The reaction mixture was diluted with water (50 mL), extracted with diethyl ether (3 x 100 mL). The combined organic layers were dried over MgSO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography using Et₂O:pentane 2:98 as mobile phase to afford 2,6-di-*tert*-butyl-4-methylphenyl 2-diazoacetate (**2d**) as a yellow solid (4.80 g, 16.64 mmol, 92%). ¹H NMR (400 MHz, CDCl₃): δ 7.12 (s, 2H, ArH), 5.00 (s, 1H, CHN₂), 2.32 (s, 3H, ArCH₃), 1.36 (s, 18H, 2 x *t*Bu); ¹³C NMR (101 MHz, CDCl₃): δ 166.3, 145.1, 142.4, 134.8, 127.0, 47.3, 35.3, 31.5, 21.5. The values of the NMR spectra are in accordance with reported literature data.⁹

Allyl 2-diazoacetate (**2f**)



Following a reported procedure,¹⁰ to a solution of allyl acetoacetate (**19**) (1.10 mL, 8.00 mmol, 1.00 equiv) and 4-acetamidobenzenesulfonyl azide (2.11 g, 8.80 mmol, 1.10 equiv) in MeCN (40 mL) at 0 °C was added dropwise Et₃N (2.23 mL, 16.0 mmol, 2.00 equiv). The reaction mixture was allowed to warm to room temperature and stirred for 3 h. The solvent was removed under reduced pressure. The residue was suspended in diethyl ether (50 mL) and the solid removed by filtration. The solvent was removed under reduced pressure. The crude product was purified by column chromatography using EtOAc:pentane 15:85 as mobile phase to afford allyl 2-diazo-3-oxobutanoate (**20**) as a yellow oil (1.23 g, 7.34 mmol, 92%). ¹H NMR (400 MHz, CDCl₃): δ 5.94 (ddt, *J* = 17.2, 10.4, 5.8 Hz, 1H, CHCH₂), 5.40 - 5.26 (m, 2H, CHCH₂), 4.73 (dt, *J* = 5.8, 1.3 Hz, 2H, CH₂O), 2.48 (s, 3H, CH₃); ¹³C NMR (101 MHz, CDCl₃): δ 190.2, 161.2, 131.6, 119.3, 66.0, 28.4. One carbon was not resolved at 101 MHz. The values of the NMR spectra are in accordance with reported literature data.¹⁰

To a solution of allyl 2-diazo-3-oxobutanoate (**20**) (0.840 g, 5.00 mmol, 1.00 equiv) in MeCN (15 mL) was added 8% aqueous KOH solution (25 mL) and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with water (15 mL), extracted with diethyl ether (3 x 30 mL). The combined organic layers were dried over MgSO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography using EtOAc:pentane 10:90 as


⁸ D. P. Hari and J. Waser, *J. Am. Chem. Soc.*, 2017, **139**, 8420.

⁹ M. P. Doyle, V. Bagheri, T. J. Wandless, N. K. Harn, D. A. Brinker, C. T. Eagle and K. L. Loh, *J. Am. Chem. Soc.* **1990**, *112*, 1906.

¹⁰ P. Müller, Y. F. Allenbach and S. Grass, *Tetrahedron: Asymmetry*, 2005, **16**, 2007.


mobile phase to afford allyl 2-diazoacetate (**2f**) as a yellow oil (154 mg, 1.22 mmol, 24%). ¹H NMR (400 MHz, CDCl₃): δ 5.92 (ddt, *J* = 17.2, 10.4, 5.7 Hz, 1H, CHCH₂), 5.38 - 5.20 (m, 2H, CHCH₂), 4.77 (s, 1H, CHN₂), 4.65 (dt, *J* = 5.7, 1.5 Hz, 2H, CH₂O); ¹³C NMR (101 MHz, CDCl₃): δ 166.6, 132.4, 118.5, 65.2, 46.4. The values of the NMR spectra are in accordance with reported literature data.¹¹

2-Diazo-*N,N*-diethylacetamide (**2g**)



Following a reported procedure,¹² diethyl amine (**21**) (0.73 g, 10 mmol, 1.0 equiv) and NaHCO₃ (2.52 g, 30.0 mmol, 3.00 equiv) were dissolved in dry CH₂Cl₂ (20 mL) and bromoacetyl bromide (**22**) (1.75 mL, 20.0 mmol, 2.00 equiv) was added slowly at 0 °C and the reaction was stirred for 6 h at room temperature, quenched with 100 mL of H₂O and the solution was extracted with CH₂Cl₂ (3 x 50 mL). The combined organic layers were washed with water (100 mL) and dried over MgSO₄, the solvent was evaporated and the residue was used in the next step without purification. The resulting 2-bromo-*N,N*-diethylacetamide (**23**) and *N,N'*-ditosylhydrazine (2.10 g, 6.08 mmol, 0.60 equiv) were dissolved in dry THF (20 mL) and cooled down to 0 °C, then DBU (2.30 mL, 15.2 mmol, 1.52 equiv) was added dropwise and stirred at room temperature for 1 h and then quenched with saturated solution of NaHCO₃ (50 mL) and extracted with diethyl ether (3 x 50 mL). The combined organic layers were dried over anhydrous MgSO₄. The solvent was removed under reduced pressure and purified by column chromatography using EtOAc:pentane 30:70 as mobile phase affording the corresponding 2-diazo-*N,N'*-diethylacetamide (**2g**) as a yellow oil (0.725 g, 5.14 mmol, 52%). ¹H NMR (400 MHz, CDCl₃): δ 4.92 (s, 1H, CHN₂), 3.26 (br s, 4H, 2 x CH₂CH₃), 1.14 (t, *J* = 7.2 Hz, 6H, 2 x CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃): 165.8, 46.4, 41.4, 13.9. The values of the NMR spectra are in accordance with reported literature data.¹³

2-Diazo-*N*-methoxy-*N*-methylacetamide (**2h**)



Following a reported procedure,¹⁴ a mixture of *N,O*-dimethylhydroxylamine hydrochloride (**24**) (2.44 g, 25.0 mmol, 1.00 equiv), 2,2,6-trimethyl-4*H*-1,3-dioxin-4-one (**17**) (5.00 mL, 37.5 mmol, 1.50 equiv) and triethylamine (3.85 mL, 27.5 mmol, 1.10 equiv) was dissolved in toluene (75 mL) and refluxed for 2 h. The reaction mixture was cooled to room temperature and washed with aqueous hydrochloric acid (90 mL, 1.0 M) and the aqueous layer was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were dried over MgSO₄ and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography using EtOAc:pentane 50:50 as mobile phase to afford *N*-methoxy-*N*-methyl-3-oxobutanamide (**25**) as a yellow oil (2.40 g, 16.5 mmol, 66%). ¹H NMR (400 MHz, CDCl₃): δ 13.65 (s, 0.13H, OH of enol form), 5.32 (s, 0.13H, vinyl *H* of enol form) 3.60 (s, 3H, OCH₃), 3.50 (s, 1.74H, CH₃COCH₂ of keto form), 3.13 (s, 2.6H, *N*-CH₃ of keto form), 3.11 (s, 0.4H, enol


¹¹ M. Bolsønes, H. T. Bonge-Hansen and T. Bonge-Hansen, *Synlett*, 2014, **25**, 221.

¹² S. Chanthamath, S. Thongjareun, K. Shibatomi and S. Iwasa, *Tetrahedron Lett.* **2012**, *53*, 4862.

¹³ D. Gauthier, R. H. Dodd and P. Dauban, *Tetrahedron* **2009**, *65*, 8542.

¹⁴ S. Müller, F. Sasse and M. E. Maier, *Eur. J. Org. Chem.* **2014**, 1025.


Diethyl (diazomethyl)phosphonate (2j)



Following a reported procedure,¹⁷ a mixture of diethyl (2-oxopropyl)phosphonate (**29**) (1.15 mL, 6.00 mmol, 1.00 equiv), tosyl azide (1.3 g, 6.6 mmol, 1.10 equiv) and triethylamine (6 mL) was stirred at room temperature for 18 h. After evaporation of the triethylamine under reduced pressure, the residue was dissolved in diethyl ether (50 mL). The precipitate was filtered off, the filtrate was evaporated and the residue was purified by column chromatography using EtOAc:pentane 50:50 as mobile phase affording the corresponding diethyl (1-diazo-2-oxopropyl)phosphonate (**30**) as a yellow oil (0.810 g, 3.68 mmol, 61%). ¹H NMR (400 MHz, CDCl₃): δ 4.04 - 4.19 (m, 4H, 2 x CH₂CH₃) 2.19 (s, 3H, CH₃), 1.30 (t, *J* = 7.0 Hz, 6H, 2 x CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃): δ 190.1 (d, *J* = 13.2 Hz), 63.4 (d, *J* = 5.6 Hz), 27.1, 16.0 (d, *J* = 6.8 Hz). The values of the NMR spectra are in accordance with reported literature data.¹⁴

Following a reported procedure,⁸ to a solution of diethyl (1-diazo-2-oxopropyl)phosphonate (**30**) (694 mg, 3.15 mmol, 1.00 equiv) in MeOH (9.0 mL) was added Na₂CO₃ (401 mg, 3.78 mmol, 1.20 equiv). The mixture was stirred at room temperature for 15 min. The precipitate was filtered off, the filtrate was evaporated and the residue was purified by column chromatography using EtOAc:pentane 50:50 as mobile phase affording the corresponding diethyl (diazomethyl)phosphonate (**2j**) as a yellow oil (533 mg, 2.99 mmol, 95%). ¹H NMR (400 MHz, CDCl₃): δ 4.17 - 4.08 (m, 4H, 2 x CH₂CH₃), 3.75 (d, *J* = 11.1 Hz, 1H, CHN₂), 1.34 (td, *J* = 7.1, 0.7 Hz, 6H, 2 x CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃): δ 62.6 (d, *J* = 5.3 Hz), 16.1 (d, *J* = 6.9 Hz). The values of the NMR spectra are in accordance with reported literature data.¹⁴ One carbon was not resolved at 101 MHz.

2,2,2-Trifluorodiazoethane (2k)




Following a reported procedure,¹⁸ under argon, 2,2,2-trifluoroethanamine hydrochloride (**31**) (0.678 g, 5.00 mmol, 1.00 equiv) and sodium nitrite (0.379 g, 5.50 mmol, 1.10 equiv) were dissolved in degassed CH₂Cl₂ (10 mL). Degassed water (1.00 mL, 55.5 mmol, 11.1 equiv) was added slowly at 0 °C. The solution was stirred for 2 h at 0 °C and 1 h at room temperature. The aqueous layer was frozen in the freezer overnight (-18 °C) and the organic layer was dried over a plug of potassium carbonate, transferred into a vial, sealed and stored at -18 °C. The concentration of the obtained solution was determined to be 0.37 M by ¹⁹F NMR analysis (according to an internal reference, PhCF₃). ¹⁹F NMR (377 MHz, CH₂Cl₂) δ -55.56. The values of the NMR spectra are in accordance with reported literature data.¹⁸

¹⁷ S. Chanthamath, S. Ozaki, K. Shibatomi and S. Iwasa, *Org. Lett.* **2014**, *16*, 3012.


¹⁸ S. Hyde, J. Veliks, B. Liégault, D. Grassi, M. Taillefer and V. Gouverneur, *Angew. Chem. Int. Ed.*, **2016**, *55*, 3785.

Ethyl 2-diazopropanoate (**2l**)



Following a reported procedure,¹⁹ DBU (1.8 mL, 12 mmol, 3.0 equiv) was added slowly to a stirred solution of ethyl 2-methylacetoacetate (**32**) (0.60 mL, 4.0 mmol, 1.0 equiv) and *p*-ABSA (1.4 g, 6.0 mmol, 1.5 equiv) in MeCN (80 mL) at 0 °C. The reaction mixture was then allowed to warm to room temperature. After stirring for 12 h, the reaction mixture was quenched with 1 M HCl (8 mL), and extracted with hexane (3 x 40 mL). The organic layers were combined, washed with a saturated solution of NaHCO₃ (40 mL), brine (40 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography using Et₂O:pentane 2:98 as mobile phase affording the corresponding ethyl 2-diazopropanoate (**2l**) as a yellow oil (241 mg, 1.88 mmol, 47%). ¹H NMR (400 MHz, CDCl₃): δ 4.20 (q, *J* = 7.1 Hz, 2H, CH₂CH₃), 1.94 (s, 3H, N₂CCH₃), 1.25 (t, *J* = 7.1 Hz, 3H, CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃): δ 167.9, 60.7, 14.5, 8.4. The values of the NMR spectra are in accordance with reported literature data.²⁰ One carbon was not resolved at 101 MHz.

3-Diazodihydrofuran-2(3H)-one (**2m**)




Following a reported procedure,²¹ sodium azide (2.42 g, 37.2 mmol, 4.00 equiv), sodium hydroxide (78 mL, 2 M in water), tetrabutylammonium bromide (30.0 mg, 0.09 mmol, 0.01 equiv) and pentane (40 mL) were mixed in a 250 mL round-bottom flask with magnetic stir bar open to the air and allowed to cool to 0 °C. With vigorous stirring, Tf₂O (3.10 mL, 18.6 mmol, 2.00 equiv) was added dropwise. After 10 min, a solution of 2-acetyl-butylolactone (**33**) (1.00 mL, 9.30 mmol, 1.00 equiv) in MeCN (35 mL) was poured into the round-bottom flask through a funnel, followed by an additional MeCN (10 mL) to complete the transfer. The initially colorless reaction mixture immediately turned yellow. After allowing to stir for 30 min at 0 °C, the mixture was diluted with ice water (25 mL) and chilled EtOAc (25 mL) and transferred to a separatory funnel. After phase separation and removal of the organic layer, the aqueous layer was washed with cold EtOAc (2 x 50 mL). The combined organic layers were dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography using EtOAc:pentane 50:50 as mobile phase affording the corresponding 3-diazodihydrofuran-2(3H)-one (**2m**) as a bright yellow crystalline solid (0.32 g, 2.8 mmol, 30%). ¹H NMR (400 MHz, CDCl₃): δ 4.38 (t, *J* = 8.0 Hz, 2H, CH₂), 3.36 (t, *J* = 8.0 Hz, 2H, CH₂); ¹³C NMR (101 MHz, CDCl₃): 170.6, 65.3, 49.4, 23.1. The values of the NMR spectra are in accordance with reported literature data.²¹

¹⁹ T. Hashimoto, Y. Naganawa and K. Maruoka, *J. Am. Chem. Soc.* **2011**, *133*, 8834.

²⁰ L. Huang and W. D. Wulff *J. Am. Chem. Soc.* **2011**, *133*, 8892.


²¹ E. S. Sattely, S. J. Meek, S. J. Malcolmson, R. R. Schrock and A. H. Hoveyda, *J. Am. Chem. Soc.* **2009**, *131*, 943.

Methyl (*E*)-2-diazopent-3-enoate (**2n**)



Following a reported procedure,²² to a stirring solution of methyl trans-pent-3-enoate (**34**) (1.00 g, 8.76 mmol, 1.00 equiv) and *p*-ABSAs (3.16 g, 13.1 mmol, 1.50 equiv) in dry MeCN (20 mL) at 0 °C, was added DBU (2.65 mL, 17.5 mmol, 2.00 equiv) slowly in 5 min. The reaction mixture was stirred at 0 °C for 1 h and then 12 h at room temperature. The reaction mixture was quenched with NH₄Cl (saturated solution, 20 mL). The aqueous layer was extracted with Et₂O (3 x 40 mL) and the combined organic layers were washed with brine (40 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography using pentane as mobile phase affording the corresponding methyl (*E*)-2-diazopent-3-enoate (**2n**) as an orange oil (950 mg, 6.78 mmol, 77%). ¹H NMR (400 MHz, CDCl₃): δ 5.73 (dd, *J* = 15.8, 1.7 Hz, 1H, CH₃CHCH), 5.38 - 5.29 (m, 1H, CH₃CHCH), 3.79 (s, 3H, OCH₃), 1.84 (dd, *J* = 6.7, 1.7 Hz, 3H, CH₃CHCH); ¹³C NMR (101 MHz, CDCl₃): δ 166.1, 120.4, 112.6, 52.0, 18.2. The values of the NMR spectra are in accordance with reported literature data.²² One carbon was not resolved at 101 MHz.

Furan-2-ylmethyl 2-diazoacetate (**2o**)




Following a reported procedure,²³ to a solution of *p*-toluenesulfonylhydrazone of glyoxylic acid chloride (**36**) (1.30 g, 5.00 mmol, 1.00 equiv.) in CH₂Cl₂ (10 mL) were added furfuryl alcohol (**35**) (475 μL, 5.50 mmol, 1.10 equiv.) and then DBU (1.89 mL, 12.5 mmol, 2.50 equiv.) dropwise at 0 °C. After stirring for 2 h at the same temperature, the reaction was stirred 30 min at room temperature and then poured into saturated NH₄Cl solution (10 mL). The organic layer was then extracted with CH₂Cl₂ (3 x 10 mL), washed with brine (20 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography using EtOAc/pentane 3:97 as eluent to afford furan-2-ylmethyl 2-diazoacetate (**2o**) as a yellow oil (534 mg, 3.21 mmol, 64%). ¹H NMR (400 MHz, CDCl₃) δ 7.42 (dd, *J* = 1.9, 0.9 Hz, 1H, ArH), 6.42 (dd, *J* = 3.3, 0.8 Hz, 1H, ArH), 6.36 (dd, *J* = 3.3, 1.8 Hz, 1H, ArH), 5.14 (s, 2H, CH₂O), 4.78 (br s, 1H, CN₂H); ¹³C NMR (101 MHz, CDCl₃) δ 166.6, 149.5, 143.5, 111.0, 110.7, 58.3, 46.5. The values of the NMR spectra are in accordance with reported literature data.²⁴

²² H. M. L. Davies and A. M. Walji, *Angew. Chem., Int. Ed.* **2005**, *44*, 1733.

²³ T. Hashimoto, N. Uchiyama and K. Maruoka, *J. Am. Chem. Soc.* **2008**, *130*, 14380.

²⁴ S. Bew, P.-A. Ashford and D. Bachera, *Synthesis* **2013**, *45*, 903.

4-(1-Diazo-2,2,2-trifluoroethyl)-1,1'-biphenyl (**2p**)



Following a reported synthesis,²⁵ a solution of 4-bromo-biphenyl (**37**) (4.66 g, 20.0 mmol, 1.00 equiv.) in anhydrous THF (100 mL) was cooled to -78 °C. Then, a 2.5 M solution of *n*-butyllithium (9.60 mL, 24.0 mmol, 1.20 equiv.) in hexanes was added dropwise. The mixture was stirred for 1 h, followed by the dropwise addition of methyl 2,2,2-trifluoroacetate (**38**) (2.21 mL, 22.0 mmol, 1.10 equiv.) in 30 min. The mixture was allowed to warm up to room temperature, stirred for 18 h and then quenched with saturated aqueous ammonium chloride solution (50 mL). Diethyl ether (50 mL) was added and the layers were separated. The aqueous layer was extracted with diethyl ether (2 x 25 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO₄, filtrated and concentrated under reduced pressure. The residue was purified by silica gel chromatography using pentane/EtOAc 90:10 as eluent to afford 1-([1,1'-biphenyl]-4-yl)-2,2,2-trifluoroethanone (**39**) as a slight yellow oil (3.37 g, 13.5 mmol, 67%). ¹H NMR (400 MHz, CDCl₃) δ 8.20 – 8.10 (m, 2H, ArH), 7.81 – 7.74 (m, 2H, ArH), 7.68 – 7.62 (m, 2H, ArH), 7.54 – 7.41 (m, 3H, ArH); ¹³C NMR (101 MHz, CDCl₃) δ 180.3 (q, *J* = 34.8 Hz), 148.4, 139.3, 130.9 (q, *J* = 2.2 Hz), 129.3, 129.1, 128.7, 127.8, 127.5, 116.9 (q, *J* = 291.4 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ -71.3. The values of the NMR spectra are in accordance with reported literature data.²⁶

Following a reported procedure,²⁶ 1-([1,1'-biphenyl]-4-yl)-2,2,2-trifluoroethanone (**39**) (3.36 g, 13.5 mmol, 1.05 equiv.) was added to EtOH (9 mL) at room temperature followed by *p*-toluenesulfonylhydrazide (2.40 g, 12.9 mmol, 1.00 equiv.) in one portion. A condenser was then attached and the contents were heated to reflux for 12 h. After this time, the solvent was removed under reduced pressure until the beginning of the formation of a solid. Then, pentane (200 mL) was added and the precipitate was collected by filtration and washed with pentane. The solid obtained was used in the next step without purification.


Following a reported procedure,²⁶ *N'*-(1-([1,1'-biphenyl]-4-yl)-2,2,2-trifluoroethylidene)-4-methylbenzenesulfonohydrazide (**40**) was dissolved in a 0.4 M solution of potassium hydroxide (3.37 g, 60.0 mmol, 2.00 equiv.) in MeOH (17.5 mL). A condenser was attached and the reaction mixture was stirred at reflux for 0.5 h. Then, the reaction was cooled to room temperature and diluted with water (20 mL). The product was extracted with Et₂O (3 x 30 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude oil was purified by silica gel chromatography using pentane as eluent to afford 4-(1-diazo-2,2,2-trifluoroethyl)-1,1'-biphenyl (**2p**) as a red solid (1.42 g, 5.44 mmol, 50%). The compound was kept at -18 °C. *R*_f = 0.70 (pentane); ¹H NMR (400 MHz, CDCl₃) δ 7.68 – 7.62 (m, 2H, ArH), 7.62 – 7.55 (m, 2H, ArH), 7.45 (dd, *J* = 8.4, 6.9 Hz, 2H, ArH), 7.41 – 7.34 (m, 1H, ArH), 7.17 (d, *J* = 8.2 Hz, 2H, ArH); ¹³C NMR (101 MHz, CDCl₃) δ 140.2, 139.0, 129.1, 128.2, 127.7, 127.0, 125.8 (q, *J* = 269.6 Hz), 122.7, 122.4; ¹⁹F NMR (376 MHz, CDCl₃) δ -57.3. One carbon was not resolved at 101 MHz. The values of the NMR spectra are in accordance with reported literature data.²⁶

²⁵ A. S. Golubev, A. F. Shidlovskii, A. S. Peregudov and N. D. Kagramanov, *Russ Chem Bull.* **2014**, 63, 2264.


²⁶ E. Emer, J. Twilton, M. Tredwell, S. Calderwood, T. L. Collier, B. Liégault, M. Taillefer and V. Gouverneur, *Org. Lett.* **2014**, 16, 6004.

3. Synthesis of ligands

Ligand **3a** was synthesized using a simple reported procedure.²⁷ **3b** was purchased directly from TCI. **3f** was purchased directly from Sigma-Aldrich.



2,2'-(propane-2,2-diyl)bis(4,4-dimethyl-4,5-dihydrooxazole) (**3c**)



Following a reported procedure,²⁸ 2-amino-2-methylpropan-1-ol (**41**) (0.952 mL, 10.5 mmol, 2.1 equiv) was added to a suspension of K_2CO_3 (2.76 g, 20.0 mmol, 4.0 equiv) DCM (50 mL) at 0 °C under argon. A solution of dimethylmalonyl dichloride (**42**) (0.660 mL, 5.00 mmol, 1.0 equiv) in DCM (10 mL) was added dropwise to the cold mixture. The mixture was allowed to warm to room temperature and stirred for 16 h. MeOH (50 mL) was added and the mixture was stirred for 2 h. The whole reaction mixture was filtered through Celite (5 g) and rinsed twice with MeOH (2 × 10 mL). The solvent was removed under reduce pressure. The crude *N1,N3*-bis(1-hydroxy-2-methylpropan-2-yl)-2,2-dimethylmalonamide (**43**) was obtained as a white residue (1.42 g) and was used directly into the next step without further purification.


The crude bisamide (**43**) was dissolved in toluene (30 mL) and heated to 70 °C under argon. Thionyl chloride (1.50 mL, 20.0 mmol, 4.0 equiv) was added in one portion and the resulting mixture was stirred at 70 °C for 5 h. The reaction was cooled to 0 °C and quenched with a saturated $NaHCO_3$ solution (15 mL). The mixture was extracted with DCM (5 × 30 mL) and the combined organic layers were dried over $MgSO_4$, filtered and the solvent was removed under reduced pressure to furnish a pale yellow oil. The residue was dissolved in 17.0 mL of a 5% methanolic NaOH solution (0.830 g of NaOH was completely dissolved in 0.850 mL H₂O and then diluted with 16.1 mL MeOH) and heated to reflux for 2 h under argon. The solvent was removed under reduced pressure and the resulting residue was partitioned between DCM (10 mL) and H₂O (10 mL). The aqueous layer was extracted with DCM (5 × 10 mL). The combined organic layers were dried over $MgSO_4$, filtered and the solvent was removed under reduced pressure to furnish afford 2,2'-(propane-2,2-diyl)bis(4,4-dimethyl-4,5-dihydrooxazole) (**3c**) as a pale yellow wax (471 mg, 2.00 mmol, 40 %). ¹H NMR (400 MHz, $CDCl_3$) δ 3.92 (s, 4H, 2 × CH_2O), 1.49 (s, 6H, 2 × CH_3), 1.27 (s, 12H, 4 × CH_3); ¹³C NMR (101 MHz, $CDCl_3$) δ 167.6, 79.4, 67.0, 38.2, 28.0, 25.4. The values of the NMR spectra are in accordance with reported literature data.²⁹

²⁷ H. Liu, H.-L. Zhang, S.-J. Wang, A.-Q. Mi, Y.-Z. Jiang and L.-Z. Gong, *Tetrahedron-Asymmetry*, **2005**, *16*, 2901.

²⁸ M. C. Paderes and S. R. Chemler, *Eur. J. Org. Chem.*, **2011**, *2011*, 3679.

²⁹ K. M. Partridge, I. A. Guzei and T. P. Yoon, *Angew. Chem. Int. Ed.*, **2010**, *49*, 930.


(4*S*,4'*S*)-2,2'-(Cyclopropane-1,1-diyl)bis(4-(*tert*-butyl)-4,5-dihydrooxazole) (**3d**)



Following a reported procedure,³⁰ to a solution of (*S*)-*tert*-leucinol (**45**) (0.94 g, 8.0 mmol, 2.0 equiv) in DCM (40 mL) was added diethyl malonimidate dihydrochloride (**44**) (0.93 g, 4.0 mmol, 1.0 equiv). The resulting cloudy solution was stirred at room temperature for 36 h. The reaction mixture was diluted with water (8 mL) and extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine (40 mL), dried over MgSO₄, and concentrated. The resulting oily residue was distilled bulb-to-bulb (Kugelrohr distillation, 150 °C at 0.2 mbar) to afford bis((*S*)-4-(*tert*-butyl)-4,5-dihydrooxazol-2-yl)methane (**46**) as a white solid (0.600 g, 2.84 mmol, 71%). ¹H NMR (400 MHz, CDCl₃) δ 4.13 (dd, *J* = 10.1, 8.7 Hz, 2H, 2 x OCH_a), 4.02 (dd, *J* = 8.7, 7.7 Hz, 2H, 2 x C(CH₃)₃CH), 3.81 (ddt, *J* = 10.1, 7.8, 1.1 Hz, 2H, 2 x OCH_b), 3.27 (t, *J* = 1.2 Hz, 2H, O(C=N)CH₂), 0.82 (s, 18H, 2 x C(CH₃)₃); ¹³C NMR (100 MHz, CDCl₃) δ 161.5, 76.0, 69.1, 34.0, 28.4, 26.0. The values of the NMR spectra are in accordance with reported literature data.³⁰

Following a reported procedure,³⁰ to a solution of bis((*S*)-4-(*tert*-butyl)-4,5-dihydrooxazol-2-yl)methane (**46**) (75 mg, 0.28 mmol, 1.0 equiv) in THF (5 mL) in a 20 mL microwave vial, was added TMEDA (85 μL, 0.56 mmol, 2.0 equiv) and *i*-Pr₂NH (40 mL, 0.28 mmol, 1.0 equiv). The solution was cooled to -78 °C and *n*-BuLi (0.38 mL, 1.5 M in hexane, 0.56 mmol, 2.0 equiv) was added. The reaction mixture was warmed to -20 °C and stirred at that temperature for 30 minutes. The solution was cooled back to -78 °C and 1,2-dibromoethane (**47**) (25 μL, 0.28 mmol, 2.0 equiv) was added. After the addition, the cold bath was removed and the reaction mixture was allowed to stir at room temperature for an additional 16 h. The reaction mixture was quenched by the addition of sat. aq. NH₄Cl (2.5 mL) and diluted with water (2 mL) to dissolve the resulting salts. The mixture was extracted with diethyl ether (3 x 10 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO₄, and concentrated. The resulting oily residue was purified by column chromatography using EtOAc/pentane 1:2 to 1:1 as mobile phase to afford (4*S*,4'*S*)-2,2'-(cyclopropane-1,1-diyl)bis(4-(*tert*-butyl)-4,5-dihydrooxazole) (**3d**) as a white solid (42 mg, 0.14 mmol, 51%). ¹H NMR (400 MHz, CDCl₃): δ 4.18 (dd, *J* = 10.0, 8.6 Hz, 2H, 2 x OCH_a), 4.10 (dd, *J* = 8.7, 7.3 Hz, 2H, 2 x C(CH₃)₃CH), 3.82 (dd, *J* = 10.0, 7.2 Hz, 2H, 2 x OCH_b), 1.52 - 1.47 (m, 2H, 2 x CH_a of CyP), 1.30 - 1.24 (m, 2H, 2 x CH_b of CyP), 0.86 (s, 18H, 2 x C(CH₃)₃); ¹³C NMR (100 MHz, CDCl₃): δ 165.4, 75.2, 69.1, 33.8, 25.7, 18.2, 15.1. The values of the NMR spectra are in accordance with reported literature data.³⁰

2,2'-(Propane-2,2-diyl)bis(4,5-dihydrooxazole) (**3e**)



Following a reported procedure,³¹ K₂CO₃ (2.76 g, 20.0 mmol, 4.0 equiv) was suspended in DCM (50 mL) at 0 °C under argon and then ethanolamine (**47**) (0.63 mL, 10.5 mmol, 2.1 equiv) was added. A solution

³⁰ S. E. Denmark and C. M. Stiff, *J. Org. Chem.*, **2000**, *65*, 5875.


³¹ L. Miao, I. Haque, M. R. Manzoni, W. S. Tham and S. R. Chemler, *Org. Lett.*, **2010**, *12*, 4739.

of dimethylmalonyl dichloride (**48**) (0.660 mL, 5.00 mmol, 1.0 equiv) in DCM (10 mL) was added dropwise to the cold mixture. The mixture was allowed to warm to room temperature and stirred for 16 h. MeOH (50 mL) was added and the mixture was stirred for 2 h. The whole reaction mixture was filtered through Celite (5 g) and rinsed twice with MeOH (2 × 10 mL). The solvent was removed under reduced pressure. The crude *N*¹,*N*³-bis(2-hydroxyethyl)-2,2-dimethylmalonamide (**49**) was obtained as a white residue (1.12 g) and was used directly into the next step without further purification.

The crude bisamide (**49**) was dissolved in toluene (30 mL) and heated to 70 °C under argon. Thionyl chloride (1.46 mL, 20.0 mmol, 4.0 equiv) was added in one portion and the resulting mixture was stirred at 70 °C for 5 h. The reaction was cooled to 0 °C and quenched with a saturated NaHCO₃ solution (15 mL). The mixture was extracted with DCM (5 × 30 mL) and the combined organic layers were dried over MgSO₄, filtered and the solvent was removed under reduced pressure to furnish a pale yellow oil. The residue was dissolved in 17.0 mL of a 5% methanolic NaOH solution (0.830 g of NaOH was completely dissolved in 0.850 mL H₂O and then diluted with 16.1 mL MeOH) and heated to reflux for 2 h under argon. The solvent was removed under reduced pressure and the resulting residue was partitioned between DCM (10 mL) and H₂O (10 mL). The aqueous phase was extracted with DCM (5 × 10 mL). The combined organic layers were dried over MgSO₄, filtered and the solvent was removed under reduced pressure to furnish afford 2,2'-(propane-2,2-diyl)bis(4,5-dihydrooxazole) (**3e**) as a pale yellow wax (412 mg, 2.26 mmol, 45 %). ¹H NMR (400 MHz, CDCl₃) δ δ 4.28 (t, *J* = 9.5 Hz, 4H, 2 × CH₂O), 3.87 (t, *J* = 9.5 Hz, 4H, 2 × CH₂N), 1.51 (s, 6H, 2 × CH₃); ¹³C NMR (101 MHz, CDCl₃) δ δ 170.0, 68.2, 54.5, 38.8, 24.4. The values of the NMR spectra are in accordance with reported literature data.³¹

4. Preparation of VBX reagents


trans-2-Phenylvinylboronic acid (**50a**), *trans*-2-(4-Methoxyphenyl)vinylboronic acid (**50b**), *trans*-2-(4-Methylphenyl)vinylboronic acid (**50c**), *trans*-2-(4-Fluorophenyl)vinylboronic acid (**50d**), *trans*-2-[4-(Trifluoromethyl)phenyl]vinylboronic acid (**50e**), 2-Cyclohexylvinylboronic acid (**50j**), *trans*-3-Phenyl-1-propen-1-ylboronic acid (**50k**), 1-Penten-1-ylboronic acid (**50l**), 1-Cyclohexenylboronic acid (**50o**), and *trans*-2-Chloromethylvinylboronic acid (**50r**) were directly purchased from Sigma Aldrich.



The ^{13}C NMR signal for carbons attached to boron was broad or did not appear in the collected spectra due to the quadrupolar splitting of ^{11}B .³²

All boronic acids analyzed under electrospray ionization-MS analysis gave complex ionization pathways.³³ Faint signals could be obtained using APPI-MS.

(*E*)-(2-(Naphthalen-1-yl)vinyl)boronic acid (**50f**)



Following a reported procedure,³⁴ catecholborane (**52**) (640 μl , 6.00 mmol, 1.20 equiv) was added dropwise to stirring neat 1-ethynynaphthalene (**51**) (711 μl , 5.00 mmol, 1.00 equiv) at 0 °C under inert atmosphere. The reaction mixture was stirred at room temperature until the gas evolution had ceased and, then was heated to 70 °C and stirred for 3 h. The resulting thick oil was dissolved in THF (8 mL) and then slowly added to an ice-cold mixture of 1:1 Et_2O /water (25 mL) and stirred for an additional 30 minutes. The two layers were separated and the aqueous layer was extracted with Et_2O (2 x 15 mL). The combined organic layers were washed with water (5 x 15 mL), dried over MgSO_4 , filtered and the solvent was evaporated under reduced pressure. The resulting crude residue was dissolved in boiling water (70 mL). The insoluble materials were discarded by hot filtration and the aqueous filtrate was allowed to cool to room temperature. The precipitate was collected by filtration to give (*E*)-(2-(naphthalen-1-yl)vinyl)boronic acid (**50f**) as a white solid (324 mg, 1.60 mmol, 33%). ^1H NMR (400 MHz, $\text{DMSO}-d_6/\text{D}_2\text{O}$ 9:1) δ 8.21 (d, $J = 8.3$ Hz, 1H, ArH), 8.09 (d, $J = 18.2$ Hz, 1H, BCHCH), 7.93 - 7.82 (m, 2H, ArH), 7.73 (d, $J = 7.2$ Hz, 1H, ArH), 7.62 - 7.44 (m, 3H, ArH), 6.20 (d, $J = 18.2$ Hz, 1H, BCHCH); ^{13}C NMR (101 MHz, $\text{DMSO}-d_6/\text{D}_2\text{O}$ 9:1) δ 143.5, 135.6, 134.0, 131.3, 129.4, 129.3, 127.3, 126.9, 126.6, 124.2, 124.0; ^{11}B NMR (128 MHz, $\text{DMSO}-d_6/\text{D}_2\text{O}$ 9:1) δ 29.0. The ^{13}C NMR signal for the carbon attached to


³² B. Wrackmeyer, *Prog. Nucl. Magn. Reson. Spectrosc.* **1979**, *12*, 227.

³³ L. Wang, C. Dai, S. K. Burroughs, S. L. Wang and B. Wang, *Chem. Eur. J.*, **2013**, *19*, 7587.

³⁴ T. Haddad, R. Gershman, R. Dilis, D. Labaree, R. B. Hochberg and R. N. Hanson, *Bioorg. Med. Chem. Lett.*, **2012**, *22*, 5999.

boron did not appear due to the quadrupolar splitting of ^{11}B . The values of the NMR spectra are in accordance with reported literature data.³⁴

(*E*)-(2-(Thiophen-2-yl)vinyl)boronic acid (**50g**)




Following a reported procedure,³⁵ CuCl (15.0 mg, 0.150 mmol, 0.03 equiv), NaOtBu (29.0 mg, 0.300 mmol, 0.06 equiv) and DPEPhos (81.0 mg, 0.150 mmol, 0.03 equiv) were dissolved in THF (5 mL) under argon. The reaction mixture was stirred for 30 min at room temperature and then, bis(pinacolato)diboron (**53**) (1.40 g, 5.50 mmol, 1.10 equiv) and THF (2.5 mL) were added and the reaction mixture was stirred for another 10 min and then 2-ethynylthiophene (**54**) (0.475 mL, 5.00 mmol, 1.00 equiv) was added, followed by MeOH (0.405 mL, 10.0 mmol, 2.00 equiv). The reactor wall was washed with THF (1.5 mL), sealed, and stirred for 4 h. The reaction mixture was filtered through a pad of Celite, washed with EtOAc and the solvent was removed under reduced pressure. The resulting oil was purified by column chromatography using EtOAc/pentane 5:95 as mobile phase affording (*E*)-4,4,5,5-tetramethyl-2-(2-(thiophen-2-yl)vinyl)-1,3,2-dioxaborolane (**55**) as a clear yellow oil (1.07 g, 4.53 mmol, 91%). ^1H NMR (400 MHz, CDCl_3) δ 7.47 (d, $J = 18.1$ Hz, 1H, CHCHB), 7.24 (d, $J = 5.1$, 1H, ArH), 7.11 - 7.05 (m, 1H, ArH), 6.99 (dd, $J = 5.1$, 3.6 Hz, 1H, ArH), 5.91 (d, $J = 18.1$ Hz, 1H, CHCHB), 1.30 (s, 12H, 4 x CH_3); ^{13}C NMR (101 MHz, CDCl_3) δ 144.1, 141.9, 127.8, 127.8, 126.4, 83.5, 24.9. The ^{13}C NMR signal for the carbon attached to boron did not appear due to the quadrupolar splitting of ^{11}B . The values of the NMR spectra are in accordance with reported literature data.³⁵

Following a reported procedure,³⁵ (*E*)-4,4,5,5-tetramethyl-2-(2-(thiophen-2-yl)vinyl)-1,3,2-dioxaborolane (**55**) (1.00 g, 4.23 mmol, 1.00 equiv), NH_4OAc (1.63 g, 21.2 mmol, 5.00 equiv), NaIO_4 (4.53 g, 21.2 mmol, 5.00 equiv) were suspended in a mixture 1:1 acetone/water (42 mL). The resulting slurry was stirred at room temperature for 16 h. It was then diluted with EtOAc (30 mL), washed successively with water (2 x 20 mL) and brine (20 mL), dried over MgSO_4 , filtered, and concentrated under reduced pressure. The crude yellow oil was dissolved with diethyl ether (20 mL) then shaken 5 min with a basic aqueous solution of sorbitol (25 mL, 1 M sorbitol, 1 M Na_2CO_3), the aqueous layer was re-acidified with 4 M HCl (25 mL, pH = 2) and extracted with diethyl ether (35 mL). The organic layer was dried over MgSO_4 , filtered and the solvent was removed under reduced pressure affording (*E*)-(2-(thiophen-2-yl)vinyl)boronic acid (**50g**) as a clear yellow solid (0.416 g, 2.70 mmol, 64%). M.p. 118-120 $^\circ\text{C}$; ^1H NMR (400 MHz, $\text{DMSO}-d_6/\text{D}_2\text{O}$ 9:1) δ 7.47 (d, $J = 5.1$ Hz, 1H, ArH), 7.36 (d, $J = 18.1$ Hz, 1H, CHCHB), 7.14 (m, 1H, ArH), 7.04 (dd, $J = 5.1$, 3.5 Hz, 1H, ArH), 5.80 (d, $J = 18.1$ Hz, 1H, CHCHB); ^{13}C NMR (101 MHz, $\text{DMSO}-d_6/\text{D}_2\text{O}$ 9:1) δ 144.0, 138.8, 128.2, 127.6, 126.4, 122.6 (br); ^{11}B NMR (128 MHz, $\text{DMSO}-d_6/\text{D}_2\text{O}$ 9:1) δ 28.5. The ^{13}C NMR signal for the carbon attached to boron was broad due to the quadrupolar splitting of ^{11}B . The values of the NMR spectra are in accordance with reported literature data.³⁶

(*E*)-(6-Methoxy-6-oxohex-1-en-1-yl)boronic acid (**50m**)


³⁵ C. Feng, H. Wang, L. Xua and P. Li, *Org. Biomol. Chem.*, **2015**, *13*, 7136.

³⁶ S. Liu and L. S. Liebeskind, *J. Am. Chem. Soc.*, **2008**, *130*, 6918.



Following a reported procedure,³⁷ a solution of 1 M dibromoborane dimethyl sulfide complex in DCM (6.00 mL, 6.00 mmol, 1.2 equiv) was added dropwise to neat methyl hex-5-ynoate (**56**) (631 mg, 5.00 mmol, 1.00 equiv) at 0 °C. The resulting solution was allowed to warm to room temperature. After stirring for 4 h, the solution was transferred slowly to an ice-cooled mixture of 2:1 diethyl ether/water (18 mL) and stirred vigorously for 15 min. The mixture was diluted with diethyl ether (20 mL) and extracted with water (2 x 10 mL). The organic layer was then shaken 5 min with a basic aqueous solution of sorbitol (25 mL, 1 M sorbitol, 1 M Na₂CO₃), the aqueous layer was re-acidified with 4 M HCl (25 mL, pH = 2) and extracted with diethyl ether (35 mL). The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure affording (*E*)-(6-methoxy-6-oxohex-1-en-1-yl)boronic acid (**50m**) as a light brown oil (517 mg, 3.01 mmol, 60 %). ¹H NMR (400 MHz, DMSO-*d*₆/D₂O 9:1) δ 6.38 (dt, *J* = 17.9, 6.4 Hz, 1H, CHCHCH₂), 5.30 (dt, *J* = 17.9, 1.6 Hz, 1H, BCHCH), 3.55 (s, 3H, OCH₃), 2.26 (t, *J* = 7.4 Hz, 2H, CH₂CO₂Me), 2.10 - 2.00 (m, 2H, CH₂BCC), 1.59 (p, *J* = 7.4 Hz, 2H, CH₂CH₂CH₂); ¹³C NMR (101 MHz, DMSO-*d*₆/D₂O 9:1) δ 174.4, 150.1, 125.2 (br), 51.8, 34.5, 33.0, 23.6. The ¹³C NMR signal for the carbon attached to boron was broad due to the quadrupolar splitting of ¹¹B. The values of the NMR spectra are in accordance with reported literature data.³⁷


(*E*)-(5-Chloropent-1-en-1-yl)boronic acid (**50n**)



A solution of 1 M dibromoborane dimethyl sulfide complex in DCM (6.00 mL, 6.00 mmol, 1.2 equiv) was added dropwise to neat 5-chloropent-1-yne (**57**) (0.523 mL, 5.00 mmol, 1.0 equiv) at 0 °C. The resulting solution was allowed to warm to room temperature. After stirring for 4 h, the solution was transferred slowly to an ice-cooled mixture of 2:1 diethyl ether/water (18 mL) and stirred vigorously for 15 min. The mixture was diluted with diethyl ether (20 mL) and extracted with water (2 x 10 mL). The organic layer was then shaken 5 min with a basic aqueous solution of sorbitol (25 mL, 1 M sorbitol, 1 M Na₂CO₃), the aqueous layer was re-acidified with 4 M HCl (25 mL, pH = 2) and extracted with diethyl ether (35 mL). The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure affording (*E*)-(5-chloropent-1-en-1-yl)boronic acid (**50n**) as a light yellow oil (461 mg, 3.11 mmol, 62 %). ¹H NMR (400 MHz, DMSO-*d*₆/D₂O 9:1) δ 6.40 (dt, *J* = 17.9, 6.5 Hz, 1H, CHCHCH₂), 5.35 (dt, *J* = 17.9, 1.5 Hz, 1H, BCHCH), 3.60 (t, *J* = 6.5 Hz, 2H, CH₂Cl), 2.19 (dtd, *J* = 7.8, 6.6, 1.6 Hz, 2H, CHCH₂CH₂), 1.79 (dq, *J* = 8.4, 6.6 Hz, 2H, CH₂CH₂Cl); ¹³C NMR (101 MHz, DMSO-*d*₆/D₂O 9:1) δ 149.0, 125.8 (br), 45.3, 32.4, 31.3; ¹¹B NMR (128 MHz, DMSO-*d*₆/D₂O 9:1) δ 27.3; IR (ν_{max}, cm⁻¹) 2961 (m), 2922 (w), 1634 (m), 1347 (s), 1305 (m), 1225 (m), 1051 (w), 998 (m), 691 (m), 652 (m); HRMS (APPI/LTQ-Orbitrap) calcd for C₅H₉BClO₂⁻ [M⁻] 147.0390; found 147.0394. The ¹³C NMR signal for the carbon attached to boron was broad due to the quadrupolar splitting of ¹¹B.

³⁷ D. Kontokosta, D. S. Mueller, H.-Y. Wang and L. L. Anderson, *Org. Lett.*, **2013**, *15*, 4830.


(E)-(3-(1,3-Dioxoisindolin-2-yl)prop-1-en-1-yl)boronic acid (50p)



Following a reported procedure,³⁵ CuCl (15.0 mg, 0.150 mmol, 0.03 equiv), NaOtBu (29.0 mg, 0.300 mmol, 0.06 equiv) and DPEPhos (81.0 mg, 0.150 mmol, 0.03 equiv) were dissolved in THF (5 mL) under argon. The reaction mixture was stirred for 30 min at room temperature and then, bis(pinacolato)diboron (**53**) (1.40 g, 5.50 mmol, 1.10 equiv) and THF (2.5 mL) were added and the reaction mixture was stirred for another 10 min and then *N*-propargylphthalimide (**58**) (0.926 g, 5.00 mmol, 1.00 equiv) was added, followed by MeOH (0.405 mL, 10.0 mmol, 2.00 equiv). The reactor wall was washed with THF (1.5 mL), sealed, and stirred for 4 h. The reaction mixture was filtered through a pad of Celite, washed with EtOAc and the solvent was removed under reduced pressure. The resulting oil was purified by column chromatography using EtOAc/pentane 15:85 as mobile phase affording (*E*)-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)isoindoline-1,3-dione (**59**) as a white solid (1.49 g, 4.75 mmol, 95%). ¹H NMR (400 MHz, CDCl₃) δ 7.85 (dd, *J* = 5.4, 3.1 Hz, 2H, ArH), 7.72 (dd, *J* = 5.5, 3.1 Hz, 2H, ArH), 6.59 (dt, *J* = 18.0, 4.5 Hz, 1H, CHCHB), 5.48 (dt, *J* = 18.0, 1.9 Hz, 1H, CHCHB), 4.38 (dd, *J* = 4.6, 1.8 Hz, 2H, CH₂N), 1.22 (s, 12H, 4 x CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 167.9, 145.4, 134.2, 132.2, 123.5, 83.5, 41.1, 24.9. The ¹³C NMR signal for the carbon attached to boron did not appear due to the quadrupolar splitting of ¹¹B. The values of the NMR spectra are in accordance with reported literature data.³⁵

Following a reported procedure,³⁵ (*E*)-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)isoindoline-1,3-dione (**59**) (1.49 g, 4.75 mmol), NH₄OAc (1.83 g, 23.7 mmol, 5.00 equiv), NaIO₄ (5.08 g, 23.7 mmol, 5.00 equiv) were suspended in a mixture 1:1 acetone/water (46 mL). The resulting slurry was stirred at room temperature for 16 h. It was then diluted with EtOAc (30 mL), washed successively with water (2 x 20 mL) and brine (20 mL), dried over MgSO₄, filtered, and concentrated under reduced pressure affording (*E*)-(3-(1,3-dioxoisindolin-2-yl)prop-1-en-1-yl)boronic acid (**50p**) as a white solid (0.805 g, 3.48 mmol, 73%). M.p. 145-147 °C; ¹H NMR (400 MHz, DMSO-*d*₆/D₂O 9:1) δ 7.95 - 7.77 (m, 4H, ArH), 6.41 (dt, *J* = 18.0, 4.3 Hz, 1H, CHCHB), 5.24 (dt, *J* = 18.0, 1.9 Hz, 1H, CHCHB), 4.22 (dd, *J* = 4.3, 1.9 Hz, 2H, CH₂N); ¹³C NMR (101 MHz, DMSO-*d*₆/D₂O 9:1) δ 168.2, 143.2, 135.2, 131.9, 124.4 (br), 123.7, 41.0; ¹¹B NMR (128 MHz, DMSO-*d*₆/D₂O 9:1) δ 26.8; IR (ν_{max}, cm⁻¹) 2985 (m), 2904 (m), 1773 (m), 1716 (s), 1427 (m), 1395 (s), 1343 (m), 1071 (s), 1055 (s), 726 (m); HRMS (APPI/LTQ-Orbitrap) calcd for C₁₁H₁₁BNO₄⁺ [M+H]⁺ 232.0776; found 232.0775. The ¹³C NMR signal for the carbon attached to boron was broad due to the quadrupolar splitting of ¹¹B.


(E)-(3-((Triisopropylsilyl)oxy)prop-1-en-1-yl)boronic acid (50q)



Following a reported procedure,³⁸ a solution of propargyl alcohol (**60**) (1.04 mL, 17.8 mmol, 1.00 equiv), imidazole (3.04 g, 44.7 mmol, 2.50 equiv), and triisopropylchlorosilane (5.73 mL, 26.8 mmol, 1.50 equiv) in DCM (30 mL) was stirred at room temperature for 16 h. The reaction mixture was diluted with DCM (30 mL) and quenched with water (10 mL). The aqueous layer was separated and extracted with DCM (2 × 15 mL). The combined organic layers were washed successively with water (2 × 15 mL) and brine (15 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography using pentane as mobile phase providing triisopropyl(prop-2-yn-1-yloxy)silane (**61**) as a colorless oil (3.23 g, 15.2 mmol, 85%). ¹H NMR (400 MHz, CDCl₃) δ 4.38 (d, *J* = 2.4 Hz, 2H, CH₂O), 2.39 (t, *J* = 2.4 Hz, 1H, CCH), 1.26 - 0.99 (m, 21H, TIPS); ¹³C NMR (101 MHz, CDCl₃) δ 82.5, 72.7, 51.7, 17.8, 12.0. The values of the NMR spectra are in accordance with reported literature data.³⁸

Catecholborane (**52**) (1.71 mL, 16.0 mmol, 1.05 equiv) was added dropwise to stirring neat triisopropyl(prop-2-yn-1-yloxy)silane (**61**) (3.23 g, 15.2 mmol, 1.00 equiv) at 0 °C under inert atmosphere. The reaction mixture was stirred at room temperature until the gas evolution had ceased and, then was heated to 70 °C and stirred for 4 h. After cooling to room temperature, the reaction mixture was diluted in Et₂O (150 mL) and 1 N NaOH (45 mL, 45 mmol) was added. After vigorous stirring for 10 min, the mixture was transferred to a separatory funnel and the layers were separated. The organic layer was washed with 1 N NaOH (60 mL), water (3 × 60 mL) and 1:1 water/brine (60 mL). The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography using Et₂O/pentane 50:50 as mobile phase affording (E)-(3-((triisopropylsilyl)oxy)prop-1-en-1-yl)boronic acid (**50q**) as a colorless oil (2.12 g, 8.21 mmol, 54%). TLC (Et₂O/pentane, 50:50): R_f = 0.37, KMnO₄; ¹H NMR (400 MHz, DMSO-*d*₆/D₂O 9:1) δ 6.46 (dt, *J* = 17.9, 3.7 Hz, 1H, CHCHB), 5.59 (dt, *J* = 17.9, 2.0 Hz, 1H, CHCHB), 4.22 (dd, *J* = 3.7, 2.0 Hz, 2H, CH₂O), 1.05 - 0.94 (m, 21H, TIPS); ¹³C NMR (101 MHz, DMSO-*d*₆/D₂O 9:1) δ 149.6, 122.0 (br), 65.1, 18.5, 12.1; ¹¹B (128 MHz, DMSO-*d*₆/D₂O 9:1) δ 26.1; IR (ν_{max}, cm⁻¹) 2942 (m), 2895 (m), 2867 (m), 1638 (m), 1462 (m), 1372 (s), 1344 (s), 1291 (s), 1258 (m), 1131 (s), 1107 (s), 1055 (m), 1017 (m), 994 (m), 953 (m), 882 (s), 771 (m), 681 (s), 663 (s), 653 (s); HRMS (APPI/LTQ-Orbitrap) calcd for C₁₂H₂₆BO₃Si⁻ [M⁻] 257.1750; found 257.1749. The ¹³C NMR signal for the carbon attached to boron was broad due to the quadrupolar splitting of ¹¹B.

(E)-(3-Methylbuta-1,3-dien-1-yl)boronic acid (50s)



Following a reported procedure,³⁹ to a flask containing Cp₂ZrHCl (64.0 mg, 0.250 mmol, 0.05 equiv) at 0 °C under argon atmosphere was added pinacolborane (**63**) (0.798 mL, 5.50 mmol, 1.10 equiv) then dropwise 2-methylbut-1-en-3-yne (**62**) (0.485 mL, 5.00 mmol, 1.00 equiv). The resulting mixture was


³⁸ M. S. Oderinde, H. N. Hunter and M. G. Organ, *Chem. Eur. J.*, **2012**, *18*, 10817.

³⁹ A. Cannillo, S. Norsikian, P. Retailleau, M.-E. T. H. Dau, B. I. Iorga and J.-M. Beau, *Chem. Eur. J.*, **2013**, *19*, 9127.

stirred at 0 °C for 30 min and then at room temperature for 24 h. The crude reaction was directly purified by column chromatography using EtOAc/pentane 2:98 as mobile phase affording 4,4,5,5-tetramethyl-2-[(1*E*)-3-methylbuta-1,3-dien-1-yl]-1,3,2-dioxaborolane (**64**) as a colorless oil (789 mg, 4.05 mmol, 81%). ¹H NMR (400 MHz, CDCl₃) δ 7.10 (d, *J* = 18.2 Hz, 1H, CHCHB), 5.56 (d, *J* = 18.2 Hz, 1H, CHCHB), 5.21 - 5.13 (m, 2H, CCH₂), 1.85 (t, *J* = 1.1 Hz, 3H, CCH₃), 1.28 (s, 12H, 4 x CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 152.3, 143.2, 120.3, 116.7 (br), 83.4, 24.9, 17.9. The ¹³C NMR signal for the carbon attached to boron was broad due to the quadrupolar splitting of ¹¹B. The values of the NMR spectra are in accordance with reported literature data.³⁹


Following a reported procedure,³⁹ to a stirred solution of 4,4,5,5-tetramethyl-2-[(1*E*)-3-methylbuta-1,3-dien-1-yl]-1,3,2-dioxaborolane (**64**) (772 mg, 3.98 mmol, 1.00 equiv) in acetone (125 mL) were added an aqueous solution of NH₄OAc (79 mL, 0.1 M, 1.50 equiv) and NaIO₄ (2.55 g, 11.9 mmol, 3.0 equiv). The cloudy mixture was stirred at room temperature for 24 h. After cautious acidification with aqueous 2 M HCl (pH = 2), the aqueous layer was extracted with AcOEt (2 x 80 mL). The combined organic layers were dried over MgSO₄, filtered and the solvent was removed under reduced pressure affording (*E*)-(3-methylbuta-1,3-dien-1-yl)boronic acid (**50s**) as a light yellow solid (200 mg, 1.79 mmol, 36%). ¹H NMR (400 MHz, CDCl₃) δ 7.42 (d, *J* = 17.8 Hz, 1H, CHCHB), 5.68 (d, *J* = 17.9 Hz, 1H, CHCHB), 5.29 (s, 1H, CCH₂), 5.27 (s, 1H, CCH₂), 1.92 (s, 3H, CCH₃); ¹³C NMR (101 MHz, CDCl₃) δ 154.9, 143.2, 121.6, 120.0 (br), 18.1; ¹¹B NMR (128 MHz, DMSO-*d*₆/D₂O 9:1) δ 19.38. The ¹³C NMR signal for the carbon attached to boron was broad due to the quadrupolar splitting of ¹¹B. The values of the NMR spectra are in accordance with reported data.³⁹

((1*E*,3*E*)-4-Phenylbuta-1,3-dien-1-yl)boronic acid (**50t**)



Catecholborane (**52**) (533 μL, 5.00 mmol, 1.00 equiv) was added dropwise to stirring neat (*E*)-but-1-en-3-yn-1-ylbenzene (**65**) (641 mg, 5.00 mmol, 1.00 equiv) at 0 °C under inert atmosphere. The reaction mixture was stirred at room temperature until the gas evolution had ceased and, then was heated to 70 °C and stirred for 1 h. The reaction was cooled to 0 °C and quenched by dropwise addition of water (3 mL). The solid was suspended in water (20 mL) and vigorously stirred at room temperature for 18 h. The mixture was extracted with diethyl ether (2 x 20 mL) and washed with water (5 x 20 mL). The organic layer was then shaken 5 min with a basic aqueous solution of sorbitol (25 mL, 1 M sorbitol, 1 M Na₂CO₃), the aqueous layer was re-acidified with 4 M HCl (25 mL, pH = 2) and extracted with diethyl ether (35 mL). The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure affording ((1*E*,3*E*)-4-phenylbuta-1,3-dien-1-yl)boronic acid (**50t**) as a off-white solid (461 mg, 3.11 mmol, 62 %). M.p. 110-112 °C; ¹H NMR (400 MHz, DMSO-*d*₆/D₂O 9:1) δ 7.54 - 7.48 (m, 2H), 7.38 - 7.30 (m, 2H), 7.30 - 7.22 (m, 1H), 7.08 - 6.87 (m, 2H), 6.69 (d, *J* = 15.4 Hz, 1H), 5.65 (d, *J* = 17.3 Hz, 1H); ¹³C NMR (101 MHz, DMSO-*d*₆/D₂O 9:1) δ 146.9, 137.0, 134.7, 131.4, 129.1, 128.6 (br), 128.4, 127.0; ¹¹B NMR (128 MHz, DMSO-*d*₆/D₂O 9:1) δ 29.2; IR (ν_{max}, cm⁻¹) 2967 (m), 2912 (m), 1622 (m), 1427 (m), 1456 (s), 1082 (s), 1021 (s); HRMS (APPI/LTQ-Orbitrap) calcd for C₁₀H₁₁BO₂⁺ [M⁺] 174.0847; found 174.0847. The ¹³C NMR signal for the carbon attached to boron was broad due to the quadrupolar splitting of ¹¹B.

(*E*)-Non-1-en-3-yn-1-ylboronic acid (**50u**)




Following a reported procedure,⁴⁰ a 100 mL flask was charged with LiTMP (883 mg, 6.00 mmol, 1.20 equiv), sealed with a septum cap, and removed from the glovebox. The reaction flask was cooled to 0 °C, and dry THF (6 mL), followed by a solution of bis[(pinacolato)boryl]methane (**67**) (1.60 g, 6.00 mmol, 1.20 equiv) in THF (12 mL) were added. The reaction was stirred for 5 minutes at 0 °C and then was cooled to -78 °C, and a solution of oct-2-ynal (**66**) (0.735 mL, 5.00 mmol, 1.00 equiv) in THF (6.00 mL) was added slowly. The reaction was stirred at -78 °C for 4 h and the solvent was removed under reduced pressure. The crude reaction mixture was purified by column chromatography using EtOAc/pentane 2:98 as mobile phase affording (*E*)-4,4,5,5-tetramethyl-2-(non-1-en-3-yn-1-yl)-1,3,2-dioxaborolane (**68**) as a clear yellow oil (805 mg, 3.24 mmol, 65 %); ¹H NMR (400 MHz, CDCl₃) δ 6.42 (dt, *J* = 18.3, 2.1 Hz, 1H, CHCHB), 5.92 (dd, *J* = 18.3, 0.6 Hz, 1H, CHCHB), 2.32 (tdd, *J* = 7.2, 2.2, 0.6 Hz, 2H, CCH₂), 1.56 - 1.48 (m, 2H, CH₂), 1.42 - 1.27 (m, 4H, 2 x CH₂), 1.26 (s, 12H, 4 x CH₃ pinacol), 0.89 (t, *J* = 7.1 Hz, 3H, CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 130.5, 95.4, 83.6, 81.0, 31.2, 28.4, 24.9, 22.3, 19.7, 14.1. The ¹³C NMR signal for the carbon attached to boron did not appear due to the quadrupolar splitting of ¹¹B. The values of the NMR spectra are in accordance with reported literature data.⁴⁰

(*E*)-4,4,5,5-Tetramethyl-2-(non-1-en-3-yn-1-yl)-1,3,2-dioxaborolane (**68**) (0.805 g, 3.24 mmol, 1.00 equiv), NH₄OAc (1.250 g, 16.22 mmol, 5.00 equiv) and NaIO₄ (3.470 g, 16.22 mmol, 5.00 equiv) were suspended in a mixture 1:1 acetone/water (30 mL). The resulting slurry was stirred at room temperature for 16 h. It was then diluted with EtOAc (30 mL), washed successively with water (2 x 20 mL) and brine (20 mL), dried over MgSO₄, filtered, and concentrated under reduced pressure. The resulting yellow oil was dissolved in diethyl ether (20 mL) then shaken 5 min with a basic aqueous solution of sorbitol (25 mL, 1 M sorbitol, 1 M Na₂CO₃), the aqueous layer was re-acidified with 4 M HCl (25 mL, pH = 2) and extracted with diethyl ether (35 mL). The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure affording (*E*)-non-1-en-3-yn-1-ylboronic acid (**50u**) as a yellow oil (0.365 g, 2.20 mmol, 68%). ¹H NMR (400 MHz, DMSO-*d*₆/D₂O 9:1) δ 6.27 (dt, *J* = 18.3, 2.1 Hz, 1H, CHCHB), 5.83 (d, *J* = 18.4 Hz, 1H, CHCHB), 2.32 (td, *J* = 7.0, 2.2 Hz, 2H, CCH₂), 1.46 (m, 2H, CH₂), 1.38 - 1.23 (m, 4H, 2 x CH₂), 0.86 (t, *J* = 7.0 Hz, 3H, CH₂CH₃); ¹³C NMR (101 MHz, DMSO-*d*₆/D₂O 9:1) δ 136.6 (br), 126.6, 93.7, 81.2, 30.6, 27.9, 21.7, 18.7, 14.0; ¹¹B NMR (128 MHz, DMSO-*d*₆/D₂O 9:1) δ 27.2; IR (ν_{max}, cm⁻¹) 2985 (m), 2904 (m), 1773 (m), 1716 (s), 1427 (m), 1395 (s), 1343 (m), 1071 (s), 1055 (s), 726 (m); HRMS (APPI/LTQ-Orbitrap) *m/z*: [M]⁺ Calcd for C₉H₁₅BO₂⁺ 166.1160; found 166.1161. The ¹³C NMR signal for the carbon attached to boron was broad due to the quadrupolar splitting of ¹¹B.


⁴⁰ J. R. Coombs, L. Zhang and J. P. Morken, *Org. Lett.*, **2015**, 17, 1708.

2-Iodosylbenzoic acid (70a)




Following a reported procedure,⁴¹ NaIO₄ (18.1 g, 85.0 mmol, 1.05 equiv) and 2-iodobenzoic acid (**69a**) (20.0 g, 81.0 mmol, 1.00 equiv) were suspended in 30% (v/v) aq. AcOH (160 mL). The mixture was vigorously stirred under reflux for 4 h and allowed to cool to room temperature. The precipitate was collected by filtration, washed on the filter with ice water (3 x 40 mL) and acetone (45 mL), and air-dried in the dark to give 2-iodosylbenzoic acid (**70a**) as a white solid (20.8 g, 79.0 mmol, 98%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.02 (dd, *J* = 7.7, 1.4 Hz, 1H, ArH), 7.97 (m, 1H, ArH), 7.85 (dd, *J* = 8.2, 0.7 Hz, 1H, ArH), 7.71 (td, *J* = 7.6, 1.2 Hz, 1H, ArH); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 167.7, 134.5, 131.5, 131.1, 130.4, 126.3, 120.4. The values of the NMR spectra are in accordance with reported literature data.⁴¹

1-Hydroxy-5-methoxy-1λ³-benzo[*d*][1,2]iodaoxol-3(1*H*)-one (70b)



Following a reported procedure,⁴² NaIO₄ (2.25 g, 10.5 mmol, 1.05 equiv) and 2-iodo-5-methoxybenzoic acid (**69b**) (2.78 g, 10.0 mmol, 1.00 equiv) were suspended in 30% (v/v) aq. AcOH (27 mL). The mixture was vigorously stirred under reflux for 4 h and allowed to cool to room temperature. The precipitate was collected by filtration, washed on the filter with ice water (3 x 8 mL) and acetone (3 x 6 mL), and air-dried in the dark to give 1-hydroxy-5-methoxy-1λ³-benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**70b**) as a white solid (2.31 g, 7.90 mmol, 79%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.00 (s, 1H, ArH), 7.72 - 7.61 (m, 1H, ArH), 7.59 - 7.47 (m, 1H, ArH), 3.88 (s, 3H, OCH₃); ¹³C NMR (101MHz, DMSO-*d*₆) δ 167.9, 162.0, 133.5, 127.6, 122.0, 115.4, 109.5, 56.4. The values of the NMR spectra are in accordance with reported literature data.⁴²

5-Fluoro-1-hydroxy-1λ³-benzo[*d*][1,2]iodaoxol-3(1*H*)-one (70c)




Following a reported procedure,⁴² NaIO₄ (2.25 g, 10.5 mmol, 1.05 equiv) and 5-fluoro-2-iodobenzoic acid (**69c**) (2.70 g, 10.0 mmol, 1.00 equiv) were suspended in 30% (v/v) aq. AcOH (27 mL). The mixture was vigorously stirred under reflux for 4 h and allowed to cool to room temperature. The precipitate was collected by filtration, washed on the filter with ice water (3 x 8 mL) and acetone (3 x 6 mL), and air-dried in the dark to give 5-fluoro-1-hydroxy-1λ³-benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**70c**) as a white solid (2.62 g, 9.30 mmol, 93%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.21 (s, 1H, ArH), 7.89 - 7.78 (m, 2H,

⁴¹ L. Kraszkiewicz and L. Skulski, *Arkivoc.* **2003**, 6, 120.

⁴² S. Bertho, R. Rey-Rodriguez, C. Colas, P. Retailleau and I. Gillaizeau, *Chem. Eur. J.*, **2017**, 23, 17674.


ArH), 7.78 - 7.72 (m, 1H, ArH); ^{13}C NMR (101 MHz, DMSO- d_6) δ 166.5, 164.0 (d, $J = 248.3$ Hz), 134.2 (d, $J = 7.3$ Hz), 128.4 (d, $J = 8.6$ Hz), 121.8 (d, $J = 24.0$ Hz), 117.5 (d, $J = 23.5$ Hz), 114.3; ^{19}F NMR (376 MHz, DMSO- d_6) δ -112.7. The values of the NMR spectra are in accordance with reported literature data.⁴²

1-Acetoxy-1,2-benziodoxol-3-(1H)-one (71)



Following a reported procedure,⁴³ 2-iodosylbenzoic acid (**70a**) (20.8 g, 79.0 mmol, 1.00 equiv) was suspended in acetic anhydride (75.0 mL, 788 mmol, 10.0 equiv) and heated to reflux (140 °C) until complete dissolution (about 15 min). The resulting clear solution was allowed to cool to room temperature and then cooled to 5 °C overnight. The white crystals were filtered, washed with pentane (3 x 30 mL) and dried under reduced pressure to afford 1-acetoxy-1,2-benziodoxol-3-(1H)-one (**71**) as a white solid (22.3 g, 73.0 mmol, 92%). ^1H NMR (CDCl_3 , 400 MHz) δ 8.24 (dd, $J = 7.6, 1.6$ Hz, 1H, ArH), 8.00 (dd, $J = 8.3, 1.0$ Hz, 1H, ArH), 7.92 (ddd, $J = 8.4, 7.2, 1.6$ Hz, 1H, ArH), 7.71 (td, $J = 7.3, 1.1$ Hz, 1H, ArH), 2.25 (s, 3 H, COCH_3); ^{13}C NMR (CDCl_3 , 100 MHz) δ 176.5, 168.2, 136.2, 133.3, 131.4, 129.4, 129.1, 118.4, 20.4. The values of the NMR spectra are in accordance with reported literature data.⁴⁴

1,1,1,3,3,3-Hexafluoro-2-(2-iodophenyl)propan-2-ol (69')




Following a reported procedure,⁴⁵ TMEDA (1.27 mL, 8.40 mmol, 0.20 equiv.) was added to a solution of *n*-BuLi (37.0 mL, 92.0 mmol, 2.20 equiv., 2.5 M in hexanes). After 15 min, the cloudy solution was cooled to 0 °C and 1,1,1,3,3,3-hexafluoro-2-phenylpropan-2-ol (**72**) (7.07 mL, 42.0 mmol, 1.00 equiv.) in THF (6.0 mL) was added dropwise. The reaction was stirred 30 min at 0 °C and then 18 h at room temperature. Then, THF (30.0 mL) was added, followed by the portionwise addition of I_2 (11.3 g, 44.5 mmol, 1.05 equiv.) at 0 °C and the mixture was stirred at 0 °C for 30 min and 4 h at room temperature. The reaction was quenched with saturated aqueous NH_4Cl (50 mL) and extracted with diethyl ether (3 x 30 mL). The combined organic layers were washed with water, brine, dried over MgSO_4 , filtered and the solvent was removed under reduced pressure. The crude product was purified by column chromatography using EtOAc/pentane 3:97 as eluent to afford 1,1,1,3,3,3-hexafluoro-2-(2-iodophenyl)propan-2-ol (**69'**) as a colorless oil (13.9 g, 37.5 mmol, 89%). ^1H NMR (400 MHz, CDCl_3) δ 8.13 (dd, $J = 7.9, 1.4$ Hz, 1H, ArH), 7.63 (d, $J = 8.2$ Hz, 1H, ArH), 7.43 (dt, $J = 8.4, 1.4$ Hz, 1H, ArH), 7.11 (dt, $J = 8.0, 1.5$ Hz, 1H, ArH), 4.23 (s, 1H, OH); ^{13}C NMR (101 MHz, CDCl_3) δ 144.7, 131.4, 130.0, 129.7, 128.0, 122.6 (q, $J = 291.4$ Hz), 90.6, 78.9 (q, $J = 32.1$ Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -73.4. The values of the NMR spectra are in accordance with reported literature data.⁴⁵

⁴³ P. Caramenti, S. Nicolai and J. Waser, *Chem. Eur. J.*, **2017**, *23*, 14702.

⁴⁴ P. Eisenberger, S. Gischig, A. Togni, *Chem. Eur. J.*, **2006**, *12*, 2579.


⁴⁵ J. Cvengroš, D. Stolz and A. Togni, *Synthesis* **2009**, 2818.

3,3-Bis(trifluoromethyl)-1*λ*³-benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**71'**)



Following a reported procedure,⁴⁶ a 500 mL flask was charged with glacial acetic acid (188 mL), 1,1,1,3,3,3-hexafluoro-2-(2-iodophenyl)propan-2-ol (**69'**) (13.9 g, 37.5 mmol, 1.00 equiv.) and cobalt(II) chloride hexahydrate (89.0 g, 0.375 mmol, 0.01 equiv.). The reaction vessel was purged with O₂ for 5 min before acetaldehyde (21.4 mL, 379 mmol, 10.0 equiv.) was added in one portion. The reaction mixture was stirred under 1 atm of O₂, delivered by inflated balloon, at room temperature for 12 h. Acetaldehyde (21.4 mL, 379 mmol, 10.0 equiv.) was added and the reaction continued for 6 h. The solvent was removed under reduced pressure and the residue was dissolved in DCM. The organic layer was washed with distilled water (50 mL) and extracted with DCM (3 x 50 mL). The organic layer was dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The obtained residue was triturated in pentane for 0.5 h, filtered and washed with pentane (operation repeated 2 times) to afford 3,3-bis(trifluoromethyl)-1- λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**71'**) as a white solid (9.91 g, 23.2 mmol, 62%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.93 (ddd, *J* = 8.4, 7.1, 1.6 Hz, 1H, Ar*H*), 7.85 – 7.69 (m, 3H, Ar*H*), 2.19 (s, 3H, (O)CCH₃); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 174.4, 134.2, 131.4, 131.0, 130.8, 129.5 – 129.0 (m), 123.1 (q, *J* = 289.5 Hz), 116.1, 84.5 – 83.7 (m), 20.0; ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -75.1. The values of the NMR spectra are in accordance with reported literature data.⁴⁷

General procedure A: Synthesis of VBX reagents:




To a suspension of 2-iodosylbenzoic acid (**70a-c**) (1.30 mmol, 1.00 equiv) in dry DCM (13 mL) was added TMSOTf (0.270 mL, 1.50 mmol, 1.15 equiv) dropwise over 10 min and stirred for 30 min at room temperature. Afterwards, the corresponding vinyl boronic acid (**50a-i**) (1.50 mmol, 1.15 equiv) was added and the reaction mixture was stirred until the reaction was completed (1 to 8 h, monitored by TLC, MeOH/DCM 5:95). Pyridine (0.121 mL, 1.50 mmol, 1.15 equiv) was added and after further stirring for 10 min at room temperature, the solvent was removed under reduced pressure. The resulting solid was dissolved in DCM (20 mL) and washed with 1 M HCl (10 mL). The aqueous layer was extracted with DCM (3 x 20 mL). The organic layers were combined, washed successively with a saturated solution of NaHCO₃ (40 mL) and water (3 x 20 mL), dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The resulting solid was dissolved again in DCM (minimum amount until dissolution) and precipitated in Et₂O (ca. 150 mL). After precipitation at 4 °C for 2 h, the solid was filtered and washed with Et₂O to afford the corresponding VBX reagent.

⁴⁶ A. Maity, S.-M. Hyun and D. C. Powers, *Nat. Chem.* **2018**, *10*, 200.


⁴⁷ P. Eisenberger, S. Gischig and A. Togni, *Chem. Eur J.* **2006**, *12*, 2579.

General procedure B: Synthesis of VBX reagents:




To a solution of the corresponding vinyl boronic acid (**50g-u**) (1.30 mmol, 1.00 equiv) in dry DCM (13 mL) was added $\text{BF}_3 \cdot \text{OEt}_2$ (0.198 mL, 1.56 mmol, 1.20 equiv) dropwise at 0 °C. After 15 minutes, 1-acetoxy-1,2-benziodoxol-3-(1H)-one (**71**) (477 mg, 1.56 mmol, 1.20 equiv) was added in one portion at 0 °C. The reaction mixture was allowed to warm up to room temperature and stirred until the reaction was completed (4 to 24 h, monitored by TLC using MeOH/DCM 5:95). The reaction was then quenched with a saturated solution of NaHCO_3 (13 mL) and stirred vigorously for 1 h. The resulting suspension was filtered and the filtrate was extracted with DCM (3 x 20 mL). The combined organic layers were washed with water (3 x 20 mL), dried over MgSO_4 , filtered and the solvent was removed under reduced pressure. The resulting solid was dissolved in DCM (minimum amount until dissolution) and precipitated in Et_2O (ca. 150 mL). After precipitation at 4 °C for 2 h, the solid was filtered and washed with Et_2O to afford the corresponding VBX reagent.

General procedure C: Synthesis of VBX reagents:



To a solution of the corresponding vinyl boronic acid (**50a – 50p**) (1.00 mmol, 1.00 equiv) in dry DCM (10 mL) was added $\text{BF}_3 \cdot \text{OEt}_2$ (0.152 mL, 1.20 mmol, 1.20 equiv) dropwise at 0 °C. After 15 minutes, 3,3-bis(trifluoromethyl)-1 λ^3 -benzo[d][1,2]iodaoxol-1(3H)-yl acetate (**71'**) (514 mg, 1.20 mmol, 1.20 equiv.) was added in one portion at 0 °C. The reaction mixture was allowed to warm up to room temperature and stirred for 1 h. The reaction mixture was then quenched with saturated aqueous NaHCO_3 solution and extracted with dichloromethane (3 times). The combined organic extracts were dried over MgSO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography using EtOAc/pentane as eluent to give the corresponding VBX reagent.

(E)-1-Styryl-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (**1a**)




Following general procedure A, starting from *trans*-2-phenylvinylboronic acid (**50a**) (221 mg, 1.50 mmol) and 2-iodosylbenzoic acid (**70a**) (343 mg, 1.30 mmol), afforded (E)-1-styryl-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (**1a**) as a white solid (351 mg, 1.00 mmol, 77%). ^1H NMR (400 MHz, MeOD) δ 8.32 - 8.25 (m, 1H, ArH), 7.97 (d, J = 15.5 Hz, 1H, ICHCHPh), 7.77 - 7.63 (m, 6H, ArH and ICHCHPh), 7.54 - 7.45 (m, 3H, ArH). ^{13}C NMR (101 MHz, MeOD) δ 170.1, 155.8, 136.7, 135.3, 134.5,

133.3, 132.1, 131.8, 130.2, 129.0, 129.0, 115.5, 100.0. The values of the NMR spectra are in accordance with reported literature data.⁴⁸

The reaction was scaled up to *trans*-2-phenylvinylboronic acid (**50a**) (1.48 g, 10.0 mmol) and 2-iodosylbenzoic acid (**70a**) (2.30 g, 8.70 mmol) affording (*E*)-1-styryl-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1a**) (2.20 g, 6.30 mmol, 72%).


(*E*)-1-(4-Methoxystyryl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1b**)



1b

Following general procedure A, starting from *trans*-2-(4-methoxyphenyl)vinylboronic acid (**50c**) (266 mg, 1.50 mmol) and 2-iodosylbenzoic acid (**70a**) (343 mg, 1.30 mmol), afforded (*E*)-1-(4-methoxystyryl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1b**) as a white solid (306 mg, 0.805 mmol, 62%). ¹H NMR (400 MHz, MeOD) δ 8.29 (dt, *J* = 5.8, 3.5 Hz, 1H, Ar*H*), 7.89 (d, *J* = 15.3 Hz, 1H, ICHCHPh), 7.78 - 7.60 (m, 5H, Ar*H*), 7.45 (d, *J* = 15.4 Hz, 1H, ICHCHPh), 7.12 - 6.95 (m, 2H, Ar*H*), 3.87 (s, 3H, OCH₃); ¹³C NMR (101 MHz, MeOD) δ 170.1, 163.7, 155.8, 135.2, 134.5, 133.3, 131.8, 130.8, 129.4, 128.9, 115.6, 115.5, 95.9, 56.0. The values of the NMR spectra are in accordance with reported literature data.⁴⁸


(*E*)-1-(4-Methylstyryl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1c**)



1c

Following general procedure A, starting from *trans*-2-(4-methylphenyl)vinylboronic acid (**50b**) (242 mg, 1.50 mmol) and 2-iodosylbenzoic acid (**70a**) (343 mg, 1.30 mmol), afforded (*E*)-1-(4-methylstyryl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1c**) as a white solid (335 mg, 0.920 mmol, 71%). ¹H NMR (400 MHz, MeOD) δ 8.32 - 8.25 (m, 1H, Ar*H*), 7.92 (d, *J* = 15.4 Hz, 1H, ICHCHPh), 7.76 - 7.64 (m, 3H, Ar*H*), 7.62 - 7.54 (m, 3H, Ar*H* and ICHCHPh), 7.31 (d, *J* = 7.9 Hz, 2H, Ar*H*), 2.42 (s, 3H, CH₃); ¹³C NMR (101 MHz, MeOD) δ 169.9, 155.7, 142.8, 135.0, 134.3, 133.8, 133.1, 131.6, 130.6, 128.8, 128.7, 115.3, 98.1, 21.3. The values of the NMR spectra are in accordance with reported literature data.⁴⁸

(*E*)-1-(4-(Trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1d**)




1d

Following general procedure A, starting from *trans*-2-[4-(trifluoromethyl)phenyl]vinylboronic acid (**50d**) (323 mg, 1.50 mmol) and 2-iodosylbenzoic acid (**70a**) (343 mg, 1.30 mmol), afforded (*E*)-1-(4-(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1d**) as a white solid (275 mg, 0.658 mmol,

⁴⁸ E. Stridfeldt, A. Seemann, M. J. Bouma, C. Dey, A. Ertan and B. Olofsson, *Chem. Eur. J.*, **2016**, *22*, 16066.

51%). ^1H NMR (400 MHz, MeOD) δ 8.30 (m, 1H, ArH), 8.05 (d, $J = 15.5$ Hz, 1H, ICHCHPh), 7.93 - 7.84 (m, 3H, ArH and ICHCHPh), 7.81 (m, 2H, ArH), 7.74 (m, 3H, ArH); ^{13}C NMR (101 MHz, MeOD) δ 170.6, 154.1, 140.6, 136.0, 134.4, 133.8, 133.7 (q, $J = 37.7$ Hz), 132.4, 129.9, 129.7, 127.5 (q, $J = 3.8$ Hz), 125.8 (q, $J = 271.5$ Hz) 115.9, 104.1; ^{19}F NMR (376 MHz, MeOD) δ -64.4. The values of the NMR spectra are in accordance with reported literature data.⁴⁸


(E)-1-(4-Fluorostyryl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (1e)



1e

Following general procedure A, starting from *trans*-2-(4-fluorophenyl)vinylboronic acid (**50e**) (248 mg, 1.50 mmol) and 2-iodosylbenzoic acid (**70a**) (343 mg, 1.30 mmol), afforded (*E*)-1-(4-fluorostyryl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (**1e**) as a white solid (424 mg, 1.152 mmol, 89%). M.p. 146-148 °C; $R_f = 0.11$ (MeOH/DCM 5:95); ^1H NMR (400 MHz, MeOD) δ 8.38 - 8.31 (m, 1H, ArH), 8.02 (d, $J = 15.2$ Hz, 1H, ICHCHPh), 7.85 - 7.71 (m, 5H, ArH), 7.66 (d, $J = 15.3$, 1H, ICHCHPh), 7.30 - 7.22 (m, 2H, ArH); ^{13}C NMR (101 MHz, MeOD) δ 170.9, 166.4 (d, $J = 251.2$ Hz), 155.9, 137.0, 134.2, 133.3 (d, $J = 3.0$ Hz), 132.6, 132.2, 131.9 (d, $J = 8.7$ Hz), 130.4, 117.7 (d, $J = 22.3$ Hz), 115.7, 98.2; ^{19}F NMR (376 MHz, MeOD) δ -110.9; IR (ν_{max} , cm^{-1}) 3018 (s), 2946 (s), 2858 (m), 1750 (s), 1731 (s), 1542 (s), 1512 (s), 1319 (s), 1271 (s), 1243 (s), 1200 (s), 1165 (s), 1124 (s), 968 (s), 838 (m); HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{11}\text{FIO}_2^+$ [$\text{M}+\text{H}$] $^+$ 368.9782; found 368.9785.


(E)-1-(2-(Naphthalen-1-yl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (1f)



1f

Following general procedure A, starting from (*E*)-2-(naphthalen-1-yl)vinylboronic acid (**50f**) (296 mg, 1.50 mmol) and 2-iodosylbenzoic acid (**70a**) (343 mg, 1.30 mmol), afforded (*E*)-1-(2-(naphthalen-1-yl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (**1f**) as a white solid (316 mg, 0.790 mmol, 61%). M.p. 164-166 °C; $R_f = 0.20$ (MeOH/DCM 5:95); ^1H NMR (400 MHz, MeOD) δ 8.79 (d, $J = 15.1$ Hz, 1H, ICHCHPh), 8.33 - 8.28 (m, 1H, ArH), 8.27 - 8.23 (m, 1H, ArH), 8.05 - 7.89 (m, 3H, ArH), 7.85 - 7.79 (m, 1H, ArH), 7.74 - 7.66 (m, 3H, ArH and ICHCHPh), 7.65 - 7.55 (m, 3H, ArH); ^{13}C NMR (101 MHz, MeOD) δ 168.7, 151.7, 133.9, 133.8, 133.1, 132.6, 131.9, 131.0, 130.8, 130.4, 128.5, 127.7, 127.0, 126.2, 125.2, 122.8, 114.3, 101.2, 78.1; IR (ν_{max} , cm^{-1}) 2985 (s), 2906 (s), 1390 (m), 1247 (m), 1227 (m), 1065 (s), 1051 (s), 896 (m), 867 (m); HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{13}\text{IO}_2^+$ [$\text{M}+\text{Na}$] $^+$ 422.9852; found 422.9851.


(E)-1-(2-(Thiophen-2-yl)vinyl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (1g)



1g

Following general procedure B, with a final purification by column chromatography using MeOH/DCM 5:95 as mobile phase to obtain the titled compound in pure form. Starting from (*E*)-(2-(thiophen-2-yl)vinyl)boronic acid (**50g**) (169 mg, 1.10 mmol) and 1-acetoxy-1,2-benziodoxol-3-(1*H*)-one (**71**) (477 mg, 1.56 mmol), afforded (*E*)-1-(non-1-en-3-yn-1-yl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1*H*)-one (**1g**) as a beige solid (145 mg, 0.407 mmol, 37%). M.p. (dec.) 201-205 °C; R_f = 0.13 (MeOH/DCM 5:95); ^1H NMR (400 MHz, MeOD/ CD_2Cl_2 9:1) δ 8.32 - 8.25 (m, 1H, ArH), 8.04 (d, J = 15.3 Hz, 1H, ICHCH), 7.74 - 7.65 (m, 3H, ArH), 7.62 (dt, J = 5.0, 0.9 Hz, 1H, ArH), 7.43 (dd, J = 3.7, 1.1 Hz, 1H, ArH), 7.29 (d, J = 15.3 Hz, 1H, ICHCH), 7.18 (dd, J = 5.1, 3.7 Hz, 1H, ArH); ^{13}C NMR (101 MHz, MeOD/ CD_2Cl_2 9:1) δ 169.8, 148.0, 140.9, 135.1, 134.2, 133.2, 132.3, 131.7, 130.7, 129.1, 128.5, 115.7, 96.3; IR (ν_{max} , cm^{-1}) 2987 (s), 2967 (s), 2907 (m), 1750 (m), 1735 (m), 1649 (m), 1573 (m), 1557 (m), 1540 (m), 1512 (m), 1452 (w), 1393 (m), 1251 (m), 1101 (w), 1068 (s), 1054 (s), 869 (m), 765 (m), 734 (m), 687 (m), 629 (s), 611 (s); HRMS (ESI/QTOF) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{10}\text{O}_2\text{S}^+$ 356.9441; found 356.9442.


(E)-5-Methoxy-1-styryl-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (1h)



1h

Following general procedure A, starting from (*E*)-styrylboronic acid (**50a**) (221 mg, 1.50 mmol) and 5-methoxy-1-hydroxy-1,2-benziodoxol-3-(1*H*)-one (**70b**) (382 mg, 1.30 mmol), afforded (*E*)-5-methoxy-1-styryl-1 λ^3 -benzo[d][1,2]iodaoxol-3(1*H*)-one (**1h**) as a white solid (422 mg, 1.11 mmol, 85%). M.p. 167-168 °C; R_f = 0.13 (MeOH/DCM 5:95); ^1H NMR (400 MHz, MeOD) δ 7.95 (d, J = 15.4 Hz, 1H, ICHCHPh), 7.82 (d, J = 3.0 Hz, 1H, ArH), 7.74 - 7.61 (m, 3H, ArH and ICHCHPh), 7.55 (d, J = 9.0 Hz, 1H, ArH), 7.52 - 7.44 (m, 3H, ArH), 7.25 (dd, J = 9.0, 3.1 Hz, 1H, ArH), 3.88 (s, 3H, OCH_3); ^{13}C NMR (101 MHz, MeOD) δ 169.9, 163.7, 155.6, 136.7, 135.9, 132.1, 130.2, 129.7, 129.0, 121.7, 117.8, 103.6, 99.6, 56.4; IR (ν_{max} , cm^{-1}) 2977 (s), 2903 (m), 1617 (w), 1580 (w), 1411 (s), 1379 (s), 1259 (m), 1052 (s), 811 (m), 881 (m); HRMS (ESI/QTOF) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{14}\text{O}_3^+$ 380.9982; found 380.9980.

(E)-5-Fluoro-1-styryl-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (1i)




1i

Following general procedure A, starting from (*E*)-styrylboronic acid (**50a**) (221 mg, 1.50 mmol) and 1-hydroxy-5-fluoro-1,2-benziodoxol-3(1*H*)-one (**70c**) (367 mg, 1.30 mmol), afforded (*E*)-5-fluoro-1-styryl-1 λ^3 -benzo[d][1,2]iodaoxol-3(1*H*)-one (**1i**) as a white solid (278 mg, 0.760 mmol, 58%). M.p. 174-176 °C;

$R_f = 0.15$ (MeOH/DCM 5:95); $^1\text{H NMR}$ (400 MHz, MeOD) δ 8.03 - 7.94 (m, 2H, ArH and ICHCHPh), 7.77 - 7.64 (m, 4H, ArH and ICHCHPh), 7.55 - 7.44 (m, 4H, ArH); $^{13}\text{C NMR}$ (101 MHz, MeOD) δ 168.7, 166.1 (d, $J = 250.5$ Hz), 156.1, 137.3, 136.6, 132.2, 131.0 (d, $J = 8.4$ Hz), 130.2, 129.0, 122.3 (d, $J = 24.0$ Hz), 119.8 (d, $J = 23.9$ Hz), 108.5, 99.7; $^{19}\text{F NMR}$ (376 MHz, MeOD) δ -113.5; IR (ν_{max} , cm^{-1}) 2987 (s), 2973 (s), 2905 (s), 1748 (m), 1737 (m), 1649 (m), 1559 (m), 1540 (m), 1512 (m), 1395 (m), 1255 (m), 1079 (s), 1054 (s), 863 (m); HRMS (ESI/QTOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{15}\text{H}_{10}\text{FINaO}_2^+$ 390.9602; Found 390.9595.


(E)-1-(2-Cyclohexylvinyl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (1j)



1j

Following general procedure B, starting from *trans*-2-cyclohexylvinyl)boronic acid (**50j**) (200 mg, 1.30 mmol) and 1-acetoxy-1,2-benziodoxol-3-(1H)-one (**71**) (477 mg, 1.56 mmol), afforded (*E*)-1-(2-cyclohexylvinyl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (**1j**) as a white solid (274 mg, 0.769 mmol, 59%). M.p. 136-138 °C; $R_f = 0.19$ (MeOH/DCM 5:95); $^1\text{H NMR}$ (400 MHz, MeOD) δ 8.31 - 8.24 (m, 1H, ArH), 7.75 - 7.65 (m, 3H, ArH), 7.13 (dd, $J = 15.1, 7.0$ Hz, 1H, ICHCHcy), 6.84 (dd, $J = 15.1, 1.2$ Hz, 1H, ICHCHcy), 2.54 - 2.41 (m, 1H, cy-H), 1.99 - 1.90 (m, 2H, cy-H), 1.89 - 1.79 (m, 2H, cy-H), 1.78 - 1.69 (m, 1H, cy-H), 1.50 - 1.21 (m, 5H, cy-H); $^{13}\text{C NMR}$ (101 MHz, MeOD) δ 170.4, 166.0, 135.6, 134.9, 133.8, 132.2, 129.2, 115.2, 99.4, 46.2, 33.2, 27.3, 27.2. The values of the NMR spectra are in accordance with reported literature data.⁴⁸


(E)-1-(3-Phenylprop-1-en-1-yl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (1k)



1k

Following general procedure B, starting from *trans*-3-Phenyl-1-propen-1-ylboronic acid (**50k**) (211 mg, 1.30 mmol) and 1-acetoxy-1,2-benziodoxol-3-(1H)-one (**71**) (477 mg, 1.56 mmol), afforded (*E*)-1-(3-phenylprop-1-en-1-yl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (**1l**) as a white solid (332 mg, 0.912 mmol, 70%). M.p. 144-145 °C; $R_f = 0.18$ (MeOH/DCM 5:95); $^1\text{H NMR}$ (400 MHz, MeOD) δ 8.30 - 8.23 (m, 1H, ArH), 7.72 - 7.64 (m, 3H, ArH), 7.41 - 7.23 (m, 6H, ArH and ICHCHBn), 6.88 (dt, $J = 14.9, 1.5$ Hz, 1H, ICHCHPh), 3.83 (dd, $J = 6.9, 1.4$ Hz, 2H, CH_2Ph); $^{13}\text{C NMR}$ (101 MHz, MeOD) δ 170.0, 159.0, 138.4, 135.2, 134.2, 133.4, 131.8, 130.0, 130.0, 129.0, 128.1, 115.0, 101.2, 42.7; IR (ν_{max} , cm^{-1}) 2987 (s), 2973 (s), 2905 (s), 1748 (m), 1737 (m), 1649 (m), 1559 (m), 1540 (m), 1512 (m), 1395 (m), 1255 (m), 1079 (s), 1054 (s), 863 (m); HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{14}\text{IO}_2^+$ $[\text{M} + \text{H}]^+$ 365.0033; found 365.0033.

(E)-1-(Pent-1-en-1-yl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (1l)




1l

Following general procedure B, starting from *trans*-1-penten-1-ylboronic acid (**50l**) (148 mg, 1.30 mmol) and 1-acetoxy-1,2-benziodoxol-3-(1H)-one (**71**) (477 mg, 1.56 mmol), afforded (*E*)-1-(pent-1-en-1-yl)-

1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1l**) as a white solid (115 mg, 0.364 mmol, 28%). M.p. (dec.) 154-160 °C; R_f = 0.15 (MeOH/DCM 5:95); ^1H NMR (400 MHz, MeOD) δ 8.34 - 8.22 (m, 1H, ArH), 7.80 - 7.63 (m, 3H, ArH), 7.16 (dt, J = 14.9, 7.0 Hz, 1H, ICHCHCH₂), 6.87 (dt, J = 15.0, 1.4 Hz, 1H, ICHCHCH₂), 2.49 (qd, J = 7.2, 1.5 Hz, 2H, CHCH₂CH₂), 1.65 (h, J = 7.4 Hz, 2H, CH₂CH₂CH₃), 1.05 (t, J = 7.4 Hz, 3H, CH₂CH₃); ^{13}C NMR (101 MHz, MeOD) δ 169.7, 160.4, 134.9, 133.1, 131.6, 128.7, 114.7, 100.1, 38.6, 22.2, 13.7; IR (ν_{max} , cm⁻¹) 2987 (s), 2973 (s), 2905 (s), 1748 (m), 1737 (m), 1649 (m), 1559 (m), 1540 (m), 1512 (m), 1395 (m), 1255 (m), 1079 (s), 1054 (s), 863 (m); HRMS (ESI) calcd for C₁₂H₁₄IO₂⁺ [M+H]⁺ 317.0033; found 317.0033.


Methyl (*E*)-6-(3-oxo-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)hex-5-enoate (1m**)**



1m

Following general procedure B, starting from (*E*)-(6-methoxy-6-oxohex-1-en-1-yl)boronic acid (**50m**) (224 mg, 1.30 mmol) and 1-acetoxy-1,2-benziodoxol-3-(1*H*)-one (**71**) (477 mg, 1.56 mmol), afforded methyl (*E*)-6-(3-oxo-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)hex-5-enoate (**1m**) (210 mg, 0.561 mmol, 43%) as an off-white solid. M.p. 147-149 °C; R_f = 0.07 (MeOH/DCM 5:95); ^1H NMR (400 MHz, MeOD) δ 8.31 - 8.23 (m, 1H, ArH), 7.78 - 7.64 (m, 3H, ArH), 7.15 (dt, J = 15.0, 6.9 Hz, 1H, ICHCH), 6.90 (dt, J = 14.9, 1.4 Hz, 1H, ICHCH), 3.68 (s, 3H, OCH₃), 2.61 - 2.50 (m, 2H, CH₂CC), 2.46 (t, J = 7.3 Hz, 2H, CH₂CO₂Me), 1.91 (p, J = 7.4 Hz, 2H, CH₂CH₂CH₂); ^{13}C NMR (101 MHz, MeOD) δ 175.2, 170.0, 159.4, 135.2, 134.6, 133.3, 131.8, 129.0, 114.9, 101.1, 52.1, 35.9, 33.8, 24.3; IR (ν_{max} , cm⁻¹) 3443 (w), 3047 (w), 2958 (w), 2922 (w), 1731 (m), 1606 (s), 1557 (m), 1440 (m), 1363 (m), 1342 (m), 1294 (w), 1205 (m), 1184 (m), 1151 (m), 1005 (m), 961 (m), 830 (m); HRMS (ESI) calcd for C₁₄H₁₆IO₄⁺ [M+H]⁺ 375.0088; found 375.0091.


(*E*)-1-(5-Chloropent-1-en-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (1n**)**



1n

Following general procedure B, starting from (*E*)-(5-chloropent-1-en-1-yl)boronic acid (**50n**) (193 mg, 1.30 mmol) and 1-acetoxy-1,2-benziodoxol-3-(1*H*)-one (**71**) (477 mg, 1.56 mmol), afforded (*E*)-1-(5-chloropent-1-en-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1n**) as a white solid (201 mg, 0.573 mmol, 44%). M.p. 133-135 °C; R_f = 0.19 (MeOH/DCM 5:95); ^1H NMR (400 MHz, MeOD) δ 8.34 - 8.24 (m, 1H, ArH), 7.83 - 7.66 (m, 3H, ArH), 7.19 (dt, J = 15.0, 6.9 Hz, 1H, ICHCHCH₂), 6.97 (dt, J = 15.0, 1.5 Hz, 1H, ICHCHCH₂), 3.70 (t, J = 6.4 Hz, 2H, CH₂Cl), 2.76 - 2.62 (m, 2H, CH₂CH₂CH), 2.09 (p, J = 6.7 Hz, 2H, CH₂CH₂Cl); ^{13}C NMR (101 MHz, MeOD) δ 168.6, 157.4, 133.8, 133.1, 131.9, 130.4, 127.6, 113.5, 100.1, 43.4, 32.5, 30.4; IR (ν_{max} , cm⁻¹) 2968 (m), 2897 (m), 1719 (w), 1596 (m), 1557 (m), 1346 (m), 1276 (m), 1261 (m), 1056 (m), 961 (m), 830 (m), 751 (s); HRMS (ESI) calcd for C₁₂H₁₃ClIO₂⁺ [M+H]⁺ 350.9643; found 350.9645.


(E)-1-(Cyclohex-1-en-1-yl)-1λ³-benzo[d][1,2]iodaoxol-3(1H)-one (1o)



1o

Following general procedure B, starting from 1-cyclohexenylboronic acid (**50o**) (164 mg, 1.30 mmol) and 1-acetoxy-1,2-benziodoxol-3-(1H)-one (**71**) (477 mg, 1.56 mmol), afforded (E)-1-(cyclohex-1-en-1-yl)-1λ³-benzo[d][1,2]iodaoxol-3(1H)-one (**1o**) as a white solid (213 mg, 0.649 mmol, 50%). M.p. 116-118 °C; R_f = 0.15 (MeOH/DCM 5:95); ¹H NMR (400 MHz, MeOD) δ 8.28 (dt, *J* = 7.2, 1.3 Hz, 1H, ArH), 7.78 - 7.66 (m, 3H, ArH), 7.07 (tt, *J* = 3.9, 1.8 Hz, 1H, ICCH), 2.73-2.68 (m, 2H, cy-H), 2.53 (tq, *J* = 6.0, 3.0 Hz, 2H, cy-H), 1.94 (pd, *J* = 6.0, 3.6 Hz, 2H, cy-H), 1.88 - 1.80 (m, 2H, cy-H); ¹³C NMR (101 MHz, MeOD) δ 170.0, 152.3, 135.8, 133.8, 132.0, 129.0, 118.6, 113.5, 35.2, 30.1, 25.7, 21.5; IR (ν_{max}, cm⁻¹) 2976 (w), 2934 (w), 2906 (w), 1651 (m), 1600 (s), 1558 (m), 1435 (m), 1377 (m), 1346 (m), 1332 (m), 1107 (s), 905 (s), 853 (m), 826 (m), 748 (s); HRMS (ESI) calcd for C₁₃H₁₄O₂⁺ [M+H]⁺ 329.0033; found 329.0031. One carbone was not resolved at 101 MHz.


(E)-2-(3-(3-Oxo-1λ³-benzo[d][1,2]iodaoxol-1(3H)-yl)allyl)isoindoline-1,3-dione (1p)



1p

Following general procedure B, with the addition of 2,2,2-trifluoroethanol (1.3 mL) after 3 h of reaction to dissolve the insoluble material. Starting from (E)-2-(3-(1,3-dioxoisoindolin-2-yl)prop-1-en-1-yl)boronic acid (**50p**) (300 mg, 1.30 mmol) and 1-acetoxy-1,2-benziodoxol-3-(1H)-one (**71**) (477 mg, 1.56 mmol), afforded (E)-2-(3-(3-oxo-1λ³-benzo[d][1,2]iodaoxol-1(3H)-yl)allyl)isoindoline-1,3-dione (**1p**) as a white solid (417 mg, 0.963 mmol, 74%). M.p. (dec.) 163-167 °C; R_f = 0.12 (MeOH/DCM 5:95); ¹H NMR (400 MHz, MeOD) δ 8.40 - 8.34 (m, 1H, ArH), 7.98 - 7.77 (m, 7H, ArH), 7.35 (dt, *J* = 14.8, 4.8 Hz, 1H, ICHCH), 7.21 (dt, *J* = 14.8, 1.6 Hz, 1H, ICHCH), 4.75 (dd, *J* = 4.8, 1.6 Hz, 2H, CH₂N); ¹³C NMR (101 MHz, MeOD) δ 171.0, 169.2, 154.8, 137.6, 135.7, 134.1, 133.4, 132.5, 131.1, 129.1, 124.5, 114.8, 100.4, 42.0; IR (ν_{max}, cm⁻¹) 2977 (s), 2917 (s), 1722 (m), 1483 (m), 1407 (s), 1374 (m), 1261 (m), 1329 (m), 1056 (s), 875 (w); HRMS (ESI) calcd for C₁₈H₁₂INNaO₄⁺ [M+Na]⁺ 455.9703; found 455.9702.

(E)-1-(3-((Triisopropylsilyl)oxy)prop-1-en-1-yl)-1λ³-benzo[d][1,2]iodaoxol-3(1H)-one (1q)




1q

Following general procedure B, starting from (E)-2-(3-((triisopropylsilyl)oxy)prop-1-en-1-yl)boronic acid (**50q**) (336 mg, 1.30 mmol) and 1-acetoxy-1,2-benziodoxol-3-(1H)-one (**71**) (477 mg, 1.56 mmol), afforded (E)-1-(3-((triisopropylsilyl)oxy)prop-1-en-1-yl)-1λ³-benzo[d][1,2]iodaoxol-3(1H)-one (**1q**) (370 mg, 0.804 mmol, 62%) as a white solid. M.p. 157-159 °C; R_f = 0.20 (MeOH/DCM 5:95); ¹H NMR (400 MHz, MeOD) δ 8.36 - 8.26 (m, 1H, ArH), 7.73 (m, 3H, ArH), 7.34 (dt, *J* = 14.7, 3.2 Hz, 1H, ICHCH), 7.08 (dt, *J* = 14.7, 2.2 Hz, 1H, ICHCH), 4.71 (dd, *J* = 3.2, 2.1 Hz, 2H, CH₂O), 1.31 - 1.10 (m, 21H, TIPS); ¹³C NMR

(101 MHz, MeOD) δ 170.3, 159.7, 135.7, 133.6, 132.9, 132.0, 129.3, 114.9, 98.7, 66.2, 18.5, 13.2; IR (ν_{\max} , cm^{-1}) 3057 (w), 2944 (w), 2863 (w), 1644 (w), 1607 (w), 1264 (m), 1129 (w), 1014 (w), 943 (w), 914 (w), 734 (s), 701 (s); HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{30}\text{O}_3\text{Si}^+$ $[\text{M}+\text{H}]^+$ 461.1003; found 461.1015.


(E)-1-(3-Chloroprop-1-en-1-yl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (1r)



1r

Following general procedure B, with the addition of 2,2,2-trifluoroethanol (1.3 mL) after 3 h of reaction to dissolve the insoluble material. Starting from *trans*-2-chloromethylvinylboronic acid (**50r**) (156 mg, 1.30 mmol) and 1-acetoxy-1,2-benziodoxol-3-(1H)-one (**71**) (477 mg, 1.56 mmol), afforded (*E*)-1-(3-chloroprop-1-en-1-yl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (**1r**) as a white solid (137 mg, 0.425 mmol, 46%). M.p. (dec.) 166-170 °C; R_f = 0.10 (MeOH/DCM 5:95); ^1H NMR (400 MHz, MeOD) δ 8.37 - 8.27 (m, 1H, ArH), 7.84 - 7.70 (m, 3H, ArH and ICHCH₂), 7.33 - 7.28 (m, 2H, ArH), 4.53 - 4.46 (m, 2H, CH₂Cl); ^{13}C NMR (101 MHz, MeOD) δ 170.3, 153.6, 136.0, 133.6, 132.9, 132.1, 129.6, 115.0, 104.3, 45.2; IR (ν_{\max} , cm^{-1}) 2987 (s), 2973 (s), 2905 (s), 1748 (m), 1737 (m), 1649 (m), 1559 (m), 1540 (m), 1512 (m), 1395 (m), 1255 (m), 1079 (s), 1054 (s), 863 (m); HRMS (ESI) calcd for $\text{C}_{10}\text{H}_9\text{ClIO}_2^+$ $[\text{M}+\text{H}]^+$ 322.9330; found 322.9332.


(E)-1-(3-Methylbuta-1,3-dien-1-yl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (1s)



1s

Following general procedure B, starting from (*E*)-(3-methylbuta-1,3-dien-1-yl)boronic acid (**50s**) (146 mg, 1.30 mmol) and 1-acetoxy-1,2-benziodoxol-3-(1H)-one (**71**) (477 mg, 1.56 mmol), afforded (*E*)-1-(3-methylbuta-1,3-dien-1-yl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (**1s**) as a beige solid (225 mg, 0.716 mmol, 55%). M.p. (dec.) 70-72 °C; R_f = 0.11 (MeOH/DCM 5:95); ^1H NMR (400 MHz, MeOD) δ 8.31 - 8.26 (m, 1H, ArH), 7.78 - 7.61 (m, 4H, ArH and ICHCHC), 7.09 (d, J = 15.2 Hz, 1H, ICHCHC), 5.53 - 5.42 (m, 2H, CCH₂), 2.05 (t, J = 1.1 Hz, 3H, CH₃); ^{13}C NMR (101 MHz, MeOD) δ 170.6, 158.7, 143.6, 135.9, 134.3, 133.8, 132.3, 129.5, 126.2, 115.5, 100.5, 18.3; IR (ν_{\max} , cm^{-1}) 2987 (s), 2896 (m), 1632 (w), 1584 (m), 1570 (m), 1407 (m), 1381 (m), 1261 (m), 1230 (m), 1054 (s), 873 (m), 813 (m); HRMS (ESI) calcd for $\text{C}_{12}\text{H}_{11}\text{IO}_2^+$ $[\text{M}+\text{Na}]^+$ 336.9696; found 336.9695.

(E)-1-((1E,3E)-4-Phenylbuta-1,3-dien-1-yl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (1t)




1t

Following general procedure B, starting from ((1E,3E)-4-phenylbuta-1,3-dien-1-yl)boronic acid (**50t**) (226 mg, 1.30 mmol) and 1-acetoxy-1,2-benziodoxol-3-(1H)-one (**71**) (477 mg, 1.56 mmol), afforded

(*E*)-1-((1*E*,3*E*)-4-phenylbuta-1,3-dien-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1t**) as a beige solid (196 mg, 0.520 mmol, 40%). M.p. (dec.) 169-173 °C; R_f = 0.17 (MeOH/DCM 5:95); ^1H NMR (400 MHz, MeOD) δ 8.35 - 8.27 (m, 1H, ArH), 7.82 - 7.68 (m, 4H, ArH and ICHCH), 7.62 - 7.56 (m, 2H, ArH), 7.45 - 7.32 (m, 3H, ArH), 7.22 (dd, J = 15.6, 10.6 Hz, 1H, CHCHPh), 7.13 (d, J = 14.7 Hz, 1H, ICHCH), 7.05 (d, J = 15.6 Hz, 1H, CHCHPh); ^{13}C NMR (101 MHz, MeOD) δ 170.4, 156.9, 143.1, 137.2, 136.0, 133.7, 133.5, 132.2, 131.0, 130.2, 129.5, 128.9, 127.8, 115.7, 100.0; IR (ν_{max} , cm^{-1}) 2975 (s), 2911 (m), 1720 (m), 1448 (m), 1409 (s), 1381 (m), 1259 (m), 1056 (s), 873 (m), 809 (m), 782 (m); HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{13}\text{I}\text{NaO}_2^+$ [$\text{M}+\text{Na}$] $^+$ 398.9852; found 398.9852.


(*E*)-1-(Non-1-en-3-yn-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (1u**)**



1u

Following general procedure B, starting from (*E*)-non-1-en-3-yn-1-ylboronic acid (**50u**) (216 mg, 1.30 mmol) and 1-acetoxy-1,2-benziodoxol-3-(1*H*)-one (**71**) (477 mg, 1.56 mmol), afforded (*E*)-1-(non-1-en-3-yn-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1u**) as a white solid (376 mg, 1.02 mmol, 79%). M.p. 139-141 °C; R_f = 0.26 (MeOH/DCM 5:95); ^1H NMR (400 MHz, MeOD) δ 8.30 - 8.22 (m, 1H, ArH), 7.77 - 7.62 (m, 3H, ArH), 7.33 (d, J = 15.5 Hz, 1H, ICHCH), 7.06 (dt, J = 15.5, 2.3 Hz, 1H, ICHCH), 2.47 (td, J = 7.0, 2.2 Hz, 2H, CCH_2CH_2), 1.66 - 1.56 (m, 2H, CCH_2CH_2), 1.51 - 1.31 (m, 4H, 2 x CH_2), 0.94 (t, J = 7.1 Hz, 3H, CH_2CH_3); ^{13}C NMR (101 MHz, MeOD) δ 170.0, 136.3, 135.4, 134.3, 133.3, 131.9, 129.1, 115.5, 111.8, 101.4, 79.2, 32.2, 29.1, 23.2, 20.2, 14.3; IR (ν_{max} , cm^{-1}) 2975 (s), 2911 (m), 1720 (m), 1448 (m), 1409 (s), 1381 (m), 1259 (m), 1056 (s), 873 (m), 809 (m), 782 (m); HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{18}\text{IO}_2^+$ [$\text{M}+\text{H}$] $^+$ 369.0346; found 369.0340.

(*E*)-1-Styryl-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (1'a**)**




1'a

Following general procedure C, starting from *trans*-2-phenylvinylboronic acid (**50a**) (148 mg, 1.00 mmol) and 3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**71'**) (514 mg, 1.20 mmol), afforded (*E*)-1-styryl-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (**1'a**) as a white solid (450 mg, 0.950 mmol, 95%). M.p. 167-168 °C; R_f = 0.57 (EtOAc/pentane 50:50); ^1H NMR (400 MHz, CDCl_3) δ 7.91 - 7.84 (m, 1H, ArH), 7.66 - 7.57 (m, 2H, ArH and ICHCHPh), 7.57 - 7.42 (m, 7H, ArH), 7.22 (d, J = 16.1 Hz, 1H, ICHCHPh); ^{13}C NMR (101 MHz, CDCl_3) δ 152.1, 135.5, 132.2, 131.1, 130.8, 130.6, 130.6, 129.3, 127.5, 127.4, 124.2 (q, J = 291.4 Hz), 111.3, 104.8, 81.4 (p, J = 29.9 Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -76.1; IR (ν_{max} , cm^{-1}) 3675 (w), 2987 (s), 2900 (s), 1407 (m), 1394 (m), 1260 (s), 1174 (s), 1147 (s), 1050 (s), 959 (m), 939 (s), 741 (s), 729 (s), 691 (s); HRMS (APPI/LTQ-Orbitrap) m/z : [$\text{M}+\text{H}$] $^+$ Calcd for $\text{C}_{17}\text{H}_{12}\text{F}_6\text{IO}^+$ 472.9832; Found 472.9827; The structure of **1'a** was confirmed by X-ray analysis. Crystals were grown by dissolving 10 mg of pure **1'a** in CDCl_3 (500 μL) at room temperature. Slow evaporation over one week provided suitable crystals. Supplementary crystallographic data for this compound have been deposited at Cambridge Crystallographic Data Centre (CCDC 1993681) and can be obtained free of charge via <https://www.ccdc.cam.ac.uk/structures/>

The reaction was scaled up to *trans*-2-phenylvinylboronic acid (**50a**) (0.740 g, 5.00 mmol) and 3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**71'**) (2.57 g, 6.00 mmol), affording (*E*)-1-styryl-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (**1'a**) (2.20 g, 4.65 mmol, 93%).


(*E*)-3,3-Bis(trifluoromethyl)-1-(4-(trifluoromethyl)styryl)-1,3-dihydro-benzo[*d*][1,2]iodaoxole (1'd**)**



1'd

Following general procedure C, starting from *trans*-2-[4-(trifluoromethyl)phenyl]vinylboronic acid (**50d**) (216 mg, 1.00 mmol) and 3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**71'**) (514 mg, 1.20 mmol), afforded (*E*)-3,3-bis(trifluoromethyl)-1-(4-(trifluoromethyl)styryl)-1,3-dihydro-benzo[*d*][1,2]iodaoxole (**1'd**) as a white solid (455 mg, 0.840 mmol, 84%). M.p. 188-187 °C; R_f = 0.73 (EtOAc/pentane 50:50); ^1H NMR (400 MHz, CDCl_3) δ 7.95 – 7.84 (m, 1H, ArH), 7.76 – 7.59 (m, 6H, ArH and ICHCHPh), 7.59 – 7.51 (m, 1H, ArH), 7.51 – 7.45 (m, 1H, ArH), 7.38 (d, J = 16.2 Hz, 1H, ICHCHPh); ^{13}C NMR (101 MHz, CDCl_3) δ 149.9, 138.7, 132.3, 132.3 (q, J = 32.8 Hz), 131.0, 130.8, 130.9 - 130.6 (m), 127.7, 127.4, 126.3 (q, J = 3.8 Hz), 124.1 (q, J = 291.6 Hz), 123.8 (q, J = 272.2 Hz), 111.2, 108.7, 81.4 (p, J = 28.9 Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -62.9, -76.1; IR (ν_{max} , cm^{-1}) 2987 (m), 2900 (m), 1323 (m), 1261 (s), 1183 (s), 1152 (s), 1119 (s), 1065 (s), 945 (s), 763 (s), 731 (s), 692 (m); HRMS (ESI/QTOF) m/z : [M+H] $^+$ Calcd for $\text{C}_{18}\text{H}_{11}\text{F}_9\text{IO}^+$ 540.9705; Found 540.9708.


(*E*)-1-(2-Cyclohexylvinyl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzobenzo[*d*][1,2]iodaoxole (1'j**)**



1'j

Following general procedure C, starting from *trans*-2-cyclohexylvinylboronic acid (**50j**) (154 mg, 1.00 mmol) and 3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**71'**) (514 mg, 1.20 mmol), afforded (*E*)-1-(2-cyclohexylvinyl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzobenzo[*d*][1,2]iodaoxole (**1'j**) as a white solid (263 mg, 0.550 mmol, 55%). M.p. 170 °C; R_f = 0.55 (EtOAc/pentane 50:50); ^1H NMR (400 MHz, CDCl_3) δ 7.85 (dq, J = 7.7, 1.5 Hz, 1H, ArH), 7.65 – 7.44 (m, 3H, ArH), 6.80 (dd, J = 15.7, 6.7 Hz, 1H, CH=CHCH), 6.44 (dd, J = 15.7, 1.3 Hz, 1H, ICH=CH), 2.36 – 2.22 (m, 1H, $\text{CH}_{\text{-cyclohexyl}}$), 1.92 – 1.76 (m, 4H, $\text{CH}_{\text{-cyclohexyl}}$), 1.76 – 1.64 (m, 1H, $\text{CH}_{\text{-cyclohexyl}}$), 1.45 – 1.13 (m, 5H, $\text{CH}_{\text{-cyclohexyl}}$); ^{13}C NMR (101 MHz, CDCl_3) δ 161.6, 131.9, 131.2, 130.6 – 130.5 (m), 130.4, 127.1, 124.3 (q, J = 292.1 Hz), 110.9, 103.1, 81.4 (p, J = 28.7 Hz), 44.4, 32.0, 25.9, 25.8; ^{19}F NMR (376 MHz, CDCl_3) δ -76.14; IR (ν_{max} , cm^{-1}) 2925 (w), 1256 (m), 1178 (s), 1149 (s), 1126 (m), 960 (m), 943 (s), 761 (s), 730 (s), 692 (m); HRMS (ESI/QTOF) m/z : [M+H] $^+$ Calcd for $\text{C}_{17}\text{H}_{18}\text{F}_6\text{IO}^+$ 479.0301; Found 479.0309.


(*E*)-1-(3-Phenylprop-1-en-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzobenzo[*d*][1,2]iodaoxole (1'k**)**



1'k

Following general procedure C, starting from *trans*-3-Phenyl-1-propen-1-ylboronic acid (**50k**) (162 mg, 1.00 mmol) and 3,3-bis(trifluoromethyl)-1λ³-benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**71'**) (514 mg, 1.20 mmol), afforded (*E*)-1-(3-phenylprop-1-en-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ³-benzobenzo[*d*][1,2]iodaoxole (**1'k**) as a white solid (416 mg, 0.860 mmol, 86%). M.p. 125-126 °C; *R*_f = 0.36 (EtOAc/pentane 50:50); ¹H NMR (400 MHz, CDCl₃) δ 7.88 – 7.80 (m, 1H, ArH), 7.58 (td, *J* = 7.4, 1.3 Hz, 1H, ArH), 7.52 (ddd, *J* = 8.6, 7.0, 1.6 Hz, 1H, ArH), 7.44 (dd, *J* = 8.2, 1.2 Hz, 1H, ArH), 7.41 – 7.34 (m, 2H, ArH), 7.33 – 7.27 (m, 1H, ArH), 7.25 – 7.20 (m, 2H, ArH), 7.01 (dt, *J* = 15.6, 6.5 Hz, 1H, CH₂CH=CH), 6.50 (dt, *J* = 15.6, 1.5 Hz, 1H, ICH=CH), 3.69 (dd, *J* = 6.5, 1.5 Hz, 2H, CH₂Ph); ¹³C NMR (101 MHz, CDCl₃) δ 154.2, 136.9, 132.0, 131.1, 130.6 – 130.4 (m), 130.5, 129.2, 128.8, 127.3, 127.28, 124.2 (q, *J* = 291.9 Hz), 111.0, 106.8, 81.3 (p, *J* = 28.9 Hz), 42.3; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.1; IR (ν_{max}, cm⁻¹) 3674 (m), 2972 (s), 2901 (s), 1394 (m), 1258 (s), 1212 (m), 1173 (s), 1144 (s), 1121 (m), 1049 (s), 961 (m), 942 (s), 767 (s), 750 (s), 707 (s), 693 (s), 679 (m); HRMS (ESI/QTOF) *m/z*: [M+H]⁺ Calcd for C₁₈H₁₄F₆O⁺ 486.9988; Found 486.9994.


(*E*)-1-(Pent-1-en-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ³-benzobenzo[*d*][1,2]iodaoxole (1'l)



1'l

Following general procedure C, starting from *trans*-1-penten-1-ylboronic acid (**50l**) (114 mg, 1.00 mmol) and 3,3-bis(trifluoromethyl)-1λ³-benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**71**) (514 mg, 1.20 mmol), afforded (*E*)-1-(pent-1-en-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ³-benzobenzo[*d*][1,2]iodaoxole (**1'l**) as a white solid (350 mg, 0.800 mmol, 80%). M.p. 150-151 °C; *R*_f = 0.39 (EtOAc/pentane 50:50); ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, *J* = 7.6 Hz, 1H, ArH), 7.64 – 7.49 (m, 3H, ArH), 6.87 (dt, *J* = 15.4, 6.7 Hz, 1H, CH=CHCH₂), 6.52 (d, *J* = 15.4 Hz, 1H, ICH=CH), 2.37 (q, *J* = 7.1 Hz, 2H, CHCH₂), 1.59 (h, *J* = 7.4 Hz, 2H, CH₂CH₂CH₃), 1.02 (t, *J* = 7.3 Hz, 3H, CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 156.4, 132.0, 131.3, 130.6, 130.5, 127.3, 124.3 (q, *J* = 291.9 Hz), 111.0, 105.1, 82.5 – 80.7 (m), 38.1, 21.6, 13.8; ¹⁹F NMR (376 MHz, CDCl₃) δ -76.1; IR (ν_{max}, cm⁻¹) 3669 (w), 2987 (s), 2972 (s), 2908 (s), 2851 (m), 1755 (m), 1734 (m), 1450 (m), 1250 (m), 1153 (m), 1104 (m), 1078 (s), 1057 (s), 966 (m), 739 (m); HRMS (APPI/LTQ-Orbitrap) *m/z*: [M+H]⁺ Calcd for C₁₄H₁₄F₆O⁺ 438.9988; Found 438.9992.

(*E*)-2-(3-(3,3-Bis(trifluoromethyl)-1λ³-benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)allyl)isoindoline-1,3-dione (1'p)



1'p


Following general procedure C, starting from (*E*)-(3-(1,3-dioxoisoindolin-2-yl)prop-1-en-1-yl)boronic acid (**50p**) (231 mg, 1.00 mmol) and 3,3-bis(trifluoromethyl)-1λ³-benzo[*d*][1,2]iodaoxol-1(3*H*)-yl acetate (**71'**) (514 mg, 1.20 mmol), afforded (*E*)-2-(3-(3,3-bis(trifluoromethyl)-1λ³-

benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)allyl)isoindoline-1,3-dione (**1'p**) as a white solid (422 mg, 0.760 mmol, 76%). M.p. 179-180 °C; $R_f = 0.18$ (EtOAc/pentane 50:50); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.90 (dd, $J = 5.5, 3.0$ Hz, 2H, Ar*H*), 7.86 – 7.74 (m, 3H, Ar*H*), 7.64 – 7.56 (m, 2H, Ar*H*), 7.56 – 7.48 (m, 1H, Ar*H*), 6.83 (dt, $J = 15.8, 5.0$ Hz, 1H, $\text{CH}_2\text{CH}=\text{CH}$), 6.72 (dt, $J = 15.8, 1.4$ Hz, 1H, $\text{CH}=\text{CHI}$), 4.56 (dd, $J = 5.0, 1.4$ Hz, 2H, NCH_2); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 167.8, 146.9, 134.7, 132.5, 131.9, 130.8, 130.6, 130.6 – 130.4 (m), 127.9, 124.1 (q, $J = 291.5$ Hz), 123.9, 111.1, 109.3, 81.2 (p, $J = 29.2$ Hz), 41.4; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -76.1; IR (ν_{max} , cm^{-1}) 3674 (m), 2973 (s), 2900 (s), 1771 (m), 1720 (s), 1421 (m), 1392 (s), 1260 (s), 1211 (m), 1173 (s), 1156 (s), 1048 (s), 978 (w), 962 (m), 944 (s), 930 (s), 761 (m), 718 (s), 693 (m); HRMS (ESI/QTOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{13}\text{F}_6\text{INO}_3^+$ 555.9839; Found 555.9839.

5. Optimization of the reaction


a) Table S1 - Intramolecular reaction

Under inert atmosphere, a solution of catalyst was prepared by mixing $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (12.6 mg, 40.0 μmol) and ligand (**3a-f**) (50.0 μmol) in DCE (5.0 mL) at 25 °C for 1 h. Then, 0.5 mL of the catalytic solution was then added to a stirring suspension of VBX (0.10 mmol, 1.00 equiv) and diazo compound (0.200 mmol, 1.00 equiv) in DCE (2.0 mL). After completion of the reaction, the solvent was removed under reduced pressure and the resulting crude oil was purified by column chromatography (EtOAc/pentane) directly without further work-up to afford the corresponding product.



entry	Ligand	diazo R ¹ =	VBX R ² =	temp.	time	yield ^a	by-product
1	3a , no Cu	H, 2a	Ph, 1a	40 °C	4 h	0%	
2	none	H, 2a	Ph, 1a	40 °C	4 h	< 5%	
3	3a	H, 2a	Ph, 1a	40 °C	4 h	90%	
4	3a	Ph, 2b	Ph, 1a	40 °C	4 h	80%	
5	3a	H, 2a	PMP, 1c	60 °C	24 h	50%	
6	3a	H, 2a	Cy, 1j	60 °C	24 h	< 5%	
7	3b	H, 2a	Ph, 1a	25 °C	1 h	95%	
8	3e	H, 2a	Ph, 1a	25 °C	24 h	< 5%	
9^b	3c	H, 2a	Ph, 1a	25 °C	1 h	95%	
10 ^b	3c	H, 2a	PMP, 1c	25 °C	4 h	81%	
11 ^b	3c	H, 2a	Cy, 1j	25 °C	4 h	99%	
12	3c	Ph, 2b	Ph, 1a	25 °C	4 h	< 5%	
13	3f	H, 2a	Ph, 1a	25 °C	24 h	< 5%	

[a] Isolated yield. [b] On 0.20 mmol scale. Ph = phenyl, Cy = cyclohexyl, PMP = para-methoxyphenyl.



Two sets of reactions conditions were identified:

- For non-substituted diazo ($R^1 = H$): $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (4 mol%) + **3c** (5 mol%) in DCE at 25 °C.
- For substituted diazo ($R^1 \neq H$): $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (4 mol%) + **3a** (5 mol%) in DCE at 40 °C.




b) Table S2 - Intermolecular/3-component reaction

Under inert atmosphere, ethyl diazoacetate (**2a**) (19.0 μL , 0.16 mmol, 2.00 equiv., 87%wt in DCM) was added to a stirred solution of Ph-VBX (**1'a**) (38 mg, 80 μmol , 1.00 equiv.), EtOH (**7a**) (x equiv.) and Cu cat. (y mol%) in CD_2Cl_2 (0.8 mL). The resulting reaction mixture was stirred at 25 °C for 1 h. After this time, CH_2Br_2 (100 μL , 0.8 M in CD_2Cl_2 , 0.08 mmol, 1.00 equiv.) was added as internal standard and the ^1H NMR spectrum of the reaction mixture was recorded.

When a ligand was used, the corresponding catalytic solution (Cu cat. + Ligand) was premixed for 1 h in CD_2Cl_2 before addition of Ph-VBX (**1'a**), EtOH (**7a**) and ethyl diazoacetate (**2a**).

entry	EBX X =	EtOH (x equiv.)	Cu cat. (y mol%)	ligand (z mol%)	temp.	yield ^a
1	O, 1a	as solvent	Cu(CH ₃ CN) ₄ BF ₄ (4 mol%)	3b (5 mol%)	25 °C	30%
2	(CF ₃) ₂ , 1'a	4.00	Cu(CH ₃ CN) ₄ PF ₆ (10 mol%)	-	25 °C	43%
3	(CF ₃) ₂ , 1'a	4.00	Cu(CH ₃ CN) ₄ PF ₆ (5 mol%)	-	25 °C	45%
4	(CF ₃) ₂ , 1'a	4.00	Cu(CH ₃ CN) ₄ PF ₆ (5 mol%)	3a (5 mol%)	25 °C	28%
5	(CF ₃) ₂ , 1'a	4.00	Cu(CH ₃ CN) ₄ PF ₆ (5 mol%)	3c (5 mol%)	25 °C	14%
6	(CF ₃) ₂ , 1'a	10.0	Cu(CH ₃ CN) ₄ PF ₆ (5 mol%)	-	25 °C	18%
7	(CF ₃) ₂ , 1'a	2.00	Cu(CH ₃ CN) ₄ PF ₆ (5 mol%)	-	25 °C	38%
8	(CF ₃) ₂ , 1'a	3.00	Cu(CH ₃ CN) ₄ PF ₆ (5 mol%)	-	25 °C	51%
9	(CF ₃) ₂ , 1'a	3.00	Cu(CH ₃ CN) ₄ BF ₄ (5 mol%)	-	25 °C	54%
10	(CF ₃) ₂ , 1'a	3.00	CuOTf toluene (5 mol%)	-	25 °C	<5%
11	(CF ₃) ₂ , 1'a	3.00	CuTC (5 mol%)	-	25 °C	13%
12	(CF ₃) ₂ , 1'a	3.00	CuCl (5 mol%)	-	25 °C	14%
13	(CF ₃) ₂ , 1'a	3.00	CuCl ₂ (5 mol%)	-	25 °C	18%
14^b	(CF₃)₂, 1'a	3.00	Cu(CH₃CN)₄BF₄ (5 mol%)	-	25 °C	59%
15 ^b	(CF ₃) ₂ , 1'a	3.00	Cu(CH ₃ CN) ₄ BF ₄ (5 mol%)	-	0 °C	< 5%
16 ^b	(CF ₃) ₂ , 1'a	3.00	Cu(CH ₃ CN) ₄ BF ₄ (5 mol%)	-	40 °C	49%

[a] Determined by ¹H NMR analysis. [b] **2a** was slowly added in 1 h as a 0.6 M solution in CD₂Cl₂ using a syringe pump.




In line with our previous work,⁴⁹ no competitive intramolecular reaction was observed with non-nucleophilic Ph-VBX **1'a**. The reaction performed better without additional ligand. Cu(CH₃CN)₄BF₄ (5 mol%) was the optimal catalyst found.

⁴⁹ G. Pisella, A. Gagnebin, and J. Waser, *Chem. Eur. J.* **2020**, DOI: 10.1002/chem.202001317.

6. Reaction mechanism


Scheme S1 – Proposed reaction mechanism



Starting with Cu(I) catalyst **I**, decomposition of diazo compound **2** would generate electrophilic copper-carbene **II**. At this stage, nucleophilic attack of the carboxylate part of the VBX reagent **1** forms copper-iodonium intermediate **III**. Direct intramolecular electrophilic vinylation leads to product **4** and regenerates catalyst **I**; With bis-trifluoromethyl reagents **1'**, the oxygen atom of the benziodoxole is not nucleophilic enough, and attack of the external alcohol **7** forms oxonium-ylide intermediate **III'**. Intermolecular alkenylation by VBX reagent **1'** with simultaneous deprotonation then generates the 3-component product **6** and release the copper catalyst **I**.

7. Oxy-vinylation reaction with VBX reagents

General procedure D: Oxy-vinylation of unsubstituted diazo compound:




Under inert atmosphere, a catalytic solution was prepared by mixing $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (12.6 mg, 40.0 μmol) and 2,2'-(propane-2,2-diyl)bis(4,4-dimethyl-4,5-dihydrooxazole) (**3c**) (11.9 mg, 50.0 μmol) in DCE (5.0 mL) at 25 °C for 1 h.

1.0 mL of the catalytic solution was then added to a suspension of VBX (**1a-u**) (0.200 mmol, 1.00 equiv) and diazo compound (**2a-k**) (0.400 mmol, 2.00 equiv) in DCE (4.0 mL).

The reaction mixture was stirred at 25 °C. After the reaction was completed (monitored by TLC, EtOAc/pentane 5:95 and MeOH/DCM 5:95), the solvent was removed under reduced pressure and the resulting crude oil was purified by column chromatography (EtOAc/pentane) directly without further work-up to afford the corresponding product (**4a-u**; **5b-j**).

General procedure E: Oxy-vinylation of substituted diazo compound:




Under inert atmosphere, a catalytic solution was prepared by mixing $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (12.6 mg, 40.0 μmol) and (1*E*,1'*E*)-*N,N'*-(ethane-1,2-diyl)bis(1-(2,6-dichlorophenyl)methanimine) (**3a**) (18.7 mg, 50.0 μmol) in DCE (5.0 mL) at 25 °C for 1 h.

1.0 mL of the catalytic solution was then added to a suspension of Ph-VBX (**1a**) (0.200 mmol, 1.00 equiv) and diazo compound (**2b-o**) (0.400 mmol, 2.00 equiv) in DCE (4.0 mL).

The reaction mixture was stirred at 40 °C. After the reaction was completed (monitored by TLC, EtOAc/pentane 5:95 and MeOH/DCM 5:95), the solvent was removed under reduced pressure and the resulting crude oil was purified by column chromatography (EtOAc/pentane, ratio indicated in the R_f measurement) directly without further work-up to afford the corresponding product (**5a-p**).


General procedure F: Oxy-vinylation of diazo compound, three-component reaction:



An oven-dried 10 mL microwave vial was charged with $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (4.72 mg, 15.0 μmol , 0.05 equiv.), VBX reagent (**1'a-p**) (0.30 mmol, 1.00 equiv.) and alcohol (**7a-e**) (0.90 mmol, 3.00 equiv.), if


solid. The vial was capped, removed from the glovebox and dry DCM (3.0 mL) was added. The alcohol was added at this point if liquid. To the resulting solution was added a 0.6 M solution of diazo compound (**2a-r**) (0.60 mmol, 2.00 equiv.) in dry DCM (1.0 mL) in 1 h *via* syringe pump at 25 °C. At the end of the addition, the reaction was continued for 1 h at the same temperature. The solvent was removed under reduced pressure and the resulting crude product was purified by column chromatography using EtOAc/pentane as eluent (the solvent ratio indicated in the R_f measurement was used), directly without further work-up to afford the corresponding product (**6b-g**).

(E)-1-Ethoxy-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (4a)




Following general procedure D, starting from (*E*)-1-styryl-1λ³-benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1a**) (70.0 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μL, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**4a**) as a colorless oil (83 mg, 0.19 mmol, 95%). R_f = 0.24 (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 8.01 (ddd, *J* = 10.8, 7.9, 1.4 Hz, 2H, Ar*H*), 7.49 - 7.41 (m, 3H, Ar*H*), 7.38 - 7.27 (m, 3H, Ar*H*), 7.19 (ddd, *J* = 7.9, 7.4, 1.7 Hz, 1H, Ar*H*), 6.93 (dd, *J* = 15.9, 1.2 Hz, 1H, CHCHPh), 6.38 (dd, *J* = 15.9, 7.1 Hz, 1H, CHCHPh), 5.87 (dd, *J* = 7.1, 1.3 Hz, 1H, OCHCC), 4.29 (qd, *J* = 7.1, 2.4 Hz, 2H, OCH₂CH₃), 1.32 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 168.5, 165.6, 141.6, 135.8, 135.7, 134.2, 133.2, 131.7, 128.8, 128.8, 128.1, 127.0, 120.7, 94.6, 74.3, 62.2, 14.3; IR (ν_{max}, cm⁻¹) 2978 (m), 2902 (m), 1735 (s), 1582 (w), 1451 (m), 1395 (m), 1369 (m), 1278 (s), 1258 (s), 1199 (m), 1129 (m), 1098 (s), 1044 (s), 1016 (s), 966 (m), 863 (m), 764 (s), 750 (s); HRMS (ESI) calcd for C₁₉H₁₇INaO₄⁺ [M+Na]⁺ 459.0064; found 459.0070.

(E)-1-Ethoxy-4-(4-methoxyphenyl)-1-oxobut-3-en-2-yl 2-iodobenzoate (4b)




Following general procedure D, starting from (*E*)-1-(4-methoxystyryl)-1λ³-benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1b**) (76.0 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μL, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-4-(4-methoxyphenyl)-1-oxobut-3-en-2-yl 2-iodobenzoate (**4b**) as a colorless oil (76 mg, 0.16 mmol, 81%). R_f = 0.12 (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 8.05 - 7.95 (m, 2H, Ar*H*), 7.44 (td, *J* = 7.6, 1.2 Hz, 1H, Ar*H*), 7.40 - 7.34 (m, 2H, Ar*H*), 7.18 (ddd, *J* = 7.9, 7.4, 1.7 Hz, 1H, Ar*H*), 6.90 - 6.82 (m, 3H, Ar*H* and CHCHPh), 6.23 (dd, *J* = 15.9, 7.4 Hz, 1H, CHCHPh), 5.83 (dd, *J* = 7.4, 1.2 Hz, 1H, OCHCC), 4.28 (qd, *J* = 7.1, 3.0 Hz, 2H, OCH₂CH₃), 3.81 (s, 3H, ArOCH₃), 1.31 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 168.7, 165.7, 160.1, 141.6, 135.6, 134.2, 133.2, 131.7, 128.4, 128.3, 128.1, 118.3, 114.2, 94.5, 74.6, 62.1, 55.5, 14.3; IR (ν_{max}, cm⁻¹) 2933 (m), 2862 (w), 2091 (w), 1731 (s), 1607 (m), 1582 (w), 1511 (s), 1465 (m), 1288 (m), 1248 (s), 1194 (m), 1175 (s), 1128 (m), 1096 (s), 1015 (s), 969 (m), 824 (m); HRMS (ESI) calcd for C₂₀H₁₉INaO₅⁺ [M+Na]⁺ 489.0169; found 489.0169.

(*E*)-1-Ethoxy-1-oxo-4-(*p*-tolyl)but-3-en-2-yl 2-iodobenzoate (**4c**)




Following general procedure D, starting from (*E*)-1-(4-methylstyryl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1c**) (72.8 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μ L, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-1-oxo-4-(*p*-tolyl)but-3-en-2-yl 2-iodobenzoate (**4c**) as a colorless oil (83 mg, 0.18 mmol, 92%). R_f = 0.26 (EtOAc/pentane 5:95); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.01 (ddd, J = 9.7, 7.9, 1.4 Hz, 2H, ArH), 7.44 (td, J = 7.6, 1.2 Hz, 1H, ArH), 7.37 - 7.29 (m, 2H, ArH), 7.23 - 7.12 (m, 3H, ArH), 6.93 - 6.85 (m, 1H, CHCHPh), 6.32 (dd, J = 15.9, 7.2 Hz, 1H, CHCHPh), 5.85 (dd, J = 7.2, 1.3 Hz, 1H, OCHCC), 4.28 (qd, J = 7.1, 2.2 Hz, 2H, OCH_2CH_3), 2.35 (s, 3H, ArCH₃), 1.31 (t, J = 7.1 Hz, 3H, OCH_2CH_3); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 168.6, 165.6, 141.6, 138.8, 135.8, 134.2, 133.2, 132.9, 131.7, 129.5, 128.1, 126.9, 119.6, 94.5, 74.5, 62.1, 21.4, 14.3; IR (ν_{max} , cm^{-1}) 2979 (m), 2906 (m), 1732 (s), 1462 (m), 1429 (m), 1372 (m), 1294 (s), 1239 (s), 1198 (s), 1127 (s), 1098 (s), 1041 (s), 1014 (s), 965 (s), 855 (m), 810 (m), 740 (s); HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{19}\text{INaO}_4^+$ [$\text{M}+\text{Na}$] $^+$ 473.0220; found 473.0220.

(*E*)-1-Ethoxy-1-oxo-4-(4-(trifluoromethyl)phenyl)but-3-en-2-yl 2-iodobenzoate (**4d**)



Following general procedure D, starting from (*E*)-1-(4-(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1d**) (84.0 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μ L, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-1-oxo-4-(4-(trifluoromethyl)phenyl)but-3-en-2-yl 2-iodobenzoate (**4d**) as a colorless oil (73 mg, 0.15 mmol, 72%). R_f = 0.22 (EtOAc/pentane 5:95); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.02 (ddd, J = 15.1, 7.9, 1.4 Hz, 2H, ArH), 7.60 (d, J = 8.2 Hz, 2H, ArH), 7.53 (d, J = 8.2 Hz, 2H, ArH), 7.46 (td, J = 7.6, 1.2 Hz, 1H, ArH), 7.24 - 7.17 (m, 1H, ArH), 6.96 (dd, J = 16.0, 1.4 Hz, 1H, CHCHPh), 6.48 (dd, J = 16.0, 6.6 Hz, 1H, CHCHPh), 5.91 (dd, J = 6.7, 1.4 Hz, 1H, OCHCC), 4.30 (qd, J = 7.1, 2.3 Hz, 2H, OCH_2CH_3), 1.33 (t, J = 7.1 Hz, 3H, OCH_2CH_3); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 168.1, 165.5, 141.7, 139.2, 134.0, 133.9, 133.4, 131.7, 130.5 (q, J = 32.6 Hz), 128.2, 127.2, 125.8 (q, J = 3.9 Hz), 124.1 (q, J = 272.0 Hz), 123.5, 94.6, 73.8, 62.4, 14.3; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -62.7; IR (ν_{max} , cm^{-1}) 2979 (m), 2914 (m), 1732 (m), 1466 (w), 1415 (m), 1374 (w), 1325 (s), 1243 (s), 1196 (m), 1166 (m), 1108 (s), 1067 (s), 1047 (s), 1014 (s), 969 (m), 857 (m), 822 (m), 742 (s); HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{16}\text{F}_3\text{INaO}_4^+$ [$\text{M}+\text{Na}$] $^+$ 526.9938; found 526.9951.


(*E*)-1-Ethoxy-4-(4-fluorophenyl)-1-oxobut-3-en-2-yl 2-iodobenzoate (**4e**)



Following general procedure D, starting from (*E*)-1-(4-fluorostyryl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1e**) (73.6 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μ L, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-4-(4-fluorophenyl)-1-oxobut-3-en-2-yl 2-iodobenzoate (**4e**) as a colorless oil (60 mg, 0.13 mmol, 66%). R_f = 0.22 (EtOAc/pentane 5:95); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.02 (dd, J = 7.9, 1.2 Hz, 1H, ArH), 7.99 (dd, J = 7.8, 1.8 Hz, 1H, ArH), 7.50 - 7.36 (m, 3H, ArH), 7.19 (td, J = 7.7, 1.7 Hz, 1H, ArH), 7.08 - 6.99 (m, 2H, ArH), 6.93 - 6.84 (m, 1H, CHCHPh), 6.30 (dd, J = 15.9, 7.1 Hz, 1H, CHCHPh),


5.85 (dd, $J = 7.1, 1.3$ Hz, 1H, OCHCC), 4.28 (qd, $J = 7.1, 3.2$ Hz, 2H, OCH₂CH₃), 1.32 (t, $J = 7.1$ Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 168.5, 165.6, 163.0 (d, $J = 248.5$ Hz), 141.6, 134.6, 134.1, 133.3, 131.9 (d, $J = 3.3$ Hz), 131.7, 128.7 (d, $J = 8.2$ Hz), 128.2, 120.5 (d, $J = 2.2$ Hz), 115.8 (d, $J = 21.7$ Hz), 94.5, 74.2, 62.2, 14.3; ¹⁹F NMR (376 MHz, CDCl₃) δ -112.7; IR (ν_{\max} , cm⁻¹) 2981 (m), 2932 (w), 1734 (s), 1601 (m), 1585 (m), 1509 (s), 1466 (m), 1423 (m), 1376 (m), 1290 (s), 1211 (s), 1131 (s), 1104 (s), 1016 (s), 967 (m), 859 (m), 826 (m), 740 (s), 716 (m); HRMS (ESI) calcd for C₁₉H₁₆FINaO₄⁺ [M+Na]⁺ 476.9970; found 476.9971.

(E)-1-Ethoxy-4-(naphthalen-1-yl)-1-oxobut-3-en-2-yl 2-iodobenzoate (4f)




Following general procedure D, starting from (*E*)-1-(2-(naphthalen-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1f**) (80.0 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μ L, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-4-(naphthalen-1-yl)-1-oxobut-3-en-2-yl 2-iodobenzoate (**4f**) as a white solid (79 mg, 0.16 mmol, 81%). M.p. 59-61 °C; $R_f = 0.18$ (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 8.15 - 8.09 (m, 1H, Ar*H*), 8.04 (dt, $J = 7.8, 1.4$ Hz, 2H, Ar*H*), 7.91 - 7.78 (m, 2H, Ar*H*), 7.71 (d, $J = 15.7$ Hz, 1H, CHCHPh), 7.64 (dt, $J = 7.2, 1.0$ Hz, 1H, Ar*H*), 7.58 - 7.42 (m, 4H, Ar*H*), 7.20 (ddd, $J = 7.9, 7.4, 1.7$ Hz, 1H, Ar*H*), 6.44 (dd, $J = 15.7, 6.9$ Hz, 1H, CHCHPh), 6.01 (dd, $J = 6.9, 1.4$ Hz, 1H, OCHCC), 4.33 (q, $J = 7.1$ Hz, 2H, OCH₂CH₃), 1.35 (t, $J = 7.1$ Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 168.4, 165.7, 141.6, 134.2, 133.7, 133.5, 133.3, 133.1, 131.7, 131.2, 129.0, 128.7, 128.2, 126.5, 126.1, 125.7, 124.5, 123.9, 123.8, 94.5, 74.4, 62.2, 14.3; IR (ν_{\max} , cm⁻¹) 3057 (w), 2985 (m), 2904 (m), 1732 (s), 1583 (m), 1464 (m), 1429 (m), 1395 (m), 1370 (m), 1335 (m), 1284 (s), 1241 (s), 1192 (s), 1131 (s), 1094 (s), 1016 (s), 967 (s), 859 (m), 775 (s), 736 (s); HRMS (ESI) calcd for C₂₃H₁₉INaO₄⁺ [M+Na]⁺ 509.0220; found 509.0233.

(E)-1-Ethoxy-1-oxo-4-(thiophen-2-yl)but-3-en-2-yl 2-iodobenzoate (4g)




Following general procedure D, starting from (*E*)-1-(2-(thiophen-2-yl)vinyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1g**) (71.2 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 mL, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-1-oxo-4-(thiophen-2-yl)but-3-en-2-yl 2-iodobenzoate (**4g**) as a clear yellow oil (67 mg, 0.15 mmol, 76%). $R_f = 0.24$ (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 8.06 - 7.95 (m, 2H, Ar*H*), 7.45 (td, $J = 7.6, 1.2$ Hz, 1H, Ar*H*), 7.24 (dt, $J = 5.0, 0.9$ Hz, 1H, Ar*H*), 7.19 (ddd, $J = 7.9, 7.4, 1.7$ Hz, 1H, Ar*H*), 7.08 - 7.00 (m, 2H, Ar*H* and CHCHPh), 6.99 (dd, $J = 5.1, 3.6$ Hz, 1H, Ar*H*), 6.20 (dd, $J = 15.7, 7.2$ Hz, 1H, CHCHPh), 5.82 (dd, $J = 7.2, 1.3$ Hz, 1H, OCHCC), 4.28 (qq, $J = 7.1, 3.6$ Hz, 2H, OCH₂CH₃), 1.32 (t, $J = 7.1$ Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 168.4, 165.6, 141.6, 140.6, 134.1, 133.3, 131.7, 128.9, 128.2, 127.7, 127.6, 125.8, 119.9, 94.6, 74.1, 62.2, 14.3; IR (ν_{\max} , cm⁻¹) 3057 (w), 2985 (m), 2904 (m), 1732 (s), 1583 (m), 1464 (m), 1429 (m), 1395 (m), 1370 (m), 1335 (m), 1284 (s), 1241 (s), 1192 (s), 1131 (s), 1094 (s), 1016 (s), 967 (s), 859 (m), 775 (s), 736 (s); HRMS (ESI) calcd for C₁₇H₁₅IO₄S [M⁺] 441.9730; found 441.9733.

(E)-1-Ethoxy-1-oxo-4-phenylbut-3-en-2-yl 2-iodo-5-methoxybenzoate (4h)




Following general procedure D, starting from (*E*)-5-methoxy-1-styryl-1λ³-benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1h**) (76.0 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μL, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-1-oxo-4-phenylbut-3-en-2-yl 2-iodo-5-methoxybenzoate (**4h**) as a colorless oil (78 mg, 0.17 mmol, 84%). *R*_f = 0.14 (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, *J* = 8.7 Hz, 1H, Ar*H*), 7.52 (d, *J* = 3.1 Hz, 1H, Ar*H*), 7.48 - 7.41 (m, 2H, Ar*H*), 7.39 - 7.27 (m, 3H, Ar*H*), 6.93 (dd, *J* = 16.0, 1.2 Hz, 1H, CHCHPh), 6.79 (dd, *J* = 8.7, 3.1 Hz, 1H, Ar*H*), 6.38 (dd, *J* = 15.9, 7.1 Hz, 1H, CHCHPh), 5.85 (dd, *J* = 7.1, 1.3 Hz, 1H, OCHCC), 4.29 (qd, *J* = 7.1, 2.8 Hz, 2H, OCH₂CH₃), 3.84 (s, 3H, ArOCH₃), 1.32 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 168.5, 165.5, 159.7, 142.1, 135.8, 135.7, 135.0, 128.8, 128.8, 127.0, 120.7, 119.8, 117.2, 82.8, 74.4, 62.1, 55.7, 14.3; IR (ν_{max}, cm⁻¹) 2986 (w), 2937 (w), 1736 (s), 1590 (m), 1565 (m), 1469 (m), 1449 (m), 1394 (m), 1368 (m), 1313 (m), 1284 (s), 1241 (s), 1213 (s), 1184 (s), 1092 (s), 1046 (s), 1029 (s), 1009 (s), 966 (s), 911 (m), 811 (m), 777 (m), 732 (s), 693 (s); HRMS (ESI) calcd for C₂₀H₁₉I O₅ [M⁺] 466.0272; found 466.0276.

(E)-1-Ethoxy-1-oxo-4-phenylbut-3-en-2-yl 5-fluoro-2-iodobenzoate (4i)



Following general procedure D, starting from (*E*)-5-fluoro-1-styryl-1λ³-benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1i**) (73.6 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μL, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-1-oxo-4-phenylbut-3-en-2-yl 5-fluoro-2-iodobenzoate (**4i**) as a colorless oil (77 mg, 0.17 mmol, 85%). *R*_f = 0.34 (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 7.97 (dd, *J* = 8.7, 5.3 Hz, 1H, Ar*H*), 7.73 (dd, *J* = 8.9, 3.1 Hz, 1H, Ar*H*), 7.48 - 7.41 (m, 2H, Ar*H*), 7.39 - 7.28 (m, 3H, Ar*H*), 7.01 - 6.88 (m, 2H, Ar*H* and CHCHPh), 6.37 (dd, *J* = 15.9, 7.2 Hz, 1H, CHCHPh), 5.85 (dd, *J* = 7.2, 1.3 Hz, 1H, OCHCC), 4.29 (qd, *J* = 7.1, 3.3 Hz, 2H, OCH₂CH₃), 1.32 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 168.3, 164.5 (d, *J* = 2.6 Hz), 162.5 (d, *J* = 249.7 Hz), 143.0 (d, *J* = 7.3 Hz), 136.1, 135.6 (d, *J* = 7.3 Hz), 135.6, 128.9, 127.0, 120.9 (d, *J* = 21.4 Hz), 120.4, 119.2 (d, *J* = 24.2 Hz), 87.6 (d, *J* = 3.6 Hz), 74.6, 62.3, 14.3; ¹⁹F NMR (376 MHz, CDCl₃) δ -113.0; IR (ν_{max}, cm⁻¹) 1736 (s), 1575 (m), 1465 (m), 1449 (m), 1394 (m), 1370 (m), 1296 (m), 1264 (s), 1241 (s), 1188 (s), 1127 (m), 1084 (m), 1017 (s), 964 (m), 819 (m), 777 (m), 734 (s), 691 (m); HRMS (ESI) calcd for C₁₉H₁₆FIO₄ [M⁺] 454.0072; found 454.0074. One carbon was not resolved at 101 MHz.


(E)-4-Cyclohexyl-1-ethoxy-1-oxobut-3-en-2-yl 2-iodobenzoate (4j)



Following general procedure D, starting from (*E*)-1-(2-cyclohexylvinyl)-1λ³-benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1j**) (71.2 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μL, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-1-oxo-5-phenylpent-3-en-2-yl 2-iodobenzoate (**4j**) as a colorless oil (88 mg, 0.20 mmol, 99%). *R*_f = 0.37 (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 8.00 (dd, *J* = 7.9, 1.2


Hz, 1H, ArH), 7.94 (dd, $J = 7.8, 1.7$ Hz, 1H, ArH), 7.42 (td, $J = 7.6, 1.2$ Hz, 1H, ArH), 7.17 (ddd, $J = 7.9, 7.4, 1.7$ Hz, 1H, ArH), 6.04 - 5.94 (m, 1H, CHCHcy), 5.66 - 5.57 (m, 2H, CHCHy and OCHCC), 4.24 (qd, $J = 7.1, 2.7$ Hz, 2H, OCH₂CH₃), 2.98 (m, 1H, cy-H), 1.80 - 1.69 (m, 4H, cy-H), 1.69 - 1.61 (m, 1H, cy-H), 1.34 - 1.03 (m, 8H, cy-H and OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 169.0, 165.7, 143.9, 141.5, 134.3, 133.1, 131.7, 128.1, 119.4, 94.5, 74.6, 61.8, 40.6, 32.5 - 32.3 (2 s, rotamer), 32.5, 32.4, 26.2, 26.0, 14.3; IR (ν_{\max} , cm⁻¹) 2977 (m), 2920 (m), 2848 (m), 1736 (s), 1579 (m), 1450 (m), 1286 (s), 1239 (s), 1190 (s), 1133 (s), 1100 (s), 1014 (s), 965 (s), 740 (s); HRMS (ESI) calcd for C₁₉H₂₃INaO₄⁺ [M+Na]⁺ 465.0533; found 465.0542.

(E)-1-Ethoxy-1-oxo-5-phenylpent-3-en-2-yl 2-iodobenzoate (4k)




Following general procedure D, starting from (*E*)-1-(3-phenylprop-1-en-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1k**) (72.8 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μ L, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-1-oxo-5-phenylpent-3-en-2-yl 2-iodobenzoate (**4k**) as a colorless oil (81 mg, 0.18 mmol, 90%). $R_f = 0.26$ (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 8.00 (dd, $J = 8.0, 1.1$ Hz, 1H, ArH), 7.94 (dd, $J = 7.8, 1.7$ Hz, 1H, ArH), 7.42 (td, $J = 7.6, 1.2$ Hz, 1H, ArH), 7.35 - 7.27 (m, 2H, ArH), 7.25 - 7.13 (m, 4H, ArH), 6.22 (dtd, $J = 14.7, 6.8, 0.8$ Hz, 1H, CHCHBn), 5.80 - 5.66 (m, 2H, CHCHBn and OCHCC), 4.26 (qd, $J = 7.1, 2.4$ Hz, 2H, OCH₂CH₃), 3.50 - 3.43 (m, 2H, CHCH₂Ph), 1.29 (t, $J = 7.1$ Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 168.6, 165.5, 141.4, 138.9, 136.3, 134.1, 133.0, 131.5, 128.6, 128.6, 128.0, 126.4, 123.1, 94.4, 74.0, 61.8, 38.6, 14.2; IR (ν_{\max} , cm⁻¹) 2981 (w), 2918 (m), 1732 (s), 1456 (m), 1429 (m), 1288 (s), 1237 (s), 1200 (s), 1129 (s), 1098 (s), 1016 (s), 973 (s), 742 (s), 699 (s); HRMS (ESI) calcd for C₂₀H₁₉INaO₄⁺ [M+Na]⁺ 473.0220; found 473.0223.

(E)-1-Ethoxy-1-oxohept-3-en-2-yl 2-iodobenzoate (4l)




Following general procedure D, starting from (*E*)-1-(1-(pent-1-en-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1l**) (63.2 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μ L, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-1-oxohept-3-en-2-yl 2-iodobenzoate (**4l**) as a colorless oil (76 mg, 0.19 mmol, 94%). $R_f = 0.37$ (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 8.00 (dd, $J = 8.0, 1.2$ Hz, 1H, ArH), 7.95 (dd, $J = 7.8, 1.7$ Hz, 1H, ArH), 7.42 (td, $J = 7.6, 1.2$ Hz, 1H, ArH), 7.21 - 7.12 (m, 1H, ArH), 6.10 - 5.99 (m, 1H, CHCHCH₂), 5.72 - 5.60 (m, 2H, CHCHCH₂ and OCHCC), 4.25 (td, $J = 7.2, 6.7$ Hz, 2H, OCH₂CH₃), 2.15 - 2.05 (m, 2H, CHCH₂CH₂), 1.45 (h, $J = 7.3$ Hz, 2H, CH₂CH₂CH₃), 1.29 (t, $J = 7.1$ Hz, 3H, OCH₂CH₃), 0.91 (t, $J = 7.4$ Hz, 3H, CH₂CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 169.0, 165.7, 141.6, 138.4, 134.3, 133.1, 131.7, 128.1, 121.9, 94.5, 74.5, 61.8, 34.5, 21.9, 14.3, 13.7; IR (ν_{\max} , cm⁻¹) 2959 (m), 2928 (m), 2867 (m), 1732 (s), 1591 (m), 1464 (m), 1431 (m), 1368 (m), 1284 (s), 1239 (s), 1192 (s), 1131 (s), 1096 (s), 1014 (s), 965 (s), 740 (s); HRMS (ESI) calcd for C₁₆H₁₉INaO₄⁺ [M+Na]⁺ 425.0220; found 425.0232.

(E)-1-Ethyl 8-methyl 2-((2-iodobenzoyl)oxy)oct-3-enedioate (4m)




Following general procedure D, starting from methyl (*E*)-6-(3-oxo-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-one (**1m**) (74.8 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μ L, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethyl 8-methyl 2-((2-iodobenzoyl)oxy)oct-3-enedioate (**4m**) as a colorless oil (77 mg, 0.17 mmol, 84%). R_f = 0.13 (EtOAc/pentane 5:95); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.00 (dd, J = 8.0, 1.1 Hz, 1H, *ArH*), 7.94 (dd, J = 7.8, 1.7 Hz, 1H, *ArH*), 7.42 (td, J = 7.6, 1.2 Hz, 1H, *ArH*), 7.21 - 7.14 (m, 1H, *ArH*), 6.01 (dtd, J = 14.8, 6.8, 0.8 Hz, 1H, *CHCHCH}_2*), 5.75 - 5.60 (m, 2H, *OCHCC* and *CHCHCH}_2*), 4.24 (q, J = 7.1 Hz, 2H, *OCH}_2\text{CH}_3*), 3.66 (s, 3H, *OCH}_3*), 2.32 (t, J = 7.5 Hz, 2H, *CH}_2\text{CO}_2\text{Me}*), 2.21 - 2.12 (m, 2H, *CHCH}_2\text{CH}_2*), 1.76 (p, J = 7.3 Hz, 2H, *CH}_2\text{CH}_2\text{CH}_2*), 1.29 (t, J = 7.1 Hz, 3H, *OCH}_2\text{CH}_3*); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 173.9, 168.7, 165.6, 141.5, 136.9, 134.2, 133.1, 131.6, 128.1, 122.8, 94.5, 74.2, 61.9, 51.7, 33.3, 31.7, 23.9, 14.3; IR (ν_{max} , cm^{-1}) 2956 (w), 1735 (s), 1606 (s), 1436 (m), 1367 (w), 1344 (m), 1292 (m), 1238 (m), 1209 (m), 1157 (m), 1096 (m), 1017 (s), 965 (m), 834 (m); HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{21}\text{INaO}_6^+$ [$\text{M}+\text{Na}$] $^+$ 483.0275; found 483.0280.

(E)-7-Chloro-1-ethoxy-1-oxohept-3-en-2-yl 2-iodobenzoate (4n)



Following general procedure D, starting from (*E*)-1-(5-chloropent-1-en-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1n**) (70.1 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μ L, 87% wt in DCM, 0.400 mmol), afforded (*E*)-7-chloro-1-ethoxy-1-oxohept-3-en-2-yl 2-iodobenzoate (**4n**) as a colorless oil (82 mg, 0.19 mmol, 94%). R_f = 0.20 (EtOAc/pentane 5:95); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.01 (dd, J = 7.9, 1.1 Hz, 1H, *ArH*), 7.94 (dd, J = 7.8, 1.7 Hz, 1H, *ArH*), 7.43 (td, J = 7.6, 1.2 Hz, 1H, *ArH*), 7.18 (td, J = 7.7, 1.7 Hz, 1H, *ArH*), 6.02 (dtd, J = 15.1, 6.9, 1.1 Hz, 1H, *CHCHCH}_2*), 5.75 (ddt, J = 15.3, 7.1, 1.4 Hz, 1H, *CHCHCH}_2*), 5.66 (dd, J = 7.1, 1.0 Hz, 1H, *OCHCC*), 4.25 (q, J = 7.1 Hz, 2H, *OCH}_2\text{CH}_3*), 3.54 (t, J = 6.5 Hz, 2H, *CH}_2\text{CH}_2\text{Cl}*), 2.35 - 2.24 (m, 2H, *CHCH}_2\text{CH}_2*), 1.96 - 1.85 (m, 2H, *CH}_2\text{CH}_2\text{CH}_2\text{Cl}*), 1.30 (t, J = 7.1 Hz, 3H, *OCH}_2\text{CH}_3*); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 168.7, 165.6, 141.6, 136.1, 134.2, 133.2, 131.6, 128.1, 123.3, 94.5, 74.1, 62.0, 44.2, 31.4, 29.5, 14.3; IR (ν_{max} , cm^{-1}) 2977 (m), 2920 (m), 2848 (m), 1736 (s), 1579 (m), 1450 (m), 1286 (s), 1239 (s), 1190 (s), 1133 (s), 1100 (s), 1014 (s), 965 (s), 740 (s); HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{18}\text{ClINaO}_4^+$ [$\text{M}+\text{Na}$] $^+$ 458.9831; found 458.9835.


1-(Cyclohex-1-en-1-yl)-2-ethoxy-2-oxoethyl 2-iodobenzoate (4o)



Following general procedure D, starting from (*E*)-1-(cyclohex-1-en-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1o**) (65.6 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μ L, 87% wt in DCM, 0.400 mmol), afforded 1-(cyclohex-1-en-1-yl)-2-ethoxy-2-oxoethyl 2-iodobenzoate (**4o**) as a colorless oil (80 mg, 0.19 mmol, 97%). R_f = 0.36 (EtOAc/pentane 5:95); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.00 (dd, J = 8.0, 1.1 Hz, 1H, *ArH*), 7.94 (dd, J = 7.8, 1.7 Hz, 1H, *ArH*), 7.42 (td, J = 7.6, 1.2 Hz, 1H, *ArH*), 7.20 - 7.14 (m, 1H, *ArH*), 6.04 - 5.99 (m, 1H, *CCHCH}_2*), 5.55 (d, J = 1.0 Hz, 1H, *OCHCC*), 4.25 (q, J = 7.1 Hz, 2H, *OCH}_2\text{CH}_3*),


2.30 - 1.18 (m, 1H, cy-H), 2.16 - 1.96 (m, 3H, cy-H), 1.74 - 1.58 (m, 4H, cy-H), 1.29 (t, $J = 7.1$ Hz, 3H, OCH_2CH_3); ^{13}C NMR (101 MHz, CDCl_3) δ 168.7, 165.9, 141.6, 134.4, 133.1, 131.7, 131.1, 130.5, 128.1, 94.5, 78.1, 61.7, 25.4, 24.9, 22.4, 22.0, 14.3; IR (ν_{max} , cm^{-1}) 2959 (m), 2928 (m), 2867 (m), 1732 (s), 1591 (m), 1464 (m), 1431 (m), 1368 (m), 1284 (s), 1239 (s), 1192 (s), 1131 (s), 1096 (s), 1014 (s), 965 (s), 740 (s); HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{19}\text{INaO}_4^+$ $[\text{M}+\text{Na}]^+$ 437.0220; found 437.0225.

(E)-5-(1,3-Dioxoisindolin-2-yl)-1-ethoxy-1-oxopent-3-en-2-yl 2-iodobenzoate (4p)




Following general procedure D, starting from (*E*)-2-(3-(3-oxo-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)allyl)isoindoline-1,3-dione (**1p**) (87.0 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μL , 87% wt in DCM, 0.400 mmol), afforded (*E*)-5-(1,3-dioxoisindolin-2-yl)-1-ethoxy-1-oxopent-3-en-2-yl 2-iodobenzoate (**4p**) as a white sticky solid (31.0 mg, 0.06 mmol, 30%). M.p. 77-78 $^{\circ}\text{C}$; $R_f = 0.31$ (EtOAc/pentane 25:75); ^1H NMR (400 MHz, CDCl_3) δ 7.99 (dd, $J = 8.0, 1.1$ Hz, 1H, ArH), 7.93 (dd, $J = 7.8, 1.7$ Hz, 1H, ArH), 7.89 - 7.81 (m, 2H, ArH), 7.77 - 7.69 (m, 2H, ArH), 7.42 (td, $J = 7.6, 1.2$ Hz, 1H, ArH), 7.17 (td, $J = 7.7, 1.7$ Hz, 1H, ArH), 6.12 (dtd, $J = 15.5, 5.9, 1.4$ Hz, 1H, CHCHCH₂N), 5.96 (ddt, $J = 15.5, 6.0, 1.4$ Hz, 1H, CHCHCH₂N), 5.71 (dd, $J = 6.0, 1.3$ Hz, 1H, OCHCC), 4.36 (dt, $J = 5.9, 1.2$ Hz, 2H, CH₂NPhth), 4.24 (qd, $J = 7.1, 0.9$ Hz, 2H, OCH₂CH₃), 1.28 (t, $J = 7.1$ Hz, 3H, OCH₂CH₃); ^{13}C NMR (101 MHz, CDCl_3) δ 168.0, 167.9, 165.4, 141.6, 134.3, 133.9, 133.2, 132.2, 131.7, 129.3, 128.1, 125.7, 123.6, 94.5, 73.1, 62.2, 38.9, 14.2; IR (ν_{max} , cm^{-1}) 3463 (w), 3053 (w), 2985 (w), 2922 (m), 2854 (w), 1733 (m), 1709 (s), 1582 (w), 1467 (m), 1430 (m), 1392 (s), 1288 (m), 1244 (m), 1200 (m), 1130 (m), 1101 (m), 1046 (m), 1017 (s), 944 (m); HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{18}\text{INNaO}_6^+$ $[\text{M}+\text{Na}]^+$ 542.0071; found 542.0082.

(E)-1-Ethoxy-1-oxo-5-((triisopropylsilyl)oxy)pent-3-en-2-yl 2-iodobenzoate (4q)




Following general procedure D, starting from (*E*)-1-(3-((triisopropylsilyl)oxy)prop-1-en-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1q**) (92.0 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μL , 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-1-oxo-5-((triisopropylsilyl)oxy)pent-3-en-2-yl 2-iodobenzoate (**4q**) as a colorless oil (94 mg, 0.17 mmol, 86%). $R_f = 0.54$ (EtOAc/pentane 5:95); ^1H NMR (400 MHz, CDCl_3) δ 8.01 (dd, $J = 8.0, 1.1$ Hz, 1H, ArH), 7.96 (dd, $J = 7.8, 1.7$ Hz, 1H, ArH), 7.42 (td, $J = 7.6, 1.2$ Hz, 1H, ArH), 7.17 (td, $J = 7.7, 1.7$ Hz, 1H, ArH), 6.14 (dtd, $J = 15.4, 3.7, 1.2$ Hz, 1H, CHCHCH₂O), 6.02 (ddt, $J = 15.4, 6.5, 2.0$ Hz, 1H, CHCHCH₂O), 5.74 (dq, $J = 6.5, 1.3$ Hz, 1H, OCHCC), 4.33 (dt, $J = 3.6, 1.7$ Hz, 2H, CH₂OTIPS), 4.25 (qd, $J = 7.1, 1.2$ Hz, 2H, OCH₂CH₃), 1.29 (t, $J = 7.1$ Hz, 3H, OCH₂CH₃), 1.17 - 1.02 (m, 21H, TIPS); ^{13}C NMR (101 MHz, CDCl_3) δ 168.6, 165.6, 141.6, 136.0, 134.2, 133.2, 131.7, 128.1, 120.8, 94.5, 73.8, 62.8, 61.9, 18.1, 14.3, 12.1; IR (ν_{max} , cm^{-1}) 2960 (m), 2941 (s), 2866 (s), 2727 (w), 1736 (s), 1463 (m), 1378 (w), 1284 (m), 1248 (s), 1200 (m), 1124 (s), 1044 (s), 1017 (s), 967 (m), 880 (s); HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{35}\text{INaO}_5\text{Si}^+$ $[\text{M}+\text{Na}]^+$ 569.1191; found 569.1197.

(E)-5-Chloro-1-ethoxy-1-oxopent-3-en-2-yl 2-iodobenzoate (4r)




Following general procedure D, starting from (*E*)-1-(3-chloroprop-1-en-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1r**) (64.5 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μ L, 87% wt in DCM, 0.400 mmol), afforded (*E*)-5-chloro-1-ethoxy-1-oxopent-3-en-2-yl 2-iodobenzoate (**4r**) as a colorless oil (26.0 mg, 0.06 mmol, 32%). R_f = 0.19 (EtOAc/pentane 5:95); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.02 (dd, J = 8.0, 1.1 Hz, 1H, Ar*H*), 7.96 (dd, J = 7.8, 1.7 Hz, 1H, Ar*H*), 7.44 (td, J = 7.6, 1.2 Hz, 1H, Ar*H*), 7.20 (ddd, J = 8.0, 7.4, 1.7 Hz, 1H, Ar*H*), 6.20 (dtd, J = 15.3, 6.4, 1.4 Hz, 1H, CHCHCH₂Cl), 6.04 (dtd, J = 15.3, 6.0, 1.3 Hz, 1H, CHCHCH₂Cl), 5.76 (dq, J = 5.9, 1.1 Hz, 1H, OCHCC), 4.27 (q, J = 7.1 Hz, 2H, OCH₂CH₃), 4.11 (dt, J = 6.4, 1.1 Hz, 2H, CH₂Cl), 1.31 (t, J = 7.2 Hz, 3H, OCH₂CH₃); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 167.9, 165.4, 141.7, 133.9, 133.3, 131.7, 131.3, 128.2, 126.0, 94.6, 72.9, 62.3, 43.6, 14.3; IR (ν_{max} , cm^{-1}) 2959 (m), 2928 (m), 2867 (m), 1732 (s), 1591 (m), 1464 (m), 1431 (m), 1368 (m), 1284 (s), 1239 (s), 1192 (s), 1131 (s), 1096 (s), 1014 (s), 965 (s), 740 (s); HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{14}\text{ClINaO}_4^+$ [$\text{M}+\text{Na}$] $^+$ 430.9518; found 430.9521.

(E)-1-Ethoxy-5-methyl-1-oxohexa-3,5-dien-2-yl 2-iodobenzoate (4s)



Following general procedure D, starting from (*E*)-1-(3-methylbuta-1,3-dien-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1s**) (62.8 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μ L, 87% wt in DCM, 0.400 mmol), afforded (*E*)-1-ethoxy-5-methyl-1-oxohexa-3,5-dien-2-yl 2-iodobenzoate (**4s**) as a colorless oil (66 mg, 0.17 mmol, 82%). R_f = 0.33 (EtOAc/pentane 5:95); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.01 (dd, J = 7.9, 1.2 Hz, 1H, Ar*H*), 7.97 (dd, J = 7.8, 1.7 Hz, 1H, Ar*H*), 7.43 (td, J = 7.6, 1.2 Hz, 1H, Ar*H*), 7.18 (ddd, J = 8.0, 7.5, 1.7 Hz, 1H, Ar*H*), 6.63 (d, J = 15.3 Hz, 1H, CHCHC), 5.85 - 5.73 (m, 2H, CHCHC and OCHCC), 5.14 - 5.09 (m, 2H, CCH₂), 4.27 (qd, J = 7.1, 1.7 Hz, 2H, OCH₂CH₃), 1.88 (t, J = 1.0 Hz, 3H, CCH₃), 1.31 (t, J = 7.1 Hz, 3H, OCH₂CH₃); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 168.6, 165.6, 141.6, 140.8, 138.5, 134.2, 133.2, 131.7, 128.1, 120.7, 119.6, 94.5, 74.3, 62.1, 18.5, 14.3; IR (ν_{max} , cm^{-1}) 2959 (m), 2928 (m), 2867 (m), 1732 (s), 1591 (m), 1464 (m), 1431 (m), 1368 (m), 1284 (s), 1239 (s), 1192 (s), 1131 (s), 1096 (s), 1014 (s), 965 (s), 740 (s); HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{17}\text{INaO}_4^+$ [$\text{M}+\text{Na}$] $^+$ 423.0064; found 423.0065.


(3*E*,5*E*)-1-Ethoxy-1-oxo-6-phenylhexa-3,5-dien-2-yl 2-iodobenzoate (4t)



Following general procedure D, starting from (*E*)-1-((1*E*,3*E*)-4-phenylbuta-1,3-dien-1-yl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1t**) (75.0 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μ L, 87% wt in DCM, 0.400 mmol), afforded (3*E*,5*E*)-1-ethoxy-1-oxo-6-phenylhexa-3,5-dien-2-yl 2-iodobenzoate (**4t**) as a colorless oil (84 mg, 0.18 mmol, 91%). R_f = 0.23 (EtOAc/pentane 5:95); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.02 (dd, J = 7.9, 1.1 Hz, 1H, Ar*H*), 7.98 (dd, J = 7.8, 1.7 Hz, 1H, Ar*H*), 7.49 - 7.38 (m,


3H, ArH), 7.37 - 7.30 (m, 2H, ArH), 7.29 - 7.22 (m, 1H, ArH), 7.19 (td, $J = 7.7, 1.8$ Hz, 1H, ArH), 6.80 (dd, $J = 15.4, 10.3$ Hz, 1H, CHCHCHCHPh), 6.75 - 6.64 (m, 2H, CHCHCHCHPh), 6.01 - 5.93 (m, 1H, CHCHCHCHPh), 5.79 (dd, $J = 7.0, 1.1$ Hz, 1H, OCHCC), 4.28 (qd, $J = 7.1, 0.9$ Hz, 2H, OCH₂CH₃), 1.32 (t, $J = 7.1$ Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 168.5, 165.6, 141.6, 136.8, 136.0, 135.5, 134.1, 133.2, 131.7, 128.8, 128.3, 128.1, 127.2, 126.8, 124.0, 94.6, 74.1, 62.1, 14.3; IR (ν_{\max} , cm⁻¹) 2985 (w), 2918 (w), 1732 (s), 1583 (w), 1466 (w), 1284 (m), 1243 (s), 1129 (m), 1100 (m), 1014 (s), 988 (m), 738 (s), 689 (s); HRMS (ESI) calcd for C₂₁H₁₉IO₄⁺ [M+Na]⁺ 485.0220; found 485.0216.

(E)-1-Ethoxy-1-oxoundec-3-en-5-yn-2-yl 2-iodobenzoate (4u)




Following general procedure D, starting from (E)-1-(non-1-en-3-yn-1-yl)-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (**1u**) (73.6 mg, 0.200 mmol) and ethyl 2-diazoacetate (**2a**) (48.0 μ L, 87% wt in DCM, 0.400 mmol), afforded (E)-1-ethoxy-1-oxoundec-3-en-5-yn-2-yl 2-iodobenzoate (**4u**) as a colorless oil (88 mg, 0.19 mmol, 97%). $R_f = 0.40$ (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 8.01 (dd, $J = 7.9, 1.1$ Hz, 1H, ArH), 7.95 (dd, $J = 7.8, 1.7$ Hz, 1H, ArH), 7.42 (td, $J = 7.6, 1.2$ Hz, 1H, ArH), 7.18 (ddd, $J = 7.9, 7.4, 1.7$ Hz, 1H, ArH), 6.17 (ddt, $J = 15.8, 6.5, 0.7$ Hz, 1H, CHCHCC), 6.02 (dtd, $J = 15.8, 2.1, 1.4$ Hz, 1H, CHCHCC), 5.72 (dd, $J = 6.6, 1.4$ Hz, 1H, OCHCC), 4.25 (qd, $J = 7.1, 2.2$ Hz, 2H, OCH₂CH₃), 2.31 (td, $J = 7.1, 2.2$ Hz, 2H, CCH₂CH₂), 1.57 - 1.48 (m, 2H, CCH₂CH₂), 1.42 - 1.21 (m, 7H, pentyl-H and OCH₂CH₃), 0.90 (t, $J = 7.1$ Hz, 3H, CH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 167.7, 165.2, 141.5, 133.7, 133.2, 131.8, 131.6, 128.0, 116.1, 94.5, 94.2, 77.5, 73.4, 62.1, 31.1, 28.2, 22.2, 19.4, 14.1, 14.0; IR (ν_{\max} , cm⁻¹) 2957 (m), 2935 (m), 2859 (w), 2219 (w), 1738 (s), 1584 (m), 1465 (m), 1429 (m), 1370 (m), 1284 (m), 1241 (s), 1196 (s), 1131 (s), 1096 (s), 1043 (m), 1027 (s), 1017 (s), 954 (s), 738 (s); HRMS (ESI) calcd for C₂₀H₂₄IO₄⁺ [M+H]⁺ 455.0714; found 455.0720.

(E)-1-Ethoxy-1-oxo-2,4-diphenylbut-3-en-2-yl 2-iodobenzoate (5a)




Following general procedure E, starting from (E)-1-styryl-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (**1a**) (70.0 mg, 0.200 mmol) and ethyl 2-diazo-2-phenylacetate (**2b**) (76.0 mg, 0.400 mmol), afforded (E)-1-ethoxy-1-oxo-2,4-diphenylbut-3-en-2-yl 2-iodobenzoate (**5a**) as a colorless oil (73 mg, 0.14 mmol, 71%). $R_f = 0.40$ (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, $J = 8.0$ Hz, 1H, ArH), 7.95 (dd, $J = 7.7, 1.7$ Hz, 1H, ArH), 7.76 - 7.64 (m, 2H, ArH), 7.52 - 7.14 (m, 11H, ArH and CHCHPh), 6.53 (d, $J = 16.3$ Hz, 1H, CHCHPh), 4.41 - 4.15 (m, 2H, OCH₂CH₃), 1.26 (t, $J = 7.2$ Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 169.8, 165.2, 141.5, 138.2, 136.2, 135.2, 133.9, 133.0, 131.2, 128.7, 128.6, 128.6, 128.4, 128.2, 127.1, 126.6, 94.1, 84.2, 62.4, 14.2; IR (ν_{\max} , cm⁻¹) 2974 (m), 2900 (m), 1735 (s), 1495 (m), 1449 (m), 1431 (m), 1276 (s), 1256 (s), 1092 (s), 1042 (s), 1016 (s), 974 (m), 764 (s), 750 (s); HRMS (ESI) calcd for C₂₄H₁₉IO₄⁺ [M+Na]⁺ 521.0220; found 521.0227. One carbon was not resolved at 101 MHz.

(E)-1-(tert-Butoxy)-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (5b)




Following general procedure D, starting from (*E*)-1-styryl-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(*1H*)-one (**1a**) (70.0 mg, 0.200 mmol) and *tert*-butyl 2-diazoacetate (**2c**) (65.0 μ L, 85% wt in DCM, 0.400 mmol), afforded (*E*)-1-(*tert*-butoxy)-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**5b**) as a white solid (90 mg, 0.19 mmol, 97%). M.p. 62-64 $^{\circ}$ C; R_f = 0.36 (EtOAc/pentane 5:95); ^1H NMR (400 MHz, CDCl_3) δ 8.01 (td, J = 7.9, 1.4 Hz, 2H, ArH), 7.47 - 7.40 (m, 3H, ArH), 7.38 - 7.32 (m, 2H, ArH), 7.32 - 7.27 (m, 1H, ArH), 7.19 (ddd, J = 7.9, 7.4, 1.8 Hz, 1H, ArH), 6.90 (dd, J = 15.9, 1.4 Hz, 1H, CHCHPh), 6.37 (dd, J = 16.0, 6.9 Hz, 1H, CHCHPh), 5.75 (dd, J = 6.9, 1.4 Hz, 1H, OCHCC), 1.51 (s, 9H, C(CH₃)₃); ^{13}C NMR (101 MHz, CDCl_3) δ 167.5, 165.7, 141.6, 135.9, 135.2, 134.4, 133.1, 131.7, 128.8, 128.6, 128.1, 127.0, 121.2, 94.5, 83.1, 74.8, 28.2; IR (ν_{max} , cm^{-1}) 2978 (m), 2902 (m), 1735 (s), 1582 (w), 1451 (m), 1395 (m), 1369 (m), 1278 (s), 1258 (s), 1199 (m), 1129 (m), 1098 (s), 1044 (s), 1016 (s), 966 (m), 863 (m), 764 (s), 750 (s); HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{21}\text{INaO}_4^+$ [M+Na] $^+$ 487.0377; found 487.0382.

(E)-1-(2,6-di-*tert*-Butyl-4-methylphenoxy)-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (5c)




Following general procedure D, starting from (*E*)-1-styryl-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(*1H*)-one (**1a**) (70.0 mg, 0.200 mmol) and 2,6-di-*tert*-butyl-4-methylphenyl 2-diazoacetate (**2d**) (115 mg, 0.400 mmol), afforded (*E*)-1-(2,6-di-*tert*-butyl-4-methylphenoxy)-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**5c**) as a white solid (123 mg, 0.200 mmol, 100%). R_f = 0.45 (EtOAc/pentane 5:95); M.p. 151-153 $^{\circ}$ C; ^1H NMR (400 MHz, CDCl_3) δ 8.02 (ddd, J = 7.8, 4.5, 1.4 Hz, 2H, ArH), 7.51 - 7.45 (m, 2H, ArH), 7.43 (td, J = 7.6, 1.2 Hz, 1H, ArH), 7.40 - 7.29 (m, 3H, ArH), 7.23 - 7.16 (m, 1H, ArH), 7.16 - 7.10 (m, 2H, ArH), 7.02 (d, J = 14.9 Hz, 1H, CHCHPh), 6.62 - 6.52 (m, 2H, CHCHPh and OCHCC), 2.32 (s, 3H, ArCH₃), 1.38 (s, 9H, C(CH₃)₃), 1.31 (s, 9H, C(CH₃)₃); ^{13}C NMR (101 MHz, CDCl_3) δ 168.5, 165.0, 145.8, 142.2, 142.1, 141.6, 136.2, 135.7, 135.2, 134.4, 133.2, 131.6, 128.9, 128.8, 128.1, 127.5, 127.2, 127.0, 120.7, 94.6, 74.1, 35.5, 35.5, 31.8, 31.4, 21.6; IR (ν_{max} , cm^{-1}) 2961 (m), 2922 (m), 1769 (s), 1742 (s), 1468 (m), 1425 (m), 1270 (s), 1247 (s), 1196 (s), 1180 (s), 1129 (s), 1100 (s), 1016 (s), 969 (m), 742 (s); HRMS (ESI) calcd for $\text{C}_{32}\text{H}_{35}\text{INaO}_4^+$ [M+Na] $^+$ 633.1472; found 633.1474; The structure of **5c** was confirmed by X-ray analysis. Crystals were grown by dissolving 10 mg of pure **5c** in a minimum amount of benzene (100 μ L) at room temperature. Slow evaporation over one week provided suitable crystals. Supplementary crystallographic data for this compound have been deposited at Cambridge Crystallographic Data Centre (CCDC 1897009) and can be obtained free of charge via <https://www.ccdc.cam.ac.uk/structures/>

(E)-1-(Benzyloxy)-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (5d)




Following general procedure D, starting from (*E*)-1-styryl-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1a**) (70.0 mg, 0.200 mmol) and benzyl 2-diazoacetate (**2e**) (88.0 μ L, 90% wt in DCM, 0.400 mmol), afforded (*E*)-1-(Benzyloxy)-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**5d**) as a colorless oil (92.0 mg, 0.19 mmol, 92%). R_f = 0.26 (EtOAc/pentane 5:95); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.02 (dd, J = 8.0, 1.1 Hz, 1H, ArH), 7.96 (dd, J = 7.8, 1.7 Hz, 1H, ArH), 7.46 - 7.27 (m, 11H, ArH), 7.19 (td, J = 7.7, 1.7 Hz, 1H, ArH), 6.90 (dd, J = 16.0, 1.3 Hz, 1H, CHCHPh), 6.37 (dd, J = 15.9, 7.1 Hz, 1H, CHCHPh), 5.93 (dd, J = 7.1, 1.3 Hz, 1H, OCHCC), 5.26 (s, 2H, OCH₂Ph); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 168.4, 165.6, 141.6, 136.0, 135.7, 135.3, 134.1, 133.3, 131.7, 128.8, 128.8, 128.8, 128.6, 128.4, 128.1, 127.0, 120.5, 94.5, 74.3, 67.7; IR (ν_{max} , cm^{-1}) 2978 (m), 2902 (m), 1735 (s), 1582 (w), 1451 (m), 1395 (m), 1369 (m), 1278 (s), 1258 (s), 1199 (m), 1129 (m), 1098 (s), 1044 (s), 1016 (s), 966 (m), 863 (m), 764 (s), 750 (s); HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{19}\text{INaO}_4^+$ [$\text{M}+\text{Na}$] $^+$ 521.0220; found 521.0235.

(E)-1-(Allyloxy)-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (5e)



Following general procedure D, starting from (*E*)-1-styryl-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1a**) (70.0 mg, 0.200 mmol) and allyl 2-diazoacetate (**2f**) (50.4 mg, 0.400 mmol), afforded (*E*)-1-(allyloxy)-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**5e**) as a colorless oil (82 mg, 0.18 mmol, 91%). R_f = 0.24 (EtOAc/pentane 5:95); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.01 (ddd, J = 10.7, 7.9, 1.4 Hz, 2H, ArH), 7.45 (td, J = 7.6, 1.2 Hz, 3H, ArH), 7.39 - 7.27 (m, 3H, ArH), 7.19 (td, J = 7.7, 1.7 Hz, 1H, ArH), 6.94 (dd, J = 16.0, 1.2 Hz, 1H, CHCHPh), 6.39 (dd, J = 15.9, 7.1 Hz, 1H, CHCHPh), 6.00 - 5.87 (m, 2H, OCHCC and OCH₂CHCH₂), 5.36 (dq, J = 17.2, 1.5 Hz, 1H, CHCH₂), 5.26 (dq, J = 10.5, 1.3 Hz, 1H, CHCH₂), 4.72 (dt, J = 5.8, 1.4 Hz, 2H, OCH₂CHCH₂); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 168.2, 165.6, 141.6, 136.0, 135.7, 134.1, 133.3, 131.7, 131.5, 128.9, 128.8, 128.1, 127.0, 120.6, 119.1, 94.6, 74.3, 66.5; IR (ν_{max} , cm^{-1}) 3063 (w), 3026 (w), 2946 (w), 1736 (s), 1585 (m), 1427 (w), 1290 (m), 1239 (s), 1188 (s), 1133 (s), 1096 (s), 1043 (m), 1014 (s), 963 (s), 937 (m), 742 (s), 689 (s); HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{17}\text{INaO}_4^+$ [$\text{M}+\text{Na}$] $^+$ 471.0064; found 471.0063.


(E)-1-(Diethylamino)-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (5f)



Following general procedure D, starting from (*E*)-1-styryl-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1a**) (70.0 mg, 0.200 mmol) and 2-diazo-*N,N*-diethylacetamide (**2g**) (56.5 mg, 0.400 mmol), afforded (*E*)-1-(diethylamino)-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**5f**) as a white solid (87 mg, 0.19 mmol,


94%). $R_f = 0.24$ (EtOAc/pentane 20:80); M.p. 113-115 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.06 (dd, $J = 7.8$, 1.7 Hz, 1H, ArH), 7.98 (dd, $J = 7.9$, 1.1 Hz, 1H, ArH), 7.46 - 7.38 (m, 3H, ArH), 7.38 - 7.27 (m, 3H, ArH), 7.15 (td, $J = 7.7$, 1.7 Hz, 1H, ArH), 6.88 (d, $J = 16.0$ Hz, 1H, CHCHPh), 6.43 (dd, $J = 16.0$, 7.9 Hz, 1H, CHCHPh), 6.12 (dd, $J = 7.9$, 0.9 Hz, 1H, OCHCC), 3.59 - 3.30 (m, 4H, $\text{N}(\text{CH}_2\text{CH}_3)_2$), 1.31 (t, $J = 7.2$ Hz, 3H, $\text{N}(\text{CH}_2\text{CH}_3)_2$), 1.17 (t, $J = 7.1$ Hz, 3H, $\text{N}(\text{CH}_2\text{CH}_3)_2$); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 166.9, 166.1, 141.3, 136.9, 135.7, 134.5, 133.0, 132.1, 128.9 (2 C), 128.1, 127.1, 122.0, 94.4, 72.9, 41.9, 41.0, 14.5, 13.0; IR (ν_{max} , cm^{-1}) 3063 (w), 3026 (w), 2946 (w), 1736 (s), 1585 (m), 1427 (w), 1290 (m), 1239 (s), 1188 (s), 1133 (s), 1096 (s), 1043 (m), 1014 (s), 963 (s), 937 (m), 742 (s), 689 (s); HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{22}\text{INNaO}_3^+$ $[\text{M}+\text{Na}]^+$ 486.0537; found 486.0535.

(E)-1-(Methoxy(methyl)amino)-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (5g)




Following general procedure D, starting from (*E*)-1-styryl-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1a**) (70.0 mg, 0.200 mmol) and 2-diazo-*N*-methoxy-*N*-methylacetamide (**2h**) (51.6 mg, 0.400 mmol), afforded (*E*)-1-(methoxy(methyl)amino)-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**5g**) as a white solid (89 mg, 0.20 mmol, 99%). $R_f = 0.27$ (EtOAc/pentane 20:80); M.p. 90-92 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.05 (dd, $J = 7.8$, 1.7 Hz, 1H, ArH), 8.00 (dd, $J = 7.9$, 1.1 Hz, 1H, ArH), 7.45 - 7.40 (m, 3H, ArH), 7.37 - 7.26 (m, 3H, ArH), 7.17 (td, $J = 7.7$, 1.7 Hz, 1H, ArH), 6.93 (d, $J = 15.9$ Hz, 1H, CHCHPh), 6.41 (dd, $J = 15.9$, 7.5 Hz, 1H, CHCHPh), 6.27 (d, $J = 7.5$ Hz, 1H, OCHCC), 3.87 (s, 3H, OCH_3), 3.27 (s, 3H, NCH_3); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 168.4, 166.0, 141.4, 136.0, 136.0, 134.4, 133.1, 132.0, 128.8, 128.7, 128.1, 127.0, 121.0, 94.4, 72.9, 61.7, 32.5; IR (ν_{max} , cm^{-1}) 3055 (w), 3020 (w), 2973 (w), 2942 (w), 1728 (s), 1681 (s), 1466 (m), 1431 (m), 1284 (m), 1251 (s), 1133 (s), 1102 (s), 1016 (m), 969 (s), 738 (s); HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{18}\text{INNaO}_4^+$ $[\text{M}+\text{Na}]^+$ 474.0173; found 474.0175.

(E)-1-(Ethoxysulfonyl)-3-phenylallyl 2-iodobenzoate (5h)




Following general procedure D, starting from (*E*)-1-styryl-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1a**) (70.0 mg, 0.200 mmol) and ethyl diazomethanesulfonate (**2i**) (60.1 mg, 0.400 mmol), afforded (*E*)-1-(ethoxysulfonyl)-3-phenylallyl 2-iodobenzoate (**5h**) as a colorless oil (96 mg, 0.20 mmol, 100%). $R_f = 0.12$ (EtOAc/pentane 5:95); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.07 (dd, $J = 8.0$, 1.2 Hz, 1H, ArH), 8.01 (dd, $J = 7.8$, 1.7 Hz, 1H, ArH), 7.51 - 7.44 (m, 3H, ArH), 7.40 - 7.30 (m, 3H, ArH), 7.27 - 7.21 (m, 1H, ArH), 7.12 - 7.03 (m, 1H, CHCHPh), 6.70 (dd, $J = 7.5$, 1.1 Hz, 1H, OCHCC), 6.40 (dd, $J = 15.9$, 7.5 Hz, 1H, CHCHPh), 4.43 (q, $J = 7.1$ Hz, 2H, OCH_2CH_3), 1.40 (t, $J = 7.1$ Hz, 3H, OCH_2CH_3); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 163.6, 142.1, 140.0, 134.8, 134.0, 132.6, 132.0, 129.6, 129.0, 128.4, 127.4, 116.0, 95.1, 84.1, 69.8, 15.5; IR (ν_{max} , cm^{-1}) 2975 (w), 2924 (w), 1742 (m), 1675 (s), 1624 (m), 1581 (m), 1364 (m), 1291 (m), 1237 (s), 1174 (s), 1129 (s), 1088 (s), 1015 (s), 968 (s), 919 (s), 739 (s), 688 (s); HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{17}\text{INaO}_5^+$ $[\text{M}+\text{Na}]^+$ 494.9734; found 494.9730.

(E)-1-(Diethoxyphosphoryl)-3-phenylallyl 2-iodobenzoate (5i)




Following general procedure D, starting from (*E*)-1-styryl-1λ³-benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1a**) (70.0 mg, 0.200 mmol) and diethyl (diazomethyl)phosphonate (**2j**) (71.3 mg, 0.400 mmol), afforded (*E*)-1-(diethoxyphosphoryl)-3-phenylallyl 2-iodobenzoate (**5i**) as a colorless oil (97 mg, 0.19 mmol, 97%). *R*_f = 0.28 (EtOAc/pentane 50:50); ¹H NMR (400 MHz, CDCl₃) δ 8.03 (dd, *J* = 7.9, 1.2 Hz, 1H, Ar*H*), 7.93 (dd, *J* = 7.8, 1.7 Hz, 1H, Ar*H*), 7.47 - 7.40 (m, 3H, Ar*H*), 7.36 - 7.27 (m, 3H, Ar*H*), 7.22 - 7.16 (m, 1H, Ar*H*), 6.91 - 6.83 (m, 1H, CHCHPh), 6.37 (ddd, *J* = 15.9, 7.6, 5.8 Hz, 1H, CHCHPh), 6.09 (ddd, *J* = 13.5, 7.6, 1.3 Hz, 1H, OCHCC), 4.27 - 4.16 (m, 4H, (O)P(OCH₂CH₃)₂), 1.33 (t, *J* = 7.1 Hz, 6H, (O)P(OCH₂CH₃)₂); ¹³C NMR (101 MHz, CDCl₃) δ 164.9 (d, *J* = 7.9 Hz), 141.7, 136.0, 135.9 (d, *J* = 3.1 Hz), 134.1, 133.3, 131.5, 128.8, 128.6, 128.2, 127.0, 120.0 (d, *J* = 4.5 Hz), 94.7, 70.6 (d, *J* = 170.7 Hz), 63.6 (dd, *J* = 9.0, 6.8 Hz), 16.7 (t, *J* = 5.8 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 17.4; IR (ν_{max}, cm⁻¹) 3057 (w), 2981 (w), 2930 (w), 2901 (w), 1734 (m), 1288 (m), 1241 (s), 1131 (m), 1096 (m), 1014 (s), 967 (s), 793 (m), 738 (s), 691 (m); HRMS (ESI) calcd for C₂₀H₂₂INaO₅P⁺ [M+Na]⁺ 523.0142; found 523.0154.

(E)-1,1,1-Trifluoro-4-phenylbut-3-en-2-yl 2-iodobenzoate (5l)



Following general procedure D, starting from (*E*)-1-styryl-1λ³-benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1a**) (70.0 mg, 0.200 mmol) and 2-diazo-1,1,1-trifluoroethane (**2k**) (1.08 mL, 0.37 M in DCM, 0.400 mmol), afforded (*E*)-1,1,1-trifluoro-4-phenylbut-3-en-2-yl 2-iodobenzoate (**5l**) as a colorless oil (88 mg, 0.20 mmol, 100%). *R*_f = 0.52 (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 8.05 (dd, *J* = 8.0, 1.2 Hz, 1H, Ar*H*), 7.93 (dd, *J* = 7.8, 1.7 Hz, 1H, Ar*H*), 7.45 (dtd, *J* = 7.7, 4.1, 1.9 Hz, 3H, Ar*H*), 7.40 - 7.29 (m, 3H, Ar*H*), 7.21 (td, *J* = 7.7, 1.7 Hz, 1H, Ar*H*), 7.00 (d, *J* = 15.9 Hz, 1H, CHCHPh), 6.24 (dd, *J* = 15.9, 7.9 Hz, 1H, CHCHPh), 6.12 - 6.02 (m, 1H, OCHCC); ¹³C NMR (101 MHz, CDCl₃) δ 164.2, 141.9, 139.6, 135.1, 133.6, 133.3, 131.6, 129.3, 128.9, 128.2, 127.2, 123.3 (q, *J* = 280.6 Hz), 117.0 (d, *J* = 1.7 Hz), 94.8, 72.4 (q, *J* = 33.8 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ -75.9; HRMS (ESI) calcd for C₁₇H₁₂F₃O₂ [M⁺] 431.9829; found 431.9846.


(E)-1-Ethoxy-2-methyl-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (5m)



Following general procedure E, starting from (*E*)-1-styryl-1λ³-benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1a**) (70.0 mg, 0.200 mmol) and ethyl 2-diazopropanoate (**2l**) (51.3 mg, 0.400 mmol), afforded (*E*)-1-ethoxy-2-methyl-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**5m**) as a colorless oil (80 mg, 0.18 mmol, 89%). *R*_f = 0.26 (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 7.99 (dd, *J* = 8.0, 1.2 Hz, 1H, Ar*H*), 7.85 (dd, *J* = 7.8, 1.7 Hz, 1H, Ar*H*), 7.45 - 7.39 (m, 3H, Ar*H*), 7.35 - 7.29 (m, 2H, Ar*H*), 7.28 - 7.23 (m, 1H, Ar*H*), 7.16 (ddd, *J* = 8.0, 7.4, 1.7 Hz, 1H, Ar*H*), 6.80 (d, *J* = 16.3 Hz, 1H, CHCHPh), 6.62 (d, *J* = 16.2 Hz, 1H, CHCHPh), 4.27 (qd, *J* = 7.1, 2.6 Hz, 2H, OCH₂CH₃), 1.92 (s, 3H, CCH₃), 1.29 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 170.7, 165.4, 141.4, 136.1, 135.3, 132.9, 131.4, 131.2, 128.8, 128.4, 128.1, 127.8,


126.9, 94.0, 81.4, 62.1, 23.2, 14.2; IR (ν_{\max} , cm^{-1}) 2963 (w), 2920 (m), 2856 (w), 1744 (m), 1345 (w), 1274 (m), 1241 (s), 1180 (s), 1131 (s), 1092 (s), 1043 (m), 1016 (s), 965 (m), 914 (m), 736 (s), 691 (s); HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{19}\text{I}\text{NaO}_4^+$ $[\text{M}+\text{Na}]^+$ 473.0220; found 473.0213.

(*E*)-2-Oxo-3-styryltetrahydrofuran-3-yl 2-iodobenzoate (**5o**)




Following general procedure E, starting from (*E*)-1-styryl-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1a**) (70.0 mg, 0.200 mmol) and 3-diazodihydrofuran-2(3*H*)-one (**2m**) (44.8 mg, 0.400 mmol), afforded (*E*)-2-oxo-3-styryltetrahydrofuran-3-yl 2-iodobenzoate (**5o**) as a thick colorless oil (78 mg, 0.18 mmol, 90%). $R_f = 0.31$ (EtOAc/pentane 20:80); ^1H NMR (400 MHz, CDCl_3) δ 8.00 (dd, $J = 7.9, 1.1$ Hz, 1H, Ar*H*), 7.91 (dd, $J = 7.8, 1.7$ Hz, 1H, Ar*H*), 7.50 - 7.39 (m, 3H, Ar*H*), 7.39 - 7.28 (m, 3H, Ar*H*), 7.18 (td, $J = 7.7, 1.7$ Hz, 1H, Ar*H*), 6.95 (d, $J = 16.2$ Hz, 1H, CHCHPh), 6.48 (d, $J = 16.2$ Hz, 1H, CHCHPh), 4.65 (td, $J = 9.2, 2.4$ Hz, 1H, OCH_2^1), 4.36 (td, $J = 9.4, 7.0$ Hz, 1H, OCH_2^2), 3.10 (dt, $J = 13.4, 9.4$ Hz, 1H, CCH_2^1), 2.90 (ddd, $J = 13.4, 7.0, 2.5$ Hz, 1H, CCH_2^2); ^{13}C NMR (101 MHz, CDCl_3) δ 172.5, 165.2, 141.6, 135.1, 134.6, 133.9, 133.4, 131.6, 129.1, 128.9, 128.2, 127.2, 123.1, 94.3, 80.4, 65.0, 33.4; IR (ν_{\max} , cm^{-1}) 2974 (m), 2900 (m), 1735 (s), 1495 (m), 1449 (m), 1431 (m), 1276 (s), 1256 (s), 1092 (s), 1127 (m), 1042 (s), 1016 (s), 974 (m), 764 (s), 750 (s); HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{15}\text{I}\text{NaO}_4^+$ $[\text{M}+\text{Na}]^+$ 456.9907; found 456.9906.

(3*E*,5*E*)-4-(Methoxycarbonyl)-6-phenylhexa-3,5-dien-2-yl 2-iodobenzoate (**5p**)



Following general procedure E, starting from (*E*)-1-styryl-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (**1a**) (70.0 mg, 0.200 mmol) and (*E*)-methyl 2-diazopent-3-enoate (**2n**) (0.400 mL, 1.0 M in pentane, 0.400 mmol), afforded (3*E*,5*E*)-4-(methoxycarbonyl)-6-phenylhexa-3,5-dien-2-yl 2-iodobenzoate (**5p**) as a colorless oil (58 mg, 0.13 mmol, 63%). $R_f = 0.22$ (EtOAc/pentane 5:95); ^1H NMR (400 MHz, CDCl_3) δ 7.99 (dd, $J = 8.0, 1.2$ Hz, 1H, Ar*H*), 7.79 (dd, $J = 7.8, 1.7$ Hz, 1H, Ar*H*), 7.53 - 7.46 (m, 2H, Ar*H*), 7.43 - 7.31 (m, 3H, Ar*H*), 7.31 - 7.27 (m, 1H, Ar*H*), 7.15 (td, $J = 7.7, 1.7$ Hz, 1H, Ar*H*), 7.09 (d, $J = 16.3$ Hz, 1H, CHCHPh), 6.97 (d, $J = 16.0$ Hz, 1H, CHCHPh), 6.71 (d, $J = 8.7$ Hz, 1H, CH_3CHCH), 6.15 (dq, $J = 8.3, 6.5$ Hz, 1H, OCHCH_3), 3.83 (s, 3H, OCH_3), 1.59 (d, $J = 6.5$ Hz, 3H, OCHCH_3); ^{13}C NMR (101 MHz, CDCl_3) δ 167.3, 165.9, 141.5, 139.3, 136.9, 135.7, 135.2, 132.8, 131.7, 131.1, 128.8, 128.5, 128.1, 127.1, 120.2, 94.2, 68.9, 52.4, 20.5; IR (ν_{\max} , cm^{-1}) 2948 (w), 2995 (w), 2844 (w), 1789 (w), 1718 (s), 1583 (m), 1436 (m), 1282 (m), 1241 (s), 1156 (m), 1129 (s), 1098 (s), 1039 (s), 1015 (s), 968 (m), 739 (s), 694 (s); HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{19}\text{I}\text{NaO}_4^+$ $[\text{M}+\text{Na}]^+$ 485.0220; found 485.0219.


(E)-Ethyl 2-ethoxy-4-phenylbut-3-enoate (6b)



6b

Following general procedure F, starting from ethanol (**7a**) (52.5 μ L, 0.900 mmol), (*E*)-1-styryl-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzo[*d*][1,2]iodaoxole (**1'a**) (142 mg, 0.300 mmol) and ethyl 2-diazoacetate (**2a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded (*E*)-ethyl 2-ethoxy-4-phenylbut-3-enoate (**6b**) as a colorless oil (28 mg, 0.12 mmol, 40%). R_f = 0.26 (EtOAc/pentane 3:97), *p*-anisaldehyde; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.43 – 7.37 (m, 2H, ArH), 7.35 – 7.29 (m, 2H, ArH), 7.29 – 7.23 (m, 1H, ArH), 6.77 (dd, J = 16.0, 1.3 Hz, 1H, HC=CHPh), 6.23 (dd, J = 15.9, 6.8 Hz, 1H, HC=CHPh), 4.51 (dd, J = 6.8, 1.4 Hz, 1H, OCHC), 4.31 – 4.18 (m, 2H, C(O)OCH₂CH₃), 3.61 (qq, J = 9.1, 7.0 Hz, 2H, OCH₂CH₃), 1.30 (t, J = 7.1 Hz, 6H, 2 x OCH₂CH₃); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 171.1, 136.2, 134.0, 128.7, 128.3, 126.9, 124.3, 79.9, 65.5, 61.4, 15.3, 14.4; IR (ν_{max} , cm^{-1}) 2980 (m), 2937 (w), 1738 (s), 1636 (m), 1451 (m), 1371 (m), 1313 (s), 1268 (s), 1189 (s), 1159 (s), 1091 (s), 1023 (s), 699 (s); HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{18}\text{NaO}_3^+$ $[M+\text{Na}]^+$ 257.1148; found 257.1146.


(E)-Furan-2-ylmethyl 2-adamantan-1-yloxy-4-cyclohexylbut-3-enoate (6c)



6c

Following general procedure F, starting from 1-adamantanol (**7b**) (161 mg, 0.90 mmol), (*E*)-1-(2-cyclohexylvinyl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzobenzo[*d*][1,2]iodaoxole (**1'j**) (143 mg, 0.300 mmol) and furan-2-ylmethyl 2-diazoacetate (**2o**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded (*E*)-furan-2-ylmethyl 2-adamantan-1-yloxy-4-cyclohexylbut-3-enoate (**6c**) as a colorless oil (47 mg, 0.12 mmol, 39%). R_f = 0.21 (EtOAc/pentane 2:98), *p*-anisaldehyde; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.41 – 7.38 (m, 1H, ArH), 6.40 (d, J = 3.2 Hz, 1H, ArH), 6.34 (dd, J = 3.3, 1.8 Hz, 1H, ArH), 5.72 (ddd, J = 15.6, 6.6, 1.4 Hz, 1H, HC=CH-cHex), 5.43 (ddd, J = 15.6, 5.9, 1.4 Hz, 1H, HC=CH-cHex), 5.12 (q, J = 13.1 Hz, 2H, CH₂Ar), 4.65 (dt, J = 5.9, 1.1 Hz, 1H, OCHC), 2.10 (p, J = 3.3 Hz, 3H, CH-aliphatic), 1.93 (dtd, J = 11.1, 7.4, 3.2 Hz, 1H, CH-aliphatic), 1.80 – 1.50 (m, 17H, CH-aliphatic), 1.33 – 0.95 (m, 5H, CH-aliphatic); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 173.0, 149.5, 143.2, 139.8, 124.1, 111.0, 110.7, 74.7, 70.8, 58.3, 41.8, 40.4, 36.4, 32.6, 32.5, 30.7, 26.3, 26.1; IR (ν_{max} , cm^{-1}) 3669 (w), 2972 (s), 2908 (s), 2851 (m), 1755 (m), 1734 (m), 1450 (m), 1250 (m), 1153 (m), 1104 (m), 1078 (s), 966 (m), 739 (m); HRMS (ESI/QTOF) m/z : $[M+\text{H}]^+$ Calcd for $\text{C}_{25}\text{H}_{35}\text{O}_4^+$ 399.2530; Found 399.2536.

(E)-Diethyl (1-ethoxyhex-2-en-1-yl)phosphonate (6d)




6d

Following general procedure F, starting from ethanol (**7a**) (52.5 μ L, 0.900 mmol), (*E*)-1-(pent-1-en-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzobenzo[*d*][1,2]iodaoxole (**1'l**) (131 mg, 0.300 mmol) and diethyl (diazomethyl)phosphonate (**2j**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded (*E*)-diethyl (1-


ethoxyhex-2-en-1-yl)phosphonate (**6d**) as a colorless oil (18 mg, 70 μ mol, 23%). R_f = 0.22 (EtOAc/pentane 50:50), *p*-anisaldehyde; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 5.87 – 5.75 (m, 1H, $\text{HC}=\text{CH}-n\text{Pr}$), 5.49 (dddt, J = 15.5, 7.8, 4.8, 1.5 Hz, 1H, $\text{HC}=\text{CH}-n\text{Pr}$), 4.22 – 4.11 (m, 4H, 2 x $\text{P}(\text{O})\text{OCH}_2\text{CH}_3$), 4.05 (ddd, J = 14.7, 7.8, 1.0 Hz, 1H, OCHC), 3.66 (dq, J = 9.3, 7.0 Hz, 1H, OCH_2CH_3), 3.49 (dq, J = 9.3, 6.9 Hz, 1H, OCH_2CH_3), 2.13 – 2.02 (m, 2H, $\text{CH}_2\text{CH}_2\text{CH}_3$), 1.43 (h, J = 7.3 Hz, 2H, $\text{CH}_2\text{CH}_2\text{CH}_3$), 1.32 (td, J = 7.1, 1.2 Hz, 6H, 2 x $\text{P}(\text{O})\text{OCH}_2\text{CH}_3$), 1.21 (t, J = 7.0 Hz, 3H, OCH_2CH_3), 0.91 (t, J = 7.4 Hz, 3H, $\text{CH}_2\text{CH}_2\text{CH}_3$); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 137.0 (d, J = 13.5 Hz), 123.6 (d, J = 3.6 Hz), 77.3 (d, J = 169.8 Hz), 66.0 (d, J = 12.6 Hz), 62.9 (dd, J = 25.4, 6.9 Hz), 34.6, 22.3 (d, J = 2.9 Hz), 16.7 (t, J = 5.0 Hz), 15.3, 13.8; $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ 20.49; IR (ν_{max} , cm^{-1}) 2968 (m), 2930 (m), 2872 (w), 1393 (w), 1251 (m), 1099 (m), 1051 (s), 1024 (s), 967 (s), 790 (m); HRMS (ESI/QTOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{12}\text{H}_{25}\text{NaO}_4\text{P}^+$ 287.1383; Found 287.1391.

(E)-Ethyl 2-((2,3-dihydro-1H-inden-2-yl)oxy)-4-(4-(trifluoromethyl)phenyl)but-3-enoate (6e)



Following general procedure F, starting from 2-indanol (**7c**) (161 mg, 0.900 mmol), (*E*)-3,3-bis(trifluoromethyl)-1-(4-(trifluoromethyl)styryl)-1,3-dihydro-benzo[*d*][1,2]iodaoxole (**1'd**) (162 mg, 0.300 mmol) and ethyl 2-diazoacetate (**2a**) (1.0 mL, 0.60 mmol, 0.6 M in DCM), afforded (*E*)-ethyl 2-((2,3-dihydro-1H-inden-2-yl)oxy)-4-(4-(trifluoromethyl)phenyl)but-3-enoate (**6e**) as a colorless oil (52 mg, 0.13 mmol, 44%). R_f = 0.12 (EtOAc/pentane 3:97), *p*-anisaldehyde; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.57 (d, J = 8.2 Hz, 2H, *ArH*), 7.46 (d, J = 8.2 Hz, 2H, *ArH*), 7.25 – 7.12 (m, 4H, *ArH*), 6.78 (dd, J = 16.0, 1.5 Hz, 1H, $\text{HC}=\text{CHAr}$), 6.37 (dd, J = 15.9, 6.0 Hz, 1H, $\text{HC}=\text{CHAr}$), 4.70 (dd, J = 6.1, 1.5 Hz, 1H, OCHC), 4.54 (tt, J = 6.6, 5.1 Hz, 1H, $\text{OCH}(\text{CH}_2)_2$), 4.27 (q, J = 7.1 Hz, 2H, OCH_2CH_3), 3.29 – 3.03 (m, 4H, 2 x CH_2Ar), 1.32 (t, J = 7.1 Hz, 3H, OCH_2CH_3); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 170.8, 140.7, 140.4, 139.7, 132.0, 130.0 (q, J = 32.6 Hz), 127.2, 127.0, 126.9, 126.8, 125.7 (q, J = 3.8 Hz), 124.8, 124.2 (q, J = 272.1 Hz), 80.3, 78.3, 61.7, 39.7, 39.3, 14.4; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -62.6; IR (ν_{max} , cm^{-1}) 2932 (w), 2359 (w), 1743 (m), 1614 (w), 1324 (s), 1261 (m), 1168 (s), 1116 (s), 1067 (s), 1024 (m), 972 (m), 831 (m), 742 (m); HRMS (ESI/QTOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{22}\text{H}_{21}\text{F}_3\text{NaO}_3^+$ 413.1335; Found 413.1342.


(E)-4-(2-(3-Chloropropoxy)-1,1,1-trifluoro-5-phenylpent-3-en-2-yl)-1,1'-biphenyl (6f)



Following general procedure F, starting from 3-chloro-1-propanol, (**7d**) (75 μ L, 0.90 mmol), (*E*)-1-(3-phenylprop-1-en-1-yl)-3,3-bis(trifluoromethyl)-1,3-dihydro-1 λ^3 -benzobenzo[*d*][1,2]iodaoxole (**1'k**) (146 mg, 0.300 mmol) and 4-(1-diazo-2,2,2-trifluoroethyl)-1,1'-biphenyl (**2p**) (1.0 mL, 0.60 mmol, 0.60 M in DCM), afforded (*E*)-4-(2-(3-chloropropoxy)-1,1,1-trifluoro-5-phenylpent-3-en-2-yl)-1,1'-biphenyl (**6f**) as a colorless oil (96 mg, 0.22 mmol, 72%). R_f = 0.45 (EtOAc/pentane 2:98); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.69 – 7.58 (m, 6H, *ArH*), 7.53 – 7.43 (m, 2H, *ArH*), 7.43 – 7.31 (m, 3H, *ArH*), 7.30 – 7.20 (m, 3H, *ArH*), 6.21 (dt, J = 15.9, 6.8 Hz, 1H, $\text{HC}=\text{CH}-\text{CH}_2\text{Ph}$), 5.95 – 5.82 (m, 1H, $\text{HC}=\text{CH}-\text{CH}_2\text{Ph}$), 3.72 (t, J = 6.4 Hz, 2H, CH_2Cl), 3.66 (t, J = 5.9 Hz, 2H, CH_2O), 3.59 (dd, J = 6.9, 1.5 Hz, 2H, CH_2Ph), 2.10 (p, J = 6.1 Hz, 2H, $\text{CH}_2\text{CH}_2\text{Cl}$); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 141.7, 140.5, 139.1, 137.6, 134.5, 129.0, 129.0, 128.8, 128.7, 127.7, 127.3, 127.0, 126.6, 125.9, 125.0 (q, J = 287.5 Hz), 81.9 (q, J = 27.4

Hz), 61.2, 41.8, 39.3, 33.1; ^{19}F NMR (376 MHz, CDCl_3) δ -74.9; IR (ν_{max} , cm^{-1}) 3668 (w), 2987 (m), 2971 (m), 2910 (m), 1487 (w), 1262 (m), 1163 (s), 1075 (s), 840 (m), 766 (m), 737 (s), 696 (s); HRMS (ESI/QTOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{26}\text{H}_{24}\text{ClF}_3\text{NaO}^+$ 467.1360; Found 467.1366.


2-((*E*)-4-(((3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-10,13-Dimethyl-17-((*R*)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl)oxy)-5,5,5-trifluoropent-2-en-1-yl)isoindoline-1,3-dione (6g)



Following general procedure F, starting from cholesterol (**7e**) (348 mg, 0.900 mmol), (*E*)-2-(3-(3,3-bis(trifluoromethyl)-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl)allyl)isoindoline-1,3-dione (**1'p**) (167 mg, 0.300 mmol) and 2-diazo-1,1,1-trifluoroethane (**2k**) (1.67 mL, 0.600 mmol, 0.36 M in DCM), afforded 2-((*E*)-4-(((3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-10,13-dimethyl-17-((*R*)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl)oxy)-5,5,5-trifluoropent-2-en-1-yl)isoindoline-1,3-dione (**6g**) (55:45 *dr* in the crude ^{19}F NMR) as a white solid (120 mg, 0.180 mmol, 61%). M.p. 158 °C; R_f = 0.23 (EtOAc/pentane 5:95), *p*-anisaldehyde; ^1H NMR (400 MHz, CDCl_3) δ 7.89 - 7.82 (m, 2H, ArH), 7.73 (dd, J = 5.5, 3.0 Hz, 2H, ArH), 6.08 - 5.96 (m, 1H, HC=CH-CH₂N), 5.75 - 5.63 (m, 1H, HC=CH-CH₂N), 5.34 - 5.26 (m, 1H, HC=C(C)₂), 4.34 (dt, J = 6.0, 1.8 Hz, 2H, CH₂N), 4.24 - 4.15 (m, 1H, CHCF₃), 3.36 - 3.23 (m, 1H, CHO), 2.36 - 2.19 (m, 2H, CH-aliphatic), 2.03 - 1.73 (m, 5H, CH-aliphatic), 1.62 - 0.79 (m, 33H, CH-aliphatic), 0.66 (s, 3H, CH-aliphatic); ^{13}C NMR (101 MHz, CDCl_3) δ 167.8, 140.4, 140.3, 134.2, 132.2, 130.5, 130.5, 126.0, 125.9, 124.0 (q, J = 281.9 Hz), 124.0 (q, J = 281.9 Hz), 123.6, 122.3, 122.3, 80.0, 79.9, 75.5 (q, J = 31.1 Hz), 75.5 (q, J = 31.1 Hz), 56.9, 56.3, 50.2, 42.4, 39.9, 39.7, 39.5, 38.9, 38.8, 37.2, 37.1, 36.8, 36.8, 36.3, 35.9, 32.0, 32.0, 29.0, 28.4, 28.2, 24.4, 24.0, 23.0, 22.7, 21.2, 19.5, 18.9, 12.0;⁵⁰ ^{19}F NMR (376 MHz, CDCl_3) δ -77.26, -77.28; IR (ν_{max} , cm^{-1}) 2949 (m), 1775 (w), 1711 (s), 1468 (w), 1429 (m), 1399 (m), 1275 (m), 1181 (m), 1150 (m), 1121 (s), 1078 (m), 944 (m), 727 (s), 714 (m); HRMS (ESI/QTOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{40}\text{H}_{54}\text{F}_3\text{NNaO}_3^+$ 676.3948; Found 676.3954.

⁵⁰ All ^{13}C signals of the diastereoisomeric mixture were not resolved.

Scale-up synthesis of **4a** using DCM as solvent and using a lower catalyst loading




A catalytic solution was prepared by mixing $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (12.6 mg, 40.0 μmol) and 2,2'-(propane-2,2-diyl)bis(4,4-dimethyl-4,5-dihydrooxazole) (**3c**) (11.9 mg, 50.0 μmol) in DCM (5.0 mL) at 25 °C for 1 h.

The catalytic solution was then added to a stirring suspension of Ph-VBX (**1a**) (700 mg, 2.00 mmol, 1.00 equiv) and ethyl 2-diazoacetate (**2a**) (0.484 mL, 4.00 mmol, 2.00 equiv) in DCM (20.0 mL).

The reaction mixture was stirred at 25 °C for 2 h, then the solvent was removed under reduced pressure and the resulting crude oil was purified by column chromatography using EtOAc/pentane 5:95 as mobile phase to afford (*E*)-1-ethoxy-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**4a**) as a colorless oil (562 mg, 1.29 mmol, 64%).


8. Product modifications

(*E*)-4-Phenylbut-3-ene-1,2-diol (**8**)



Following a reported procedure,⁸ (*E*)-1-ethoxy-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**4a**) (87.2 mg, 0.200 mmol, 1.00 equiv) was dissolved in anhydrous THF (2.00 mL) under N₂ in a 5 mL microwave vial. Then LiAlH₄ (2.4 M in THF, 0.300 mL, 0.600 mmol, 3.00 equiv) was added at 0 °C and stirred for 1 h. The resulting solution was quenched by the addition of saturated aqueous potassium sodium tartrate (2.00 mL) and the biphasic mixture was stirred for 1 h at room temperature. Then the reaction mixture was diluted with water (2.0 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over MgSO₄, filtered and the solvent removed under reduced pressure. The crude product was purified by column chromatography using EtOAc/pentane 50:50 as mobile phase affording (*E*)-4-phenylbut-3-ene-1,2-diol (**8**) as a white solid (30.0 mg, 0.183 mmol, 91%). ¹H NMR (400 MHz, CDCl₃) δ 7.42 - 7.18 (m, 5H, ArH), 6.70 (dd, *J* = 16.0, 1.3 Hz, 1H, CHCHPh), 6.21 (dd, *J* = 16.0, 6.3 Hz, 1H, CHCHPh), 4.44 (m, 1H, HOCHCC), 3.76 (dd, *J* = 11.2, 3.6 Hz, 1H, CH₂OH), 3.61 (dd, *J* = 11.2, 7.3 Hz, 1H, CH₂OH), 2.09 (br s, 2H, 2 x OH); ¹³C NMR (101 MHz, CDCl₃) δ 136.4, 132.4, 128.8, 128.1, 127.8, 126.7, 73.3, 66.6. The values of the NMR spectra are in accordance with reported literature data.⁵¹


Ethyl 3-benzyl-4-hydroxy-5-oxo-2-phenethyl-2,5-dihydrofuran-2-carboxylate (**9**)



DBU (0.151 mL, 1.00 mmol, 10.0 equiv) was added to a solution of (*E*)-1-ethoxy-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**4a**) (43.6 mg, 0.100 mmol, 1.00 equiv) in ethanol (1 mL). The resulting solution was stirred 6 h at 50 °C. The solvent was removed under reduced pressure and the resulting crude product was purified by column chromatography using MeOH/DCM 2:98 as mobile phase affording ethyl 3-benzyl-4-hydroxy-5-oxo-2-phenethyl-2,5-dihydrofuran-2-carboxylate (**9**) as a white solid (17 mg, 0.046 mmol, 93%). M.p. 111-113 °C; R_f = 0.55 (MeOH/DCM 3:97); ¹H NMR (400 MHz, CDCl₃) δ 7.33 - 7.27 (m, 2H, ArH), 7.27 - 7.21 (m, 5H, ArH), 7.20 - 7.14 (m, 1H, ArH), 7.01 - 6.94 (m, 2H, ArH), 5.78 (br s, 1H, OH), 3.95 (q, *J* = 7.1 Hz, 2H, OCH₂CH₃), 3.67 (s, 2H, CCH₂Ph), 2.55 - 2.32 (m, 3H, CH₂), 2.19 - 2.05 (m, 1H, CH₂), 1.15 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 169.1, 168.0, 140.4, 139.1, 136.2, 130.9, 129.1, 128.9, 128.6, 128.5, 127.2, 126.4, 87.2, 62.6, 36.0, 30.2, 29.3, 14.0; IR (ν_{max}, cm⁻¹) 2919 (w), 1739 (s), 1292 (m), 1249 (m), 1218 (m), 1136 (m), 1105 (m), 1017 (m), 748 (s), 691 (m), 668 (s); HRMS (ESI) calcd for C₂₂H₂₃O₅⁺ [M+H]⁺ 367.1540; found [M+H]⁺ 367.1549.


⁵¹ T. Saravanan, R. Selvakumar, M. Doble and A. Chadha, *Tetrahedron: Asymmetry*, **2012**, *23*, 1360.

(E)-ethyl 4-phenylhepta-2,6-dienoate (**10**)




To a solution of (*E*)-1-ethoxy-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**4a**) (87.2 mg, 0.200 mmol, 1.00 equiv) and allyltrimethylsilane (**73**) (48.0 μL , 0.300 mmol, 1.50 equiv) in dry DCM (2.0 mL) was added TiCl_4 (23.0 μL , 0.210 mmol, 1.05 equiv) dropwise at $0\text{ }^\circ\text{C}$ under N_2 . The reaction was stirred 15 minutes at $0\text{ }^\circ\text{C}$ and then quenched with a saturated solution of NaHCO_3 (2.0 mL). The layers were separated and the aqueous layer was extracted with DCM (3 x 5 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO_4 , filtered and the solvent was removed under reduced pressure. The crude product was purified by column chromatography using DCM/pentane 10:90 as mobile phase affording (*E*)-ethyl 4-phenylhepta-2,6-dienoate (**10**) as a colorless oil (38.0 mg, 0.165 mmol, 83 %). $R_f = 0.50$ (DCM/pentane 50:50); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.36 - 7.28 (m, 2H, ArH), 7.27 - 7.15 (m, 3H, ArH), 7.09 (dd, $J = 15.7, 7.5$ Hz, 1H, CHCHCO₂Et), 5.78 (dd, $J = 15.7, 1.4$ Hz, 1H, CHCHCO₂Et), 5.69 (ddt, $J = 17.1, 10.1, 6.9$ Hz, 1H, CHCH₂), 5.10 - 4.96 (m, 2H, CHCH₂), 4.17 (q, $J = 7.2$ Hz, 2H, OCH₂CH₃), 3.50 (qd, $J = 7.5, 1.3$ Hz, 1H, PhCHCH₂), 2.56 (tt, $J = 7.1, 1.3$ Hz, 2H, PhCHCH₂), 1.27 (t, $J = 7.1$ Hz, 3H, OCH₂CH₃); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 166.7, 151.0, 141.7, 135.7, 128.8, 128.0, 127.0, 121.3, 117.2, 60.5, 48.4, 39.3, 14.4; IR (ν_{max} , cm^{-1}) 2975 (m), 2924 (m), 1718 (s), 1650 (m), 1456 (w), 1368 (m), 1311 (m), 1270 (m), 1233 (m), 1168 (s), 1045 (m), 981 (m), 916 (m), 759 (m), 699 (s); HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{19}\text{O}_2^+$ $[\text{M}+\text{H}]^+$ 231.1380; found 231.1377.

(E)-Ethyl 4-phenylhepta-2,5,6-trienoate (**11**)




To a solution of (*E*)-1-ethoxy-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**4a**) (87.2 mg, 0.200 mmol, 1.00 equiv) and propargyltrimethylsilane (**74**) (60.0 μL , 0.400 mmol, 2.00 equiv) in dry DCM (2.0 mL) was added TiCl_4 (23.0 μL , 0.210 mmol, 1.05 equiv) dropwise at $-78\text{ }^\circ\text{C}$ under N_2 . The reaction was allowed to warm slowly to $0\text{ }^\circ\text{C}$ and then quenched with a saturated solution of NaHCO_3 (2.0 mL). The layers were separated and the aqueous layer was extracted with DCM (3 x 5 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO_4 , filtered and the solvent was removed under reduced pressure. The crude product was purified by column chromatography using EtOAc/pentane 2:98 as mobile phase affording (*E*)-ethyl 4-phenylhepta-2,5,6-trienoate (**11**) as a colorless oil (27.0 mg, 0.118 mmol, 59 %). $R_f = 0.54$ (DCM/pentane 50:50); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.38 - 7.31 (m, 2H, ArH), 7.29 - 7.20 (m, 3H, ArH), 7.13 (dd, $J = 15.6, 7.0$ Hz, 1H, CHCHCO₂Et), 5.84 (dd, $J = 15.6, 1.5$ Hz, 1H, CHCHCO₂Et), 5.37 (q, $J = 6.8$ Hz, 1H, CHCCH₂), 4.82 (dd, $J = 6.6, 2.7$ Hz, 2H, CHCCH₂), 4.18 (q, $J = 7.1$ Hz, 3H, PhCH and OCH₂CH₃), 1.28 (t, $J = 7.1$ Hz, 3H, OCH₂CH₃); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 208.6, 166.6, 149.4, 140.9, 128.9, 128.1, 127.3, 121.9, 91.9, 77.2, 60.5, 47.4, 14.4; IR (ν_{max} , cm^{-1}) 2982 (m), 2924 (m), 2853 (w), 1958 (w), 1715 (s), 1650 (m), 1454 (m), 1367 (m), 1307 (m), 1269 (m), 1232 (m), 1169 (s), 1071 (m), 1040 (s), 982 (m), 853 (m); HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{17}\text{O}_2^+$ $[\text{M}+\text{H}]^+$ 229.1223; found 229.1220.

(E)-Ethyl 4-azido-4-phenylbut-2-enoate (12) and (E)-Ethyl 2-azido-4-phenylbut-3-enoate (12')



To a solution of (*E*)-1-ethoxy-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**4a**) (87.2 mg, 0.200 mmol, 1.00 equiv) and azidotrimethylsilane (**75**) (40.0 μ L, 0.300 mmol, 1.50 equiv) in dry DCM (2.0 mL) was added TiCl₄ (23.0 μ L, 0.210 mmol, 1.05 equiv) dropwise at -20 °C under N₂. The reaction was allowed to warm to room temperature and then quenched with a saturated solution of NaHCO₃ (2.0 mL). The layers were separated and the aqueous layer was extracted with DCM (3 x 5 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The crude product was purified by column chromatography using DCM/pentane 10:90 as mobile phase affording an isomeric mixture of (*E*)-ethyl 4-azido-4-phenylbut-2-enoate (**12**) and (*E*)-ethyl 2-azido-4-phenylbut-3-enoate (**12'**) as a colorless oil, 70:30 mixture of **12** and **12'** (40 mg, 0.17 mmol, 86%). ¹H NMR (400 MHz, CDCl₃) δ 7.45 - 7.28 (m, 5H, ArH), 6.94 (dd, *J* = 15.5, 5.7 Hz, 1H, CHCHCO₂Et), 6.14 (dd, *J* = 15.5, 1.6 Hz, 1H, CHCHCO₂Et), 5.18 (dd, *J* = 5.7, 1.6 Hz, 1H, N₃CHCC), 4.33 - 4.18 (m, 2H, OCH₂CH₃), 1.34 - 1.28 (m, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 165.9, 144.0, 129.3, 129.1, 127.6, 127.0, 123.0, 65.6, 60.9, 14.4 for γ -azidated ester (**12**); ¹H NMR (400 MHz, CDCl₃) δ 7.45 - 7.28 (m, 5H, ArH), 6.77 (dd, *J* = 15.8 Hz, 1.2 Hz, 1H, PhCHCH), 6.27 (dd, *J* = 15.8, 7.5 Hz, 1H, PhCHCH), 4.54 (dd, *J* = 7.5, 1.3 Hz, 1H, N₃CHCO₂Et), 4.33 - 4.18 (m, 2H, OCH₂CH₃), 1.34 - 1.28 (m, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 169.1, 136.6, 136.0, 135.5, 128.9, 128.9, 120.8, 63.9, 62.4, 14.3 for α -azidated ester (**12'**). The values of the NMR spectra are in accordance with reported literature data.⁵²

(E)-1-Ethoxy-2-methyl-1-oxo-4-phenylbut-3-en-2-yl 2-((E)-3-methoxy-3-oxoprop-1-en-1-yl)benzoate (13)




A flame dried 8 mL microwave vial was charged with (*E*)-1-ethoxy-2-methyl-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**5m**) (45.0 mg, 0.100 mmol, 1.00 equiv), bis(triphenylphosphine)palladium (II) chloride (3.51 mg, 5.00 μ mol, 0.05 equiv), triphenylphosphine (1.31 mg, 5.00 μ mol, 0.05 equiv) and trimethylamine (0.5 mL). The resulting reaction mixture was degassed by "pump-freeze-thaw" cycles (3 times) *via* a syringe needle and then methyl acrylate (**76**) (45.0 μ L, 0.500 mmol, 5.00 equiv) was added by syringe and the reaction mixture was stirred at 80 °C for 24 h. The solvent was removed under reduced pressure and the product was purified by column chromatography using EtOAc/pentane 15:85 as mobile phase affording (*E*)-1-ethoxy-2-methyl-1-oxo-4-phenylbut-3-en-2-yl 2-((*E*)-3-methoxy-3-oxoprop-1-en-1-yl)benzoate (**13**) as a thick colorless oil (27.0 mg, 66.1 μ mol, 66%). R_f = 0.32 (EtOAc/pentane 15:85); ¹H NMR (400 MHz, CDCl₃) δ 8.45 (d, *J* = 15.9 Hz, 1H, ArCHCHCO₂Me), 7.99 (dd, *J* = 7.8, 1.4 Hz, 1H, ArH), 7.66 - 7.59 (m, 1H, ArH), 7.59 - 7.54 (m, 1H, ArH), 7.47 (td, *J* = 7.5, 1.5 Hz, 1H, ArH), 7.44 - 7.39 (m, 2H, ArH), 7.37 - 7.30 (m, 2H, ArH), 7.29 - 7.22 (m, 1H, ArH), 6.77 (d, *J* = 16.2 Hz, 1H, CHCHPh), 6.65 (d, *J* = 16.2 Hz, 1H, CHCHPh), 6.34 (d, *J* = 15.9 Hz, 1H, ArCHCHCO₂Me), 4.28 (qd, *J* = 7.1, 1.9 Hz, 2H, OCH₂CH₃), 3.74 (s, 3H, OCH₃), 1.93 (s, 3H, CCH₃), 1.29 (t, *J* = 7.1 Hz, 3H,

⁵² Y. Sawama, S. Nagata, Y. Yabe, K. Morita, Y. Monguchi and H. Sajiki, *Chem. Eur. J.*, **2012**, *18*, 16608.


OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 170.8, 167.0, 165.8, 144.0, 136.3, 136.1, 132.7, 131.4, 131.0, 130.3, 129.6, 128.8, 128.4, 128.0, 127.9, 127.0, 120.8, 81.3, 62.1, 51.9, 23.2, 14.2; IR (ν_{max}, cm⁻¹) 2991 (m), 2956 (m), 2926 (m), 1715 (s), 1636 (w), 1479 (w), 1448 (m), 1377 (w), 1315 (m), 1269 (s), 1196 (m), 1173 (m), 1121 (m), 1071 (s), 1044 (m), 1021 (m), 972 (m), 865 (m); HRMS (ESI) calcd for C₂₄H₂₄NaO₆⁺ [M+Na]⁺ 431.1465; found 431.1472.

(E)-1-Ethoxy-1-oxo-4-phenylbut-3-en-2-yl benzoate (**14**)



Following a reported procedure,⁵³ in a 20 mL Schlenk flask, (*E*)-1-ethoxy-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**4a**) (43.6 mg, 0.100 mmol, 1.00 equiv), DABCO (112 mg, 1.00 mmol, 10.0 equiv) and Pd/C (5.0 mg) were suspended in MeOH (10 mL). The reaction flask was evacuated and backfilled with argon (3 times) before being evacuated and backfilled with H₂ (1 atm). The reaction was stirred 10 min at room temperature, then the hydrogen was evacuated and replaced with argon. The reaction mixture was filtered through a pad of celite and the filtrate was evaporated under reduced pressure. The crude product was purified by column chromatography using EtOAc/pentane 95:5 as mobile phase affording (*E*)-1-ethoxy-1-oxo-4-phenylbut-3-en-2-yl benzoate (**14**) as a colorless oil (24.0 mg, 77.0 μmol, 77 %). R_f = 0.29 (EtOAc/pentane 5:95); ¹H NMR (400 MHz, CDCl₃) δ 8.19 - 8.10 (m, 2H, ArH), 7.65 - 7.55 (m, 1H, ArH), 7.53 - 7.41 (m, 4H, ArH), 7.40 - 7.27 (m, 3H, ArH), 6.92 (dd, *J* = 16.0, 1.3 Hz, 1H, CHCHPh), 6.41 (dd, *J* = 15.9, 7.0 Hz, 1H, CHCHPh), 5.85 (dd, *J* = 7.0, 1.3 Hz, 1H, OCHCC), 4.27 (qd, *J* = 7.1, 5.1 Hz, 2H, OCH₂CH₃), 1.30 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 168.8, 165.9, 135.8, 135.4, 133.6, 130.1, 129.5, 128.8, 128.7, 128.6, 127.0, 121.2, 73.8, 62.0, 14.3; IR (ν_{max}, cm⁻¹) 3057 (w), 3030 (w), 1748 (m), 1724 (s), 1452 (m), 1315 (w), 1272 (s), 1251 (m), 1196 (m), 1106 (s), 1069 (m), 1024 (m), 965 (m), 738 (m), 712 (s), 689 (s); HRMS (ESI) calcd for C₁₉H₁₈NaO₄⁺ [M+Na]⁺ 333.1097; found 333.1099.

(Z)-1-Ethoxy-1-oxo-4-phenylbut-3-en-2-yl benzoate (**15**)



Following a reported procedure,⁵⁴ a flame dried 8 mL microwave vial with a rubber septum and magnetic stirring bar was charged with (*E*)-1-ethoxy-1-oxo-4-phenylbut-3-en-2-yl 2-iodobenzoate (**4a**) (43.6 mg, 0.100 mmol, 1.00 equiv), MeCN (1.0 mL), tributylamine (240 μL, 1.00 mmol, 10.0 equiv), formic acid (38 μL, 1.00 mmol, 10.0 equiv) and *fac*-Ir(ppy)₃ (1.64 mg, 2.50 μmol, 0.025 equiv). The resulting reaction mixture was degassed by “pump-freeze-thaw” cycles (3 times) *via* a syringe needle and placed in a 250 mL beaker with blue LEDs wrapped inside. The reaction mixture was stirred at 40 °C for 18 h. The solvent was removed under reduced pressure and the product was purified by column chromatography using DCM/pentane 50:50 as mobile phase affording (*Z*)-1-ethoxy-1-oxo-4-phenylbut-3-en-2-yl benzoate (**15**) as a white solid (25.2 mg, 82.0 μmol, 82%). M.p. 76-78 °C; R_f = (DCM/pentane 50:50); ¹H NMR (400 MHz, CDCl₃) δ 8.11 - 8.03 (m, 2H, ArH), 8.60 - 7.54 (m, 1H, ArH),

⁵³ N. Faucher, Y. Ambroise, J.-C. Cintrat, E. Doris, F. Pillon and B. Rousseau, *J. Org. Chem.*, **2002**, *67*, 932.

⁵⁴ J. D. Nguyen, E. M. D’Amato, J. M. R. Narayanam and C. R. J. Stephenson, *Nat. Chem.*, **2012**, *4*, 854.

7.51 - 7.28 (m, 7H, ArH), 6.94 (d, $J = 11.4$ Hz, 1H, CHCHPh), 6.05 (dd, $J = 9.8, 0.9$ Hz, 1H, OCHCC), 5.91 (dd, $J = 11.4, 9.9$ Hz, 1H, CHCHPh), 4.28 (q, $J = 7.1$ Hz, 2H, OCH₂CH₃), 1.30 (t, $J = 7.1$ Hz, 3H, OCH₂CH₃); ¹³C NMR (101 MHz, CDCl₃) δ 169.2, 165.8, 136.8, 135.4, 133.5, 130.1, 129.5, 129.0, 128.7, 128.5, 128.3, 123.0, 70.3, 62.0, 14.2; IR (ν_{\max} , cm⁻¹) 3065 (w), 3024 (w), 2981 (w), 1750 (s), 1722 (s), 1452 (m), 1370 (w), 1333 (w), 1315 (m), 1278 (s), 1258 (s), 1194 (m), 1100 (s), 1069 (s), 1026 (s), 814 (m), 773 (m), 710 (s); HRMS (ESI) calcd for C₁₉H₁₈NaO₄⁺ [M+Na]⁺ 333.1097; found 333.1106.


9. Enantioselective transformation

Table S3: Preliminary results for the enantioselective transformation

Under inert atmosphere, a catalytic solution was prepared by mixing Cu cat. (4.00 μ mol, 0.08 equiv), and BOX ligand (**3b-d**) (5.00 μ mol, 0.10 equiv) in DCE (0.500 mL) at 25 $^{\circ}$ C for 1 h.



0.250 mL of the catalytic solution was then added to a stirring suspension of VBX (0.05 mmol, 1.00 equiv) and diazo compound (0.10 mmol, 2.00 equiv) in DCE (1.0 mL).

The reaction mixture was stirred at the indicated temperature and time (monitored by TLC (EtOAc/pentane 5:95 and MeOH/DCM 5:95)) and the solvent was removed under reduced pressure. The resulting crude oil was purified by PTLC (EtOAc/pentane) directly without further work-up to afford the corresponding allylic ester product.





entry	diazo R ¹ =	VBX R ² =	Cu cat.	ligand	temp.	time	yield ^a	ee ^b
1	Et	Ph	Cu(CH ₃ CN) ₄ BF ₄	3b	25 $^{\circ}$ C	2 h	> 90%	14%
2	Et	Ph	Cu(OTf) ₂	3b	25 $^{\circ}$ C	2 h	> 90%	13%
3	Et	Ph	Cu(CH ₃ CN) ₄ BF ₄	3d	25 $^{\circ}$ C	2 h	> 90%	33%
4	Et	Ph	Cu(CH ₃ CN) ₄ BF ₄	3d	0 $^{\circ}$ C	8 h	50%	20%
5 ^c	Et	Ph	Cu(CH ₃ CN) ₄ BF ₄	3d	25 $^{\circ}$ C	2 h	> 90%	40%
6 ^d	Et	Ph	Cu(CH ₃ CN) ₄ BF ₄	3d	25 $^{\circ}$ C	2 h	56%	30%
7	Et	Ph	Cu(OTf) ₂	3d	25 $^{\circ}$ C	2 h	> 90%	30%
8 ^e	Et	Ph	Cu(CH ₃ CN) ₄ BF ₄	3d	25 $^{\circ}$ C	2 h	> 90%	23%
9	Et	Cy	Cu(CH ₃ CN) ₄ BF ₄	3d	25 $^{\circ}$ C	< 1h	> 90%	30%
10	BHT	Ph	Cu(CH ₃ CN) ₄ BF ₄	3d	25 $^{\circ}$ C	< 1h	> 90%	50%



[a] Crude ¹H NMR yield using CH₂Br₂ as internal standard. [b] Obtained by chiral HPLC. [c] Using DCE/acetone 1:1 as solvent. [d] Using DCE/*t*AmOH 1:1 as solvent. In this case, the three-component product **6a** was also observed (19%). [e] Dropwise addition of the diazo in 1 h (0.6 M solution in DCE). Et = ethyl, Ph = phenyl, Cy = cyclohexyl, BHT = 2,6-di-*tert*-butyl-4-methylphenyl.





HPLC of compound 4a (entry 3)



HPLC of compound 4j (entry 9)




HPLC of compound 5c (entry 10)



10. Crystals data


Compound 1'a. CCDC number 1993681.



The ORTEP picture has been obtained by using a probability level of 50% for the ellipsoid display.

Empirical formula	$C_{17}H_{11}F_6IO$	
Formula weight	472.16	
Temperature	100.00(10) K	
Wavelength	0.71073 Å	
Crystal system	Monoclinic	
Space group	$P2_1/c$	
Unit cell dimensions	$a = 11.1353(5)$ Å	$\alpha = 90^\circ$.
	$b = 15.0180(6)$ Å	$\beta = 106.691(5)^\circ$.
	$c = 10.6385(5)$ Å	$\gamma = 90^\circ$.
Volume	$1704.12(14)$ Å ³	
Z	4	
Density (calculated)	1.840 Mg/m ³	
Absorption coefficient	1.942 mm ⁻¹	
F(000)	912	
Crystal size	0.514 x 0.114 x 0.098 mm ³	
Theta range for data collection	2.415 to 33.022°.	
Index ranges	$-16 \leq h \leq 16, -22 \leq k \leq 21, -16 \leq l \leq 15$	
Reflections collected	7694	
Independent reflections	7694	
Completeness to $q = 25.242^\circ$	99.9 %	
Absorption correction	Gaussian	
Max. and min. transmission	1.000 and 0.696	
Refinement method	Full-matrix least-squares on F^2	
Data / restraints / parameters	7694 / 0 / 227	
Goodness-of-fit on F^2	0.914	
Final R indices [$I > 2\sigma(I)$]	$R_1 = 0.0264, wR_2 = 0.0545$	
R indices (all data)	$R_1 = 0.0419, wR_2 = 0.0568$	
Largest diff. peak and hole	1.621 and -0.734 e.Å ⁻³	

Compound 5c. CCDC number 1897009.




The ORTEP picture has been obtained by using a probability level of 50% for the ellipsoid display.


Empirical formula	C ₃₂ H ₃₅ IO ₄	
Formula weight	610.50	
Temperature	101(1) K	
Wavelength	1.54184 Å	
Crystal system	Triclinic	
Space group	<i>P</i> -1	
Unit cell dimensions	<i>a</i> = 10.8114(6) Å	α = 81.599(4)°.
	<i>b</i> = 10.9975(5) Å	β = 82.906(5)°.
	<i>c</i> = 12.6115(7) Å	γ = 78.119(4)°.
Volume	1444.84(13) Å ³	
<i>Z</i>	2	
Density (calculated)	1.403 Mg/m ³	
Absorption coefficient	8.972 mm ⁻¹	
<i>F</i> (000)	624	
Crystal size	0.635 x 0.181 x 0.049 mm ³	
Theta range for data collection	3.559 to 75.162°.	
Index ranges	-13 ≤ <i>h</i> ≤ 13, -13 ≤ <i>k</i> ≤ 10, -15 ≤ <i>l</i> ≤ 15	
Reflections collected	10366	
Independent reflections	5771 [<i>R</i> _{int} = 0.0382]	
Completeness to theta = 67.684°	99.9 %	
Absorption correction	Analytical	
Max. and min. transmission	0.675 and 0.116	
Refinement method	Full-matrix least-squares on <i>F</i> ²	
Data / restraints / parameters	5771 / 0 / 341	
Goodness-of-fit on <i>F</i> ²	1.039	
Final <i>R</i> indices [<i>I</i> > 2σ(<i>I</i>)]	<i>R</i> ₁ = 0.0400, <i>wR</i> ₂ = 0.1027	
<i>R</i> indices (all data)	<i>R</i> ₁ = 0.0464, <i>wR</i> ₂ = 0.1072	
Largest diff. peak and hole	0.919 and -1.211 e.Å ⁻³	

11. Spectra of new compounds


$^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6/\text{D}_2\text{O}$ 9:1) of compound **50n**




$^{13}\text{C-NMR}$ (101 MHz, $\text{DMSO-}d_6/\text{D}_2\text{O}$ 9:1) of compound **50n**




¹H-NMR (400 MHz, DMSO-*d*₆/D₂O 9:1) of compound 50p




¹³C-NMR (101 MHz, DMSO-*d*₆/D₂O 9:1) of compound 50p




¹H-NMR (400 MHz, DMSO-*d*₆/D₂O 9:1) of compound 50q




¹³C-NMR (101 MHz, DMSO-*d*₆/D₂O 9:1) of compound 50q




¹H-NMR (400 MHz, DMSO-d₆/D₂O 9:1) of compound 50t




¹³C-NMR (101 MHz, DMSO-d₆/D₂O 9:1) of compound 50t




¹H-NMR (400 MHz, DMSO-d₆/D₂O 9:1) of compound 50u




¹³C-NMR (101 MHz, DMSO-d₆/D₂O 9:1) of compound 50u




¹H-NMR (400 MHz, CD₃OD) of compound 1e




¹³C-NMR (101 MHz, CD₃OD) of compound 1e




¹⁹F-NMR (376 MHz, CD₃OD) of compound 1e




¹H-NMR (400 MHz, CD₃OD) of compound 1f




¹³C-NMR (101 MHz, CD₃OD) of compound 1f




¹H-NMR (400 MHz, CD₃OD/CD₂Cl₂ 9:1) of compound **1g**




¹³C-NMR (101 MHz, CD₃OD/CD₂Cl₂ 9:1) of compound **1g**




¹H-NMR (400 MHz, CD₃OD) of compound 1h




¹³C-NMR (101 MHz, CD₃OD) of compound 1h




$^1\text{H-NMR}$ (400 MHz, CD_3OD) of compound **1i**




$^{13}\text{C-NMR}$ (101 MHz, CD_3OD) of compound **1i**




¹⁹F-NMR (376 MHz, CD₃OD) of compound **1i**




¹H-NMR (400 MHz, CD₃OD) of compound **1j**




¹³C-NMR (101 MHz, CD₃OD) of compound **1j**




¹H-NMR (400 MHz, CD₃OD) of compound 1k




¹³C-NMR (101 MHz, CD₃OD) of compound 1k




¹H-NMR (400 MHz, CD₃OD) of compound **1**




¹³C-NMR (101 MHz, CD₃OD) of compound **1**




¹H-NMR (400 MHz, CD₃OD) of compound **1m**




¹³C-NMR (101 MHz, CD₃OD) of compound **1m**




¹H-NMR (400 MHz, CD₃OD) of compound **1n**




¹³C-NMR (101 MHz, CD₃OD) of compound **1n**




¹H-NMR (400 MHz, CD₃OD) of compound 1o




¹³C-NMR (101 MHz, CD₃OD) of compound 1o




¹H-NMR (400 MHz, CD₃OD) of compound 1p




¹³C-NMR (101 MHz, CD₃OD) of compound 1p




¹H-NMR (400 MHz, CD₃OD) of compound 1q




¹³C-NMR (101 MHz, CD₃OD) of compound 1q




¹H-NMR (400 MHz, CD₃OD) of compound 1r




¹³C-NMR (101 MHz, CD₃OD) of compound 1r




¹H-NMR (400 MHz, CD₃OD) of compound 1s




¹³C-NMR (101 MHz, CD₃OD) of compound 1s




¹H-NMR (400 MHz, CD₃OD) of compound 1t




¹³C-NMR (101 MHz, CD₃OD) of compound 1t




¹H-NMR (400 MHz, CD₃OD) of compound 1u




¹³C-NMR (101 MHz, CD₃OD) of compound 1u




¹H-NMR (400 MHz, CDCl₃) of compound 1'a




¹³C-NMR (101 MHz, CDCl₃) of compound 1'a




¹⁹F-NMR (376 MHz, CDCl₃) of compound 1'a




¹H-NMR (400 MHz, CDCl₃) of compound 1'd




¹³C-NMR (101 MHz, CDCl₃) of compound 1'd




¹⁹F-NMR (376 MHz, CDCl₃) of compound 1'd




¹H-NMR (400 MHz, CDCl₃) of compound 1'j




¹³C-NMR (101 MHz, CDCl₃) of compound 1'j




¹⁹F-NMR (376 MHz, CDCl₃) of compound 1j



¹H-NMR (400 MHz, CDCl₃) of compound 1'k




¹³C-NMR (101 MHz, CDCl₃) of compound 1'k




¹⁹F-NMR (376 MHz, CDCl₃) of compound 1'k




¹H-NMR (400 MHz, CDCl₃) of compound 1'




¹³C-NMR (101 MHz, CDCl₃) of compound 1'




¹⁹F-NMR (376 MHz, CDCl₃) of compound 1'




¹H-NMR (400 MHz, CDCl₃) of compound 1'p




¹³C-NMR (101 MHz, CDCl₃) of compound 1'p




¹⁹F-NMR (376 MHz, CDCl₃) of compound 1'p




$^1\text{H-NMR}$ (400 MHz, CDCl_3) of compound **4a**




$^{13}\text{C-NMR}$ (101 MHz, CDCl_3) of compound **4a**




¹H-NMR (400 MHz, CDCl₃) of compound 4b




¹³C-NMR (101 MHz, CDCl₃) of compound 4b




¹H-NMR (400 MHz, CDCl₃) of compound 4d




¹³C-NMR (101 MHz, CDCl₃) of compound 4d




¹⁹F-NMR (376 MHz, CDCl₃) of compound 4d




$^1\text{H-NMR}$ (400 MHz, CDCl_3) of compound **4e**




$^{13}\text{C-NMR}$ (101 MHz, CDCl_3) of compound **4e**




¹⁹F-NMR (376 MHz, CDCl₃) of compound **4e**




¹H-NMR (400 MHz, CDCl₃) of compound 4g




¹³C-NMR (101 MHz, CDCl₃) of compound 4g




¹H-NMR (400 MHz, CDCl₃) of compound 4h




¹³C-NMR (101 MHz, CDCl₃) of compound 4h




¹⁹F-NMR (376 MHz, CDCl₃) of compound **4i**




¹H-NMR (400 MHz, CDCl₃) of compound 4k




$^1\text{H-NMR}$ (400 MHz, CDCl_3) of compound **4I**




$^{13}\text{C-NMR}$ (101 MHz, CDCl_3) of compound **4I**




$^1\text{H-NMR}$ (400 MHz, CDCl_3) of compound **4m**




$^{13}\text{C-NMR}$ (101 MHz, CDCl_3) of compound **4m**




¹H-NMR (400 MHz, CDCl₃) of compound 4n




¹³C-NMR (101 MHz, CDCl₃) of compound 4n




¹H-NMR (400 MHz, CDCl₃) of compound **4q**




¹³C-NMR (101 MHz, CDCl₃) of compound **4q**




$^1\text{H-NMR}$ (400 MHz, CDCl_3) of compound **4s**




$^{13}\text{C-NMR}$ (101 MHz, CDCl_3) of compound **4s**




¹H-NMR (400 MHz, CDCl₃) of compound 4t




¹³C-NMR (101 MHz, CDCl₃) of compound 4t




¹H-NMR (400 MHz, CDCl₃) of compound 4u




¹³C-NMR (101 MHz, CDCl₃) of compound 4u




¹H-NMR (400 MHz, CDCl₃) of compound 5a




¹³C-NMR (101 MHz, CDCl₃) of compound 5a




$^1\text{H-NMR}$ (400 MHz, CDCl_3) of compound **5b**




$^{13}\text{C-NMR}$ (101 MHz, CDCl_3) of compound **5b**




¹H-NMR (400 MHz, CDCl₃) of compound 5c




¹³C-NMR (101 MHz, CDCl₃) of compound 5c




¹H-NMR (400 MHz, CDCl₃) of compound 5d




¹³C-NMR (101 MHz, CDCl₃) of compound 5d




¹H-NMR (400 MHz, CDCl₃) of compound 5g




¹³C-NMR (101 MHz, CDCl₃) of compound 5g




¹H-NMR (400 MHz, CDCl₃) of compound 5h




¹³C-NMR (101 MHz, CDCl₃) of compound 5h




¹H-NMR (400 MHz, CDCl₃) of compound 5i




¹³C-NMR (101 MHz, CDCl₃) of compound 5i




³¹P-NMR (126 MHz, CDCl₃) of compound **5i**




¹H-NMR (400 MHz, CDCl₃) of compound 5I




¹³C-NMR (101 MHz, CDCl₃) of compound 5I




¹⁹F-NMR (376 MHz, CDCl₃) of compound 5I




¹H-NMR (400 MHz, CDCl₃) of compound 5m




¹³C-NMR (101 MHz, CDCl₃) of compound 5m




¹H-NMR (400 MHz, CDCl₃) of compound 5p




¹³C-NMR (101 MHz, CDCl₃) of compound 5p




¹H-NMR (400 MHz, CDCl₃) of compound 6b




¹³C-NMR (101 MHz, CDCl₃) of compound 6b




¹H-NMR (400 MHz, CDCl₃) of compound 6c




¹³C-NMR (101 MHz, CDCl₃) of compound 6c




³¹P-NMR (162 MHz, CDCl₃) of compound 6d




¹H-NMR (400 MHz, CDCl₃) of compound 6e




¹³C-NMR (101 MHz, CDCl₃) of compound 6e




¹⁹F-NMR (376 MHz, CDCl₃) of compound 6e




¹H-NMR (400 MHz, CDCl₃) of compound 6f




¹³C-NMR (101 MHz, CDCl₃) of compound 6f




¹⁹F-NMR (376 MHz, CDCl₃) of compound 6f




¹H-NMR (400 MHz, CDCl₃) of compound 6g




¹³C-NMR (101 MHz, CDCl₃) of compound 6g




¹⁹F-NMR (376 MHz, CDCl₃) of compound 6g




¹H-NMR (400 MHz, CDCl₃) of compound 9




¹³C-NMR (101 MHz, CDCl₃) of compound 9




¹H-NMR (400 MHz, CDCl₃) of compound 10




¹³C-NMR (101 MHz, CDCl₃) of compound 10




¹H-NMR (400 MHz, CDCl₃) of compound **11**




¹³C-NMR (101 MHz, CDCl₃) of compound **11**




¹H-NMR (400 MHz, CDCl₃) of compound 13




¹³C-NMR (101 MHz, CDCl₃) of compound 13




$^1\text{H-NMR}$ (400 MHz, CDCl_3) of compound **14**



$^{13}\text{C-NMR}$ (101 MHz, CDCl_3) of compound **14**



$^1\text{H-NMR}$ (400 MHz, CDCl_3) of compound **15**



$^{13}\text{C-NMR}$ (101 MHz, CDCl_3) of compound **15**

